
<html lang="en"     class="pb-page"  data-request-id="00e3674b-32ee-4749-afdd-f6aaf460f182"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;issue:issue:10.1021/jmcmar.2021.64.issue-9;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.1c00382;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Potent and Brain-Penetrant Tau Tubulin Kinase 1 (TTBK1) Inhibitors that Lower Tau Phosphorylation In Vivo" /></meta><meta name="dc.Creator" content="Tamara  Halkina" /></meta><meta name="dc.Creator" content="Jaclyn L.  Henderson" /></meta><meta name="dc.Creator" content="Edward Y.  Lin" /></meta><meta name="dc.Creator" content="Martin K.  Himmelbauer" /></meta><meta name="dc.Creator" content="J. Howard  Jones" /></meta><meta name="dc.Creator" content="Marta  Nevalainen" /></meta><meta name="dc.Creator" content="Jun  Feng" /></meta><meta name="dc.Creator" content="Kristopher  King" /></meta><meta name="dc.Creator" content="Michael  Rooney" /></meta><meta name="dc.Creator" content="Joshua L.  Johnson" /></meta><meta name="dc.Creator" content="Douglas J.  Marcotte" /></meta><meta name="dc.Creator" content="Jayanth V.  Chodaparambil" /></meta><meta name="dc.Creator" content="P. Rajesh  Kumar" /></meta><meta name="dc.Creator" content="Thomas A.  Patterson" /></meta><meta name="dc.Creator" content="Paramasivam  Murugan" /></meta><meta name="dc.Creator" content="Eli  Schuman" /></meta><meta name="dc.Creator" content="LaiYee  Wong" /></meta><meta name="dc.Creator" content="Thomas  Hesson" /></meta><meta name="dc.Creator" content="Sarah  Lamore" /></meta><meta name="dc.Creator" content="Channa  Bao" /></meta><meta name="dc.Creator" content="Michael  Calhoun" /></meta><meta name="dc.Creator" content="Hannah  Certo" /></meta><meta name="dc.Creator" content="Brenda  Amaral" /></meta><meta name="dc.Creator" content="Gregory M.  Dillon" /></meta><meta name="dc.Creator" content="Rab  Gilfillan" /></meta><meta name="dc.Creator" content="Felix Gonzalez-Lopez  de Turiso" /></meta><meta name="dc.Description" content="Structural analysis of the known NIK inhibitor 3 bound to the kinase domain of TTBK1 led to the design and synthesis of a novel class of azaindazole TTBK1 inhibitors exemplified by 8 (cell IC50: 57..." /></meta><meta name="Description" content="Structural analysis of the known NIK inhibitor 3 bound to the kinase domain of TTBK1 led to the design and synthesis of a novel class of azaindazole TTBK1 inhibitors exemplified by 8 (cell IC50: 57..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 4, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00382" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00382" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00382" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00382" /></link>
        
    
    

<title>Discovery of Potent and Brain-Penetrant Tau Tubulin Kinase 1 (TTBK1) Inhibitors that Lower Tau Phosphorylation In Vivo | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00382" /></meta><meta property="og:title" content="Discovery of Potent and Brain-Penetrant Tau Tubulin Kinase 1 (TTBK1) Inhibitors that Lower Tau Phosphorylation In Vivo" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0024.jpeg" /></meta><meta property="og:description" content="Structural analysis of the known NIK inhibitor 3 bound to the kinase domain of TTBK1 led to the design and synthesis of a novel class of azaindazole TTBK1 inhibitors exemplified by 8 (cell IC50: 571 nM). Systematic optimization of this series of analogs led to the discovery of 31, a potent (cell IC50: 315 nM) and selective TTBK inhibitor with suitable CNS penetration (rat Kp,uu: 0.32) for in vivo proof of pharmacology studies. The ability of 31 to inhibit tau phosphorylation at the disease-relevant Ser 422 epitope was demonstrated in both a mouse hypothermia and a rat developmental model and provided evidence that modulation of this target may be relevant in the treatment of Alzheimer’s disease and other tauopathies." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00382"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00382">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00382&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00382&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00382&amp;href=/doi/10.1021/acs.jmedchem.1c00382" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 9</span><span class="cit-fg-pageRange">, 6358-6380</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/9" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00375" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00442" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Potent and Brain-Penetrant Tau Tubulin Kinase 1 (TTBK1) Inhibitors that Lower Tau Phosphorylation In Vivo</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Tamara Halkina</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tamara Halkina</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#681c0705094600090403010609280a01070f0d06460b0705"><span class="__cf_email__" data-cfemail="dda9b2b0bcf3b5bcb1b6b4b3bc9dbfb4b2bab8b3f3beb2b0">[email protected]</span></a>. Telephone: 617-679-3382.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tamara++Halkina">Tamara Halkina</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jaclyn L. Henderson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jaclyn L. Henderson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jaclyn+L.++Henderson">Jaclyn L. Henderson</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7097-1350" title="Orcid link">http://orcid.org/0000-0002-7097-1350</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Edward Y. Lin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Edward Y. Lin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Edward+Y.++Lin">Edward Y. Lin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Martin K. Himmelbauer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Martin K. Himmelbauer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Martin+K.++Himmelbauer">Martin K. Himmelbauer</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4960-4457" title="Orcid link">http://orcid.org/0000-0003-4960-4457</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">J. Howard Jones</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">J. Howard Jones</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=J.+Howard++Jones">J. Howard Jones</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Marta Nevalainen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marta Nevalainen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marta++Nevalainen">Marta Nevalainen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jun Feng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jun Feng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jun++Feng">Jun Feng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kristopher King</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kristopher King</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Drug Metabolism and Pharmacokinetics, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kristopher++King">Kristopher King</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael Rooney</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Rooney</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Drug Metabolism and Pharmacokinetics, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Rooney">Michael Rooney</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Joshua L. Johnson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joshua L. Johnson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Drug Metabolism and Pharmacokinetics, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joshua+L.++Johnson">Joshua L. Johnson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Douglas J. Marcotte</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Douglas J. Marcotte</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Physical Biochemistry and Molecular Design, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Douglas+J.++Marcotte">Douglas J. Marcotte</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jayanth V. Chodaparambil</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jayanth V. Chodaparambil</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Physical Biochemistry and Molecular Design, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jayanth+V.++Chodaparambil">Jayanth V. Chodaparambil</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">P. Rajesh Kumar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">P. Rajesh Kumar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Physical Biochemistry and Molecular Design, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=P.+Rajesh++Kumar">P. Rajesh Kumar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thomas A. Patterson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas A. Patterson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Physical Biochemistry and Molecular Design, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas+A.++Patterson">Thomas A. Patterson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paramasivam Murugan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paramasivam Murugan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Bioassays, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paramasivam++Murugan">Paramasivam Murugan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eli Schuman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eli Schuman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Bioassays, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eli++Schuman">Eli Schuman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">LaiYee Wong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">LaiYee Wong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Bioassays, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=LaiYee++Wong">LaiYee Wong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thomas Hesson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas Hesson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Bioassays, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas++Hesson">Thomas Hesson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sarah Lamore</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sarah Lamore</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Preclinical Safety, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sarah++Lamore">Sarah Lamore</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Channa Bao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Channa Bao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Emerging Neurosciences Research Unit, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Channa++Bao">Channa Bao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael Calhoun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Calhoun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Emerging Neurosciences Research Unit, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Calhoun">Michael Calhoun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hannah Certo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hannah Certo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Emerging Neurosciences Research Unit, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hannah++Certo">Hannah Certo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brenda Amaral</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brenda Amaral</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Emerging Neurosciences Research Unit, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brenda++Amaral">Brenda Amaral</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gregory M. Dillon</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gregory M. Dillon</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Emerging Neurosciences Research Unit, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gregory+M.++Dillon">Gregory M. Dillon</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rab Gilfillan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rab Gilfillan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rab++Gilfillan">Rab Gilfillan</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Felix Gonzalez-Lopez de Turiso</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Felix Gonzalez-Lopez de Turiso</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#2e484b42475600494140544f424b5442415e4b544a4b5a5b5c475d416e4c4741494b40004d4143"><span class="__cf_email__" data-cfemail="6204070e0b1a4c050d0c18030e07180e0d12071806071617100b110d22000b0d05070c4c010d0f">[email protected]</span></a>. Telephone: 617-914-1295.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Felix+Gonzalez-Lopez++de+Turiso">Felix Gonzalez-Lopez de Turiso</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9736-0907" title="Orcid link">http://orcid.org/0000-0001-9736-0907</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00382&amp;href=/doi/10.1021%2Facs.jmedchem.1c00382" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 9</span><span class="cit-pageRange">, 6358–6380</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 4, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>2 March 2021</li><li><span class="item_label"><b>Published</b> online</span>4 May 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 May 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00382" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00382</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6358%26pageCount%3D23%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DTamara%2BHalkina%252C%2BJaclyn%2BL.%2BHenderson%252C%2BEdward%2BY.%2BLin%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D9%26contentID%3Dacs.jmedchem.1c00382%26title%3DDiscovery%2Bof%2BPotent%2Band%2BBrain-Penetrant%2BTau%2BTubulin%2BKinase%2B1%2B%2528TTBK1%2529%2BInhibitors%2Bthat%2BLower%2BTau%2BPhosphorylation%2BIn%2BVivo%26numPages%3D23%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6380%26publicationDate%3DMay%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00382"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1586</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00382" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Potent and Brain-Penetrant Tau Tubulin Kinase 1 (TTBK1) Inhibitors that Lower Tau Phosphorylation In Vivo&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Tamara&quot;,&quot;last_name&quot;:&quot;Halkina&quot;},{&quot;first_name&quot;:&quot;Jaclyn&quot;,&quot;last_name&quot;:&quot;L. Henderson&quot;},{&quot;first_name&quot;:&quot;Edward&quot;,&quot;last_name&quot;:&quot;Y. Lin&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;K. Himmelbauer&quot;},{&quot;first_name&quot;:&quot;J.&quot;,&quot;last_name&quot;:&quot;Howard Jones&quot;},{&quot;first_name&quot;:&quot;Marta&quot;,&quot;last_name&quot;:&quot;Nevalainen&quot;},{&quot;first_name&quot;:&quot;Jun&quot;,&quot;last_name&quot;:&quot;Feng&quot;},{&quot;first_name&quot;:&quot;Kristopher&quot;,&quot;last_name&quot;:&quot;King&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Rooney&quot;},{&quot;first_name&quot;:&quot;Joshua&quot;,&quot;last_name&quot;:&quot;L. Johnson&quot;},{&quot;first_name&quot;:&quot;Douglas&quot;,&quot;last_name&quot;:&quot;J. Marcotte&quot;},{&quot;first_name&quot;:&quot;Jayanth&quot;,&quot;last_name&quot;:&quot;V. Chodaparambil&quot;},{&quot;first_name&quot;:&quot;P.&quot;,&quot;last_name&quot;:&quot;Rajesh Kumar&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;A. Patterson&quot;},{&quot;first_name&quot;:&quot;Paramasivam&quot;,&quot;last_name&quot;:&quot;Murugan&quot;},{&quot;first_name&quot;:&quot;Eli&quot;,&quot;last_name&quot;:&quot;Schuman&quot;},{&quot;first_name&quot;:&quot;LaiYee&quot;,&quot;last_name&quot;:&quot;Wong&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;Hesson&quot;},{&quot;first_name&quot;:&quot;Sarah&quot;,&quot;last_name&quot;:&quot;Lamore&quot;},{&quot;first_name&quot;:&quot;Channa&quot;,&quot;last_name&quot;:&quot;Bao&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Calhoun&quot;},{&quot;first_name&quot;:&quot;Hannah&quot;,&quot;last_name&quot;:&quot;Certo&quot;},{&quot;first_name&quot;:&quot;Brenda&quot;,&quot;last_name&quot;:&quot;Amaral&quot;},{&quot;first_name&quot;:&quot;Gregory&quot;,&quot;last_name&quot;:&quot;M. Dillon&quot;},{&quot;first_name&quot;:&quot;Rab&quot;,&quot;last_name&quot;:&quot;Gilfillan&quot;},{&quot;first_name&quot;:&quot;Felix&quot;,&quot;last_name&quot;:&quot;Gonzalez-Lopez de Turiso&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;04&quot;,&quot;issue&quot;:&quot;9&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;6358-6380&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00382&quot;},&quot;abstract&quot;:&quot;Structural analysis of the known NIK inhibitor 3 bound to the kinase domain of TTBK1 led to the design and synthesis of a novel class of azaindazole TTBK1 inhibitors exemplified by 8 (cell IC50: 571 nM). Systematic optimization of this series of analogs led to the discovery of 31, a potent (cell IC50: 315 nM) and selective TTBK inhibitor with suitable CNS penetration (rat Kp,uu: 0.32) for in vivo proof of pharmacology studies. The ability of 31 to inhibit tau phosphorylation at the disease-relevant Ser 422 epitope was demonstrated in both a mouse hypothermia and a rat developmental model and provided evidence that modulation of this target may be relevant in the treatment of Alzheimer’s disease and other tauopathies.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00382&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00382" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00382&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00382" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00382&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00382" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00382&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00382&amp;href=/doi/10.1021/acs.jmedchem.1c00382" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00382" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00382" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00382%26sid%3Dliteratum%253Aachs%26pmid%3D33944571%26genre%3Darticle%26aulast%3DHalkina%26date%3D2021%26atitle%3DDiscovery%2Bof%2BPotent%2Band%2BBrain-Penetrant%2BTau%2BTubulin%2BKinase%2B1%2B%2528TTBK1%2529%2BInhibitors%2Bthat%2BLower%2BTau%2BPhosphorylation%2BIn%2BVivo%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D9%26spage%3D6358%26epage%3D6380%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290969" title="Cell and molecular biology">Cell and molecular biology</a>,</li><li><a href="/action/doSearch?ConceptID=290682" title="Post-translational modification">Post-translational modification</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/9" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/jmcmar.2021.64.issue-9/20210513/jmcmar.2021.64.issue-9.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Structural analysis of the known NIK inhibitor <b>3</b> bound to the kinase domain of TTBK1 led to the design and synthesis of a novel class of azaindazole TTBK1 inhibitors exemplified by <b>8</b> (cell IC<sub>50</sub>: 571 nM). Systematic optimization of this series of analogs led to the discovery of <b>31</b>, a potent (cell IC<sub>50</sub>: 315 nM) and selective TTBK inhibitor with suitable CNS penetration (rat K<sub>p,uu</sub>: 0.32) for in vivo proof of pharmacology studies. The ability of <b>31</b> to inhibit tau phosphorylation at the disease-relevant Ser 422 epitope was demonstrated in both a mouse hypothermia and a rat developmental model and provided evidence that modulation of this target may be relevant in the treatment of Alzheimer’s disease and other tauopathies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48201" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48201" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Tau tubulin kinase 1 (TTBK1) is a kinase that is specifically expressed in the CNS<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> and has been reported to phosphorylate tau at a number of disease-related epitopes.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> Hyperphosphorylated tau, which aggregates in the form of neurofibrillary tangles (NFTs), is a key pathological hallmark in a number of neurodegenerative diseases, including Alzheimer’s disease (AD),<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> and is thought to play a significant role in the progression of disease. Consequently, reducing tau phosphorylation has been proposed as a therapeutic strategy to prevent NFT formation<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> and slow neurodegeneration.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> To test this hypothesis, small molecule inhibitors that modulate tau phosphorylation through multiple pathways have been identified and advanced to the clinic. In particular, small molecule GSK3 inhibitors have progressed to late stage clinical trials but, after more than three decades, these studies have not led to an FDA-approved therapeutic and an opportunity exists to identify alternative targets to modulate tau phosphorylation.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> Within this context, modulation of TTBK1 activity might be a superior strategy given that this kinase is only expressed in the CNS and its upregulation has been linked to AD pathology in humans.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p last">Despite the potential advantage of targeting TTBK1 with a small molecule inhibitor, this approach is not without risk. Specifically, a closely related isoform (TTBK2, 88% identity and 96% similarity to TTBK1 in the kinase domain) with a role in cellular processes such as ciliogenesis has been identified and it is unclear what selectivity profile would be needed to develop a safe and efficacious therapeutic for a chronic indication such as AD.<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12−14)</a> In addition, the few TTBK1 inhibitors reported in the literature are not suitable for proof of pharmacology studies due to lack of potency and CNS penetration. Furthermore, the premise that small molecule inhibition of TTBK1 leads to reduction of tau phosphorylation had not been demonstrated in preclinical animal models.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> In this report, we describe the discovery of potent and selective TTBK1 inhibitors leading to <b>31</b>, a tool compound with suitable properties to interrogate the link between TTBK1 inhibition and tau phosphorylation in vivo.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53571" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53571" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">At the outset, we anticipated that the identification of potent and brain-penetrant TTBK1 inhibitors might be challenging given that staurosporine, a pan-kinase inhibitor, is inactive against this kinase at a 100 μM concentration.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> In addition, compounds <b>1</b><a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and <b>2</b><a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), which had been reported as TTBK1 inhibitors, were found to have very weak activity in a TTBK1 biochemical assay (<b>1</b>, IC<sub>50</sub>: 4.61 μM; <b>2</b>, IC<sub>50</sub>: 2.51 μM).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> To identify a more suitable candidate for optimization, a number of approaches were explored, including a systematic examination of the off-target activity of known kinase inhibitors.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> This strategy led to the identification of a compound with significant TTBK1 activity, the NF-κB inducing kinase (NIK) inhibitor <b>3</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, this analog was reported to have >50% TTBK1 inhibition at a 100 nM concentration).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The potency of this compound was confirmed in both a biochemical assay (TTBK1 IC<sub>50</sub>: 199 nM, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) and a cellular assay (IC<sub>50</sub>: 1.85 μM for the inhibition of tau phosphorylation at Ser 422; see <a href="/doi/suppl/10.1021/acs.jmedchem.1c00382/suppl_file/jm1c00382_si_001.pdf" class="ext-link">Supporting Information</a>). Subsequent evaluation of <b>3</b> in an in vitro MDCK–MDR1 assay revealed a high efflux ratio (ER) of 110, predicting low unbound exposure in the brain.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Profile of TTBK1 inhibitors reported in the literature.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To enable a structure-based design optimization approach, the X-ray cocrystal structure of <b>3</b> in complex with the human kinase domain of TTBK1 (at a 1.5 Å resolution, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) was elucidated. This structure showed that the aminopyrimidine ring made two hydrogen bond contacts with the backbone of the hinge residues Gln 108 and Gln 110. Notably, the alkyne group displaced the catalytic lysine and projected the tertiary alcohol through a narrow tunnel into the back pocket of the protein, thus positioning this group in an ideal orientation to interact with both the backbone N–H of Phe 177 and the carboxylic acid of Glu 77 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>a–c). This structure also suggested that the N–H bond of the indole was solvent exposed and that the three methylene groups of the seven-membered ring helped maintain the planarity of the molecule rather than making any contacts with the protein.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Cocrystal structure of <b>3</b> (magenta) with the human kinase domain of TTBK1 highlighting key interactions in the active site (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JXX">7JXX</a>). (b) Surface view illustrating key elements of tertiary kinase structure and showcasing the narrow entrance to the back pocket. A water molecule in the lipophilic back pocket is displayed as a red sphere. (c) Schematic representation of the binding mode of <b>3</b> in the kinase domain of TTBK1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Our initial optimization of analog <b>3</b> focused on truncating the cycloheptadiene ring to reduce its structural complexity and allow for quick analog synthesis and optimization. We hypothesized that the resulting indole <b>4</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) would maintain the key interactions observed in the X-ray structure of <b>3</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), although an increased entropy of <b>4</b> relative to <b>3</b> may lead to an initial reduction in potency. As predicted, compound <b>4</b> was fivefold less potent relative to its tetracyclic precursor (<b>4</b>, IC<sub>50</sub>: 1022 nM vs <b>3</b>, IC<sub>50</sub>: 199 nM). To induce coplanarity of the indole and the aminopyrimidine rings, a nitrogen atom at the 2-position of the indole was introduced, and the resulting indazole <b>5</b> demonstrated an improvement in potency (<b>5</b>, IC<sub>50</sub>: 185 nM, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The high ER of <b>5</b> was mitigated by methylation of N1 of the indazole to afford <b>6</b>, which had a similar level of cellular potency relative to <b>3</b> (<b>6</b>, cell IC<sub>50</sub>: 1.42 μM and ER: 2.0 vs <b>3</b>, cell IC<sub>50</sub>: 1.85 μM and ER: 11).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Initial simplification of the TTBK1 pharmacophore.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To improve the potency of these inhibitors, we sought to engage the catalytic lysine (Lys 63, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>a) in a direct hydrogen bond with the indazole core by introducing a hydrogen bond acceptor at the 5-position of indazole <b>6</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Gratifyingly, the resulting azaindazole <b>7</b> was nearly fourfold more potent in the biochemical assay relative to <b>6</b> (<b>7</b>, IC<sub>50</sub>: 96 nM vs <b>6</b>, IC<sub>50</sub>: 352 nM, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) although this compound also had a high ER (19). However, subsequent synthesis of the regioisomeric N1-linked azaindazole <b>8</b> led to an analog with similar potency (cell IC<sub>50</sub>: 571 nM) and significantly lower ER (5.5). The improvement in the ER of <b>8</b> was rationalized by its lower predicted basic pKa relative to <b>7</b> (<b>8</b>, N5 pKa: 4.9 vs <b>7</b>, N5 pKa: 5.8).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Identification of azaindazole TTBK1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Subsequent systematic modification of the 5,6-fused heterocycle led to the discovery of compounds with improved potency (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Specifically, both azaindole <b>9</b> and azaindoline <b>10</b> displayed improved potency relative to <b>8</b> (<b>9</b>, cell IC<sub>50</sub>: 114 nM and <b>10</b>, cell IC<sub>50</sub>: 177 nM vs <b>8</b>, cell IC<sub>50</sub>: 571 nM). However, despite the reduced polar surface area (PSA) (<b>9</b>, PSA: 90 and <b>10</b>, PSA: 88 vs <b>8</b>, PSA: 103), these compounds were found to be P-gp substrates (<b>9</b>, ER: 10; <b>10</b>, ER: 26).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The observed increase in the ER of these analogs was consistent with progressively increasing predicted basicity of N5 from <b>8</b> (pKa: 4.9) to <b>9</b> (pKa: 5.7) to <b>10</b> (pKa: 7.4, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), suggesting that the ER is correlated with the basicity of these compounds rather than with their PSA. We therefore hypothesized that replacing N5 of <b>9</b> with a non-basic functional group may lower the ER without disrupting the putative interaction with the protein. Consistent with our prediction, indole analogs <b>11</b> and <b>12</b> (with 5-OMe and 5-F substitution, respectively) showed a significantly reduced ER of 3.0 and 0.8, respectively, but this reduction of the ER was accompanied by a greater than 15-fold loss in cellular potency relative to <b>9</b> (<b>11</b>, cell IC<sub>50</sub>: 2.50 μM; <b>12</b>, cell IC<sub>50</sub>: 1.85 μM vs <b>9</b>, cell IC<sub>50</sub>: 114 nM).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Systematic Optimization of the 5,6-Fused Ring System</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0017.gif" alt="" id="gr16" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Results represent the arithmetic mean of a minimum of two determinations.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">MDCK–MDR1 human P-gp transfected cell line. P<sub>app(A–B)</sub>: apparent permeability apical-to-basolateral (10<sup>–6</sup> cm/s); ER = B–A/A–B efflux ratio.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Cl<sub>int.</sub></p></div></div><div></div></div><div class="NLM_p">Having explored the impact of modifying the central 5,6-fused heterocyclic core, we pursued optimization of the putative solvent-exposed substituents in <b>9</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). We hypothesized that substitution at positions C3 or C4 could impart desirable physicochemical properties without disrupting the key hinge and back pocket hydrogen bonds. As expected, a variety of aliphatic substituents were tolerated (cell IC<sub>50</sub>: 98–742 nM, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>); however, the ER remained generally high. Two notable exceptions were the C4-methyl ether <b>13</b> (ER: 2.9) and the C3-piperidine <b>17</b> (ER: 1.2). Unfortunately, these analogs were relatively weak inhibitors in the cellular assay (<b>13</b>, cell IC<sub>50</sub>: 742 nM; <b>17</b>, cell IC<sub>50</sub>: 737 nM).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR of the C3 and C4 Substitution of the 5-Azaindole Core</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0018.gif" alt="" id="gr17" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Results represent the arithmetic mean of a minimum of two determinations.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">MDCK–MDR1 human P-gp transfected cell line. P<sub>app(A–B)</sub>: apparent permeability apical-to-basolateral (10<sup>–6</sup> cm/s); ER = B–A/A–B efflux ratio.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Cl<sub>int.</sub></p></div></div><div></div></div><div class="NLM_p">In an attempt to improve the cellular potency of these inhibitors, we looked extensively at the substituents reaching into the back pocket within both the azaindazole and the azaindole series. Both the vector and the immediate environment of the tertiary alcohol were found to be critical to potency and only small changes to the alkyl substituents were tolerated. Specifically, extending one of the methyl groups in <b>8</b> and <b>9</b> by one carbon provided a three- to fivefold improvement in biochemical potency compared to their parent compounds (<b>18</b>, IC<sub>50</sub>: 18 nM, and <b>19</b>, IC<sub>50</sub>: 2.3 nM, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Optimization of alkyne substitution in the back pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Elucidation of an X-ray cocrystal structure of <b>18</b> with TTBK1 (at a 2.2 Å resolution, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) helped understand the interactions of this inhibitor with the active site and established its absolute stereochemistry. As expected, <b>18</b> had a similar binding mode to that of compound <b>3</b>. The aminopyrimidine hinge binder was coplanar with the azaindazole core, and the tertiary alcohol reached into the back pocket through the narrow tunnel flanked by Met 107 and Lys 63. Consistent with our hypothesis, the additional interaction of N5 was confirmed to be a direct hydrogen bond with Lys 63. The boost in potency provided by the ethyl group can be explained by the displacement of a water molecule (visualized as a red sphere in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b) from the hydrophobic back pocket and the resulting favorable van der Waals interactions of the ethyl group with lipophilic protein residues (Leu 81 and Phe 177).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) Overlay of the cocrystal structures of <b>3</b> (magenta) and <b>18</b> (cyan) in the human kinase domain of TTBK1 highlighting key interactions of <b>18</b> with the hinge and Lys 63 (only cartoon for the protein from the X-ray cocrystal structure of <b>18</b> is shown for clarity, PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JXY">7JXY</a>). (b) Protein surface view of the cocrystal structure of <b>18</b> (cyan) with the human kinase domain of TTBK1 showing interactions in the back pocket. (c) Schematic representation of the binding mode of <b>18</b> in the kinase domain of TTBK1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Attempts to replace the alkyne within the context of both the azaindazole and the azaindole cores were largely unsuccessful (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Although our computational modeling using the X-ray cocrystal structure of <b>18</b> with TTBK1 suggested reasonable docking poses that could maintain the key hydrogen bonds in the back pocket, most non-alkyne analogs, including a known bioisostere bicyclo[1.1.1]pentane <b>27</b>,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> were inactive. The only analogs that retained some activity against TTBK1 were alkenes <b>20</b> and <b>24</b> (IC<sub>50</sub>: 1.94 and 0.41 μM, respectively), and fully saturating the side chain led to a greater than 10-fold loss in potency (<b>21</b>, 16.9 μM).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR of the Substituent in the Back Pocket</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0019.gif" alt="" id="gr18" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Results represent the arithmetic mean of a minimum of two determinations.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">MDCK–MDR1 human P-gp transfected cell line. P<sub>app(A–B)</sub>: apparent permeability apical-to-basolateral (10<sup>–6</sup> cm/s); ER = B–A/A–B efflux ratio.</p></div></div><div></div></div><div class="NLM_p">As a suitable isostere for the alkyne pharmacophore could not be identified,<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> the chemical reactivity of this functional group was explored in glutathione (GSH) conjugation experiments (see <a href="/doi/suppl/10.1021/acs.jmedchem.1c00382/suppl_file/jm1c00382_si_001.pdf" class="ext-link">Supporting Information</a>). A selection of inhibitors was incubated with GSH for up to 4 h, and it was observed that all the inhibitors with fully aromatic cores (<b>6, 12, 17, 18</b>, and <b>19</b>, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) were >99% unmodified under the experimental conditions. In contrast, compound <b>10</b>, with a partially saturated azaindoline core, was not stable (17% GSH addition observed, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Cytotoxicity and GSH Stability Data</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0020.gif" alt="" id="gr19" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Results represent the arithmetic mean of a minimum of two determinations.</p></div></div><div></div></div><div class="NLM_p">Despite the high chemical stability of many of the alkynes in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, all these inhibitors were found to be highly cytotoxic in a HepG2 in vitro assay. It is important to note that the cytotoxicity in this assay could not be due to on-target TTBK1 inhibition since these cells do not express TTBK1 (see <a href="/doi/suppl/10.1021/acs.jmedchem.1c00382/suppl_file/jm1c00382_si_001.pdf" class="ext-link">Supporting Information</a>). Additional cytotoxicity data from a larger set of analogs with different core and alkyne substituents were also found to not be favorable (data not shown), which prompted us to investigate the impact of modifying the hinge binder. Initially, monomethylation of the primary amine in <b>9</b> led to compound <b>28</b> that had a slightly improved cytotoxicity profile, albeit with a significant reduction in biochemical potency (<b>28</b>, IC<sub>50</sub>: 124 nM vs <b>9</b>, IC<sub>50</sub>: 9.8 nM) (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Shifting the primary amine from C2 to C6 of the pyrimidine in <b>19</b> afforded <b>29</b> with a greatly reduced cytotoxicity of over 20 μM and an improvement in potency relative to <b>28</b> (<b>29</b>, cell IC<sub>50</sub>: 37 nM vs <b>28</b>, cell IC<sub>50</sub>: 1646 nM, <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Useful levels of cellular potency and an acceptable cytotoxicity profile were ultimately achieved by further modifying the C6 substitution of the 2-aminopyrimidine. Thus, incorporation of a methyl group at the C6-position led to compound <b>30</b>, which had good cellular potency (IC<sub>50</sub>: 224 nM) and a moderate level of cytotoxicity in HepG2 cells (Glu IC<sub>50</sub>/Gal IC<sub>50</sub>: 3.2/3.8 μM). Replacing the methyl group in <b>30</b> with a 6-methoxy substituent led to the discovery of <b>31</b>, an analog with low ER (3.7), a satisfactory level of both biochemical and cellular potency (IC<sub>50</sub>: 2.7 and 315 nM, respectively), and low cytotoxicity (Glu IC<sub>50</sub>/Gal IC<sub>50</sub>: 8.9/10 μM). A regioisomer of <b>31</b> with the C5-methyl ether substitution was also synthesized, but despite its good potency (<b>32</b>, cell IC<sub>50</sub>: 239 nM), this analog had a high ER (57) and was cytotoxic at sub-micromolar concentrations.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Hinge Binder Optimization</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0021.gif" alt="" id="gr20" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Results represent the arithmetic mean of a minimum of two determinations except where indicated.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">MDCK–MDR1 human P-gp transfected cell line. P<sub>app(A–B)</sub>: apparent permeability apical-to-basolateral (10<sup>–6</sup> cm/s); ER = B–A/A–B efflux ratio.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Only one determination.</p></div></div><div></div></div><div class="NLM_p">As a further assessment of compound safety liabilities, we progressed our top compounds into kinase selectivity screening using the DiscoverX kinome panel (468 kinases). Compounds <b>19</b> and <b>31</b> (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>, bottom) both showed an excellent selectivity profile. The selectivity of <b>31</b> was confirmed in follow-up dose–response experiments, in which this inhibitor was tested against the major off-target kinases observed in the kinome panel (see <a href="/doi/suppl/10.1021/acs.jmedchem.1c00382/suppl_file/jm1c00382_si_001.pdf" class="ext-link">Supporting Information</a>). These assays revealed that only CK1δ and PRKD1 were inhibited with less than a 20-fold selectivity over TTBK1 and that <b>31</b> had very weak activity against NIK (>400-fold selectivity vs TTBK1). Notably, inhibitors <b>18</b>, <b>19</b>, and <b>31</b> were not selective against TTBK2 in a biochemical assay, indicating that inhibition of this isoform was not responsible for the observed cytotoxicity. In addition, compound <b>31</b> was also evaluated in a Eurofins panel against 68 common target proteins which revealed that only Adenosine A<sub>1</sub>, A<sub>2A</sub>, and A<sub>3</sub> were potential off targets (61, 64, and 73% inhibition, respectively, at a 10 μM test concentration).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Kinase Selectivity Profile and Cytotoxicity of Key Analogs<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0022.gif" alt="" id="gr21" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Dendrograms are shown for a compound test concentration of 1 μM (Image generated using TREE<i>spot</i> Software Tool and reprinted with permission from KINOME<i>scan</i>, a division of DiscoveRx Corporation, DISCOVERX CORPORATION 2010).</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Results represent the arithmetic mean of a minimum of two determinations.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0023.gif" alt="" id="gr22" /></img></p></div></div><div></div></div><div class="NLM_p">Further characterization of compounds <b>18</b>, <b>19</b>, and <b>31</b> revealed that all three analogs had good solubility and permeability and did not inhibit the human Ether-à-go-go-Related Gene (hERG) channel at a concentration up to 30 μM in an in vitro assay (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Compound <b>18</b> also had low in vitro intrinsic clearance in human liver microsomes (HLM) and low in vivo rat clearance. In contrast, <b>19</b> and <b>31</b> had good HLM stability but a significantly lower rat liver microsomal (RLM) stability, which translated to high in vivo clearance. The CNS penetration of these analogs was tested in rat K<sub>p,uu</sub> experiments (see <a href="/doi/suppl/10.1021/acs.jmedchem.1c00382/suppl_file/jm1c00382_si_001.pdf" class="ext-link">Supporting Information</a>). These studies revealed that while <b>18</b> and <b>19</b> had low brain penetration (K<sub>p,uu</sub> < 0.1), compound <b>31</b> had an improved K<sub>p,uu</sub> of 0.32, making it a good candidate for in-depth in vivo proof of pharmacology experiments.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Profile of TTBK1 Inhibitors <b>18</b>, <b>19</b>, and <b>31</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">analog</th><th class="colsep0 rowsep0" align="center">HLM/RLM (mL/min/kg)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">Sol. (pH 6.8) (μg/mL)</th><th class="colsep0 rowsep0" align="center">MDCK–LE<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a> P<sub>A–B</sub>/P<sub>B–A</sub></th><th class="colsep0 rowsep0" align="center" char=".">hERG IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">MDCK–MDR1 P<sub>app(A–B)</sub>/<u class="uu">ER</u><a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">RPPB/HPPB (f<sub>u</sub>)</th><th class="colsep0 rowsep0" align="center">Rat/Mouse Cl (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char=".">Rat K<sub>p,uu</sub><a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left"><5/36</td><td class="colsep0 rowsep0" align="char" char=".">46</td><td class="colsep0 rowsep0" align="left">25/16</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="left">3.3/<u class="uu">5.7</u></td><td class="colsep0 rowsep0" align="left">13/8.8</td><td class="colsep0 rowsep0" align="left">17<a class="ref internalNav" href="#t7fn5" aria-label="e">e</a>/–</td><td class="colsep0 rowsep0" align="char" char=".">0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">11/155</td><td class="colsep0 rowsep0" align="char" char=".">44</td><td class="colsep0 rowsep0" align="left">32/19</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="left">3.0/<u class="uu">8.6</u></td><td class="colsep0 rowsep0" align="left">5.2/2.7</td><td class="colsep0 rowsep0" align="left">64<a class="ref internalNav" href="#t7fn6" aria-label="f">f</a>/–</td><td class="colsep0 rowsep0" align="char" char=".">0.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">16/219</td><td class="colsep0 rowsep0" align="char" char=".">45</td><td class="colsep0 rowsep0" align="left">27/21</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="left">7.8/<u class="uu">3.7</u></td><td class="colsep0 rowsep0" align="left">1.2/2.1</td><td class="colsep0 rowsep0" align="left">62<a class="ref internalNav" href="#t7fn7" aria-label="g">g</a>/67<a class="ref internalNav" href="#t7fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="char" char=".">0.32</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Cl<sub>int</sub>.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">MDCKII cell line with low expression of P-gp. P<sub>A–B</sub>: permeability apical-to-basolateral (10<sup>–6</sup> cm/s). P<sub>B–A</sub>: permeability basolateral-to-apical (10<sup>–6</sup> cm/s).</p></div><div class="footnote" id="t7fn3"><sup><sup>c</sup></sup><p class="last">MDCK–MDR1 human P-gp transfected cell line. P<sub>app(A–B)</sub>: apparent permeability apical-to-basolateral (10<sup>–6</sup> cm/s); ER = B–A/A–B efflux ratio.</p></div><div class="footnote" id="t7fn4"><sup><sup>d</sup></sup><p class="last">DMA/EtOH/PG/water in a 1:1:3:5 ratio was used as a vehicle.</p></div><div class="footnote" id="t7fn5"><sup><sup>e</sup></sup><p class="last"><i>V</i><sub>dss</sub>: 2480 mL/kg, <i>t</i><sub>1/2</sub>: 4.3 h.</p></div><div class="footnote" id="t7fn6"><sup><sup>f</sup></sup><p class="last"><i>V</i><sub>dss</sub>: 2170 mL/kg, <i>t</i><sub>1/2</sub>: 3.6 h.</p></div><div class="footnote" id="t7fn7"><sup><sup>g</sup></sup><p class="last"><i>V</i><sub>dss</sub>: 4870 mL/kg, <i>t</i><sub>1/2</sub>: 3.6 h.</p></div><div class="footnote" id="t7fn8"><sup><sup>h</sup></sup><p class="last"><i>V</i><sub>dss</sub>: 474 mL/kg, <i>t</i><sub>1/2</sub>: 0.1 h.</p></div></div></div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> In Vivo Pharmacology</h3><div class="NLM_p">To assess the ability of compound <b>31</b> to inhibit in vivo tau phosphorylation at disease-relevant sites, two different animal models were utilized: a mouse isoflurane-induced hypothermia model (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) and a rat developmental model (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). In the first model, the in vivo tau phosphorylation was induced by subjecting the animals to an isoflurane anesthesia, which leads to an increase in tau phosphorylation by temperature-dependent inhibition of the phosphatase PP2A.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> This study was performed in wild-type C57Bl/6 mice to ensure that both tau and tau kinases were present at physiological levels. Five minutes prior to the isoflurane treatment, the animals were administered with TTBK1 inhibitor <b>31</b> at a range of concentrations (2.5, 7, 20, 60, and 180 mg/kg; via intraperitoneal (I.P.) administration) and the isoflurane treatment continued for a period of 1 h. This treatment resulted in a 10 degree drop in the body temperature of each animal (there was no difference in body temperature between the compound and vehicle-treated groups), and at the end of the isoflurane treatment, the animals were euthanized and the cortex of each hemisphere was dissected and flash frozen. For each subject, one cortical hemisphere was taken for western blot analysis of tau phosphorylation and one cortical hemisphere was used to determine the levels of compound <b>31</b> in the brain. Total drug in the brain was determined by measuring total compound exposure in cortical tissue via LC–MS/MS and these values were corrected to free concentration using an experimentally derived unbound free fraction value of <b>31</b> in brain tissue. As expected, we observed a substantial increase in tau phosphorylation at the TTBK1 epitope Ser 422 following isoflurane treatment when compared to non-hypothermic control animals (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>; <i>p</i> = 0.0236; unaltered western blot images are available in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00382/suppl_file/jm1c00382_si_001.pdf" class="ext-link">Figure S1</a>). Animals that received 180 mg/kg compound <b>31</b> demonstrated a significant reduction in tau phosphorylation at Ser 422 when compared to vehicle-treated animals (<i>p</i> = 0.0039). In addition, although not statistically significant, there was a trend indicating a dose-responsive effect of compound <b>31</b> on tau phosphorylation levels at Ser 422 (20 mg/kg, 21% decrease and 60 mg/kg, 60% decrease, respectively, in tau phosphorylation at Ser 422 vs vehicle-treated control).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Inhibitor <b>31</b> was administered at 2.5, 7, 20, 60, and 180 mg/kg to 2 month-old, male C57Bl/6 mice (<i>n</i> = 4–6 per group) 5 min prior to isoflurane-induced hypothermia. At the 20, 60, and 180 mg/kg groups, tau phosphorylation at Ser 422 was attenuated relative to non-hypothermic controls. Phosphorylation signal at Ser 422 was normalized to the level of total tau in each sample. Data are represented as the mean +/– SEM. (*<i>p</i> = 0.0236; **<i>p</i> = 0.0039 relative to vehicle). The level of tau phosphorylation at Ser 422 was normalized to the amount of total tau within a sample. To determine the effect of hypothermia on tau phosphorylation levels, an unpaired <i>t</i>-test was run directly comparing animals with or without isoflurane treatment. To determine drug treatment effects, an ordinary one-way ANOVA was used across all groups that underwent hypothermia. A Tukey’s multiple comparisons test was used to look for effects between groups using the vehicle-treated hypothermia group as the control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Inhibitor <b>31</b> was administered at 80 mg/kg (I.P.) to post-natal day 10 rats. Tau phosphorylation at Ser 422 was attenuated at 0.5, 1, 3, and 6 h timepoints. Phosphorylation signal at Ser 422 was normalized to the level of total tau in each sample. Data are represented as the mean +/– SEM. (<i>p</i> = 0.0525, <i>t</i> = 0.5 h; <i>p</i> = 0.004, <i>t</i> = 1 h; <i>p</i> = 0.0019, <i>t</i> = 3 h; <i>p</i> = 0.0021, <i>t</i> = 6 h; <i>p</i> = 0.1552, <i>t</i> = 24 h). A one-way ANOVA was used to look for significance across timepoints. A Tukey’s multiple comparisons test was used to look for effects between groups, using the level of phosphorylation at Ser 422 present at the 0 h timepoint as the control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Due to the biological constraints of maintaining animals in a hypothermic state for long periods of time (maximum time under isoflurane was 1 h), a rat developmental model of tau phosphorylation was also explored. This model relied on the reported observation that, during brain development, tau phosphorylation is significantly elevated at multiple epitopes, including Ser 422, for several weeks after birth (see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00382/suppl_file/jm1c00382_si_001.pdf" class="ext-link">Figure S2</a>). To take advantage of this feature, we designed an experiment to understand the temporal correlation between brain drug exposure and inhibition of tau phosphorylation. In this study, compound <b>31</b> was administered I.P. to post-natal day 10 rats at an 80 mg/kg dose (this dose was selected using the data from a previous hypothermia study, an 80 mg/kg dose was predicted to sustain coverage of the cellular IC<sub>90</sub>). Groups of animals were sacrificed at several timepoints following treatment, and cortical samples from each hemisphere were isolated to determine the tau phosphorylation level and drug concentration in the brain (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>, time: 0.5–24 h; see also Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00382/suppl_file/jm1c00382_si_001.pdf" class="ext-link">Figure S3</a>). Our results demonstrate a significant lowering of tau phosphorylation at Ser 422 within 1 h after administration of compound <b>31</b> (<i>p</i> = 0.0525, <i>t</i> = 0.5 h; <i>p</i> = 0.004, <i>t</i> = 1 h; <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). This effect lasted for longer than 6 h (<i>p</i> = 0.0019, <i>t</i> = 3 h; <i>p</i> = 0.0021, <i>t</i> = 6 h; <i>p</i> = 0.1552, <i>t</i> = 24 h; <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), and tau phosphorylation level returned to baseline 24 h after administration of the TTBK1 inhibitor. Twenty-four hours following compound administration, no detectable levels of <b>31</b> were found in the brain. At this time point, tau phosphorylation at Ser 422 returned to pre-treatment levels, indicating that the observed lowering of tau phosphorylation was due to the effect of compound <b>31</b> and not due to a physiological lowering of tau phosphorylation within the subjects over time.</div><div class="NLM_p last">To exclude the possibility that the effects of compound <b>31</b> on tau phosphorylation could be the result of unseen neuronal toxicity, we tested this inhibitor in vitro at a dose range from 0.0625 to 100 μM. In this experiment, primary mouse neuronal cultures at DIV14 were placed in an Incucyte system (Essen Biosciences) for live-cell imaging at 20× magnification and analysis of neurite branching was used as a surrogate of neuron health. For each dose concentration, a total of eight biological replicates were used and, at each timepoint, five images were captured for each well and values were averaged per well. For all experiments, the addition of 10% triton solution was used as a positive control to show the window of maximal effect for this assay. This experiment demonstrated that, at acute timepoints (up to 1 h following administration), compound <b>31</b> had no effect on neurite length when tested up to 100 μM (see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00382/suppl_file/jm1c00382_si_001.pdf" class="ext-link">Figure S4</a>). To test if this compound had chronic effects on neuron health, we also imaged every 6 h and up to 24 h following treatment. In this second experiment, we observed that compound <b>31</b> did cause a significant decrease in neurite length at the 50 and 100 μM concentrations beginning at 12–18 h following treatment (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00382/suppl_file/jm1c00382_si_001.pdf" class="ext-link">Figure S4</a>). However, it must be noted that, in our in vivo experiments, we saw significant lowering of tau phosphorylation at free drug levels much lower than these neurotoxic values (mouse isoflurane-induced hypothermia, 10 μM; rat developmental model, 5 μM). In addition, in the western blots from the in vivo experiments, we saw no effect of our compound on lowering other neuronal proteins that were used as normalization controls (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00382/suppl_file/jm1c00382_si_001.pdf" class="ext-link">Figure S1</a>, Tau5). Overall, these data demonstrate that inhibition of TTBK1 with the selective inhibitor <b>31</b> led to an acute lowering of tau phosphorylation at Ser 422 in two preclinical animal models and that this effect was due to inhibition of the kinase activity of TTBK1. It is important to note that the Ser 422 epitope was specifically chosen for these studies because it is a direct phosphorylation site of TTBK1 and is not affected by TTBK2 activity in neurons.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> In addition, significant increases in the phosphorylation of tau at Ser 422 are detected early in the disease course of AD<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and the number of tau-Ser 422 immuno-positive neurons correlates with cholinergic neuron loss and cognitive impairment in disease.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The studies presented here demonstrate that the effects of compound <b>31</b> on tau phosphorylation are both dose- and time-dependent and further validate TTBK1 as a potential drug target for the treatment of AD and related tauopathies.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Chemistry</h3><div class="NLM_p">The synthesis of analogs <b>4–7</b> was enabled by the preparation of intermediates <b>35–38</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Specifically, intermediates <b>35</b> and <b>36</b> were accessed from commercially available indole <b>33</b> and indazole <b>34</b> following a tosylation reaction with TsCl in DCM. Intermediate <b>37</b> was synthesized from <b>34</b> by alkylation with MeI and NaOH in THF. In contrast, intermediate <b>38</b> was synthesized from iodoindazole <b>47</b>, which was alkylated by reaction with MeI and NaH in DMF and was subsequently reacted in a Stille reaction with tributyl(1-ethoxyvinyl)stannane and Pd(PPh<sub>3</sub>)<sub>4</sub>. The resulting intermediates <b>35</b>–<b>38</b> were reacted with DMF–DMA at 80–100 °C to provide intermediates <b>39–42</b>, which were converted to the desired aminopyrimidines <b>43–46</b> by treatment with guanidine thiocyanate and NaOEt in hot EtOH. The desired TTBK1 inhibitors <b>4–7</b> were synthesized from <b>43–46</b> under modified Sonogashira coupling conditions (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><figure id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>4</b>–<b>7</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>33</b>, TsCl, NEt<sub>3</sub>, DCM, 16 h, 68%; (b) <b>34</b>, TsCl, NEt<sub>3</sub>, DMAP, DCM, 2 h, 75%; (c) <b>34</b>, NaOH, MeI, THF, 3 h, 91%; (d) NaH, MeI, DMF, 30 °C, 2.5 h, 54%; (e) Tributyl(1-ethoxyvinyl)stannane, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 80 °C, 4 h, 90%; (f) DMF–DMA, 80–100 °C, 3–48 h; (g) Guanidine thiocyanate, NaOEt, EtOH, 80–90 °C, 3–40 h, 55–56% over two steps; (h) 2-Methylbut-3-yn-2-ol, Pd(PPh<sub>3</sub>)<sub>4</sub>, NaI, Zn, NEt<sub>3</sub>, DBU, DMSO, 90 or 100 °C, 16 h, 15–76%.</p></p></figure><div class="NLM_p">Analogs <b>8–15</b> were synthesized from commercially available building blocks <b>49–56</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>; note that compound <b>54</b> can also be prepared in three steps from more readily available 4,6-dichloro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine, see <a href="/doi/suppl/10.1021/acs.jmedchem.1c00382/suppl_file/jm1c00382_si_001.pdf" class="ext-link">Supporting Information</a>). These starting materials were reacted with 4-chloropyrimidin-2-amine in the presence of base to provide intermediates <b>57–63</b> and <b>65</b>. Intermediate <b>63</b> was subjected to an S<sub>N</sub>Ar reaction with morpholine to provide intermediate <b>64</b>, and intermediate <b>66</b> was accessed by a Suzuki reaction of <b>64</b> with cyclopropylboronic acid. The desired analogs <b>8–15</b> were prepared via a modified Sonogashira coupling between 2-methylbut-3-yn-2-ol and intermediates <b>57–62</b>, <b>64</b>, and <b>66,</b> respectively. Analogs <b>18</b> and <b>19</b> were synthesized from intermediates <b>57</b> and <b>58</b>, respectively, using 3-methylpent-1-yn-3-ol and similar coupling conditions.</div><figure id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>8</b>–<b>15</b> and <b>18</b>–<b>19</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>57–62</b>, 4-Chloropyrimidin-2-amine, NaH, DMF, 60–80 °C, 1–18 h, 40–94%; (b) <b>63</b>, 4-Chloropyrimidin-2-amine, DBU, DMF, 140 °C, 2 h; (c) <b>65</b>, 4-Chloropyrimidin-2-amine, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 120 °C, 2 h; (d) Morpholine, DBU, DMF, 150 °C, 12 h, 31%; (e) Cyclopropylboronic acid, Pd(dtbpf)Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, dioxane, 140 °C, 1 h, 52%; (f) 2-Methylbut-3-yn-2-ol, Pd(PPh<sub>3</sub>)<sub>4</sub>, NaI, Zn, NEt<sub>3</sub>, DBU, DMSO, 90 or 100 °C, 1–24 h, 6.5–47%; (g) 3-Methylpent-1-yn-3-ol, NaI, Pd(PPh<sub>3</sub>)<sub>4</sub>, Zn, DBU, Et<sub>3</sub>N, DMSO, 90 or 100 °C; (h) Chiral separation, 34% from <b>57</b>, 15% from <b>58</b>.</p></p></figure><div class="NLM_p">The synthesis of analogs <b>16</b> and <b>17</b> started with azaindole <b>67</b>, which was protected with SEM-Cl and reacted with the corresponding boronic ester to provide intermediates <b>69</b> and <b>70</b>. Subsequent reduction with PtO<sub>2</sub> and deprotection furnished intermediates <b>73</b> and <b>74</b>, which were reacted with 4-chloropyrimidin-2-amine and NaH in hot DMF to provide <b>75</b> and <b>76</b>. Compound <b>76</b> was deprotected with HCl and methylated by reductive amination with formaldehyde and NaCNBH<sub>3</sub>. A subsequent modified Sonogashira reaction with 2-methylbut-3-yn-2-ol provided <b>16</b> and racemic <b>17</b>, which was purified by chiral SFC (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>16</b> and <b>17</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) SEM-Cl, NaH, DMF, 0 °C to rt, 4.5 h, 86%; (b) 2-(3,6-Dihydro-2<i>H</i>-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, Pd(dtbpf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane/water, 110 °C, 1 h, 89%; (c) <i>tert</i>-Butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate, Pd(dppf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane/water, 100 °C, 2 h, 53%; (d) PtO<sub>2</sub>, H<sub>2</sub> (1 atm), EtOAc/EtOH, rt, 3–4 h, 91%; (e) TBAF, ethylene diamine, THF, 60–65 °C, 3 h, 83–86%; (f) <b>73</b>, 4-Chloropyrimidin-2-amine, NaH, DMF, 110 °C, 40 min, 73%; (g) <b>74</b>, 4-Chloropyrimidin-2-amine, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 90 °C, 4 h, 80%; (h) HCl, EtOAc, rt, 2 h; (i) Formaldehyde, NaCNBH<sub>3</sub>, MeOH, rt, 2 h, 35% over 2 steps; (j) 2-Methyl-3-yn-2-ol, Pd(PPh<sub>3</sub>)<sub>4</sub>, NaI, Zn, Et<sub>3</sub>N, DBU, DMSO, 95 °C, 5–20 h, 29–45%; (k) Chiral separation.</p></p></figure><div class="NLM_p">The synthesis of analogs <b>20</b> and <b>21</b> started with compound <b>8</b>, which was treated with Red-Al to furnish <b>20</b> or with H<sub>2</sub> and Pd/C to provide analog <b>21</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). Compounds <b>22</b> and <b>23</b> were synthesized from intermediate <b>57</b>, which was treated with 3-methylazetidin-3-ol and SPhos third-generation precatalyst in the presence of <i>t</i>-BuONa to provide <b>22</b>, or with (4-hydroxyphenyl)boronic acid in the presence of Pd(dppf)Cl<sub>2</sub> to give <b>23</b>.</div><figure id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0014.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>18</b>–<b>21</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Red-Al, THF, 0 °C to rt, 14 h, 16.7%; (b) H<sub>2</sub>, Pd/C, MeOH, 1 h, 57%; (c) 3-Methylazetidin-3-ol, SPhos-Pd-G3, <i>t</i>-BuONa, dioxane, 90 °C, 17 h, 8%; (d) (4-Hydroxyphenyl)boronic acid, Pd(dppf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane/water, 90 °C, 17 h, 57%.</p></p></figure><div class="NLM_p">The synthesis of compound <b>24</b> was carried out by treating alkyne <b>9</b> with Red-Al to provide the desired <i>trans</i>-alkene (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). Analog <b>25</b> was synthesized starting with intermediate <b>58</b>, which was reacted under Pd-mediated coupling conditions with ethyl 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopropane-1-carboxylate to furnish intermediate <b>78</b>. Subsequent reaction with excess MeLi provided compound <b>25</b>. The synthesis of <b>26</b> started with commercially available ketone <b>79,</b> which was reacted with 4-methylbenezenesulfonohydrazide to provide the tosyl hydrazone <b>80</b>. This intermediate was then reacted with <b>58</b> under Pd-mediated conditions to afford cyclobutene intermediate <b>81</b>. Grignard reaction of <b>81</b> with excess MeMgBr provided <b>82</b>, which was hydrogenated to provide the desired analog <b>26</b>. The synthesis of bicyclopentane <b>27</b> started with commercially available intermediate <b>83</b>, which underwent S<sub>N</sub>Ar reaction with 4-chloropyrimidin-2-amine after deprotonation with NaH in DMF. Subsequent reaction of <b>84</b> with excess MeMgBr provided compound <b>27</b>.</div><figure id="sch5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0015.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>24</b>–<b>27</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Red-Al, THF, 0 °C to rt, 16 h, 92%; (b) Ethyl 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopropane-1-carboxylate, Pd(dtbpf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 100 °C, 6 h, 18%; (c) MeLi, THF, −78 °C, 4 h, 37%; (d) 4-Methylbenzenesulfonohydrazide, MeOH, 2 h, 86%; (e) <b>80</b>, Pd(MeCN)<sub>2</sub>Cl<sub>2</sub>, dppp, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 95 °C, 20 h, 21%; (f) MeMgBr, THF, 1 h, 29%; (g) H<sub>2</sub>, Pd/C, MeOH, EtOAc, 16 h, 75%; (h) 4-Chloropyrimidin-2-amine, NaH, DMF; (i) TMSCHN<sub>2</sub>, MeOH, DCM, 1.5 h; (j) MeMgBr, THF, 1 h, 15% from <b>83</b>.</p></p></figure><div class="NLM_p">The synthesis of compounds <b>28–32</b> followed the general synthetic route described in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>. Indole <b>50</b> or indoline <b>51</b> was treated under S<sub>N</sub>Ar conditions with the corresponding chloroheteroaryl electrophile to provide intermediates <b>85–89</b> (note that intermediate <b>85</b> was isolated as a productive side product (forming via the oxidation of the azaindoline core to the azaindole core) during the S<sub>N</sub>Ar reaction of <b>51</b> with 4-chloro-<i>N</i>-methylpyrimidin-2-amine). These intermediates were coupled with the corresponding alkynes under modified Sonogashira conditions to provide the desired analogs <b>28–32</b>.</div><figure id="sch6" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0016.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>28</b>–<b>32</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, DMF, rt to 70 °C, 13–87%; (b) NaI, Pd(PPh<sub>3</sub>)<sub>4</sub>, Zn, DBU, NEt<sub>3</sub>, DMSO, 100 °C, 2–14 h; (c) Chiral separation, 1.7–48%.</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70667" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70667" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">TTBK1 is a CNS-specific kinase that has been implicated in the pathological phosphorylation of tau in AD and frontotemporal dementia (FTD). A systematic search of the off-target activity of known kinase inhibitors led to the identification of the NIK inhibitor <b>3</b>, which served as a suitable starting point in our TTBK1 inhibitor program. An X-ray cocrystal structure of <b>3</b> bound to the kinase domain of TTBK1 guided the initial optimization of this series of analogs. Specifically, we hypothesized that truncation of the heptadiene ring in <b>3</b> and introduction of a nitrogen atom instead of C5 of the indole would lead to compounds with improved profile (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). This hypothesis was confirmed by analog <b>7</b>, which had good TTBK1 activity in both biochemical and cellular assays. The high ER (19) of compound <b>7</b> was partially addressed by the synthesis of the regioisomeric azaindazole <b>8</b> (ER: 5.5). Subsequent optimization of both the 5,6-fused heterocyclic core and the substituents projected to the back pocket of the protein led to the discovery of the potent TTBK1 inhibitors <b>18</b> and <b>19</b>, which showed high levels of cytotoxicity. This liability was mitigated by C6 substitution of the aminopyrimidine hinge binder leading to inhibitor <b>31</b>, a potent (cell IC<sub>50</sub>: 315 nM) and brain-penetrant (rat K<sub>p,uu</sub>: 0.32) TTBK1 inhibitor with a suitable profile for in vivo proof of pharmacology studies. The ability of <b>31</b> to inhibit tau phosphorylation at a therapeutically relevant epitope (Ser 422) was established in both a mouse isoflurane-induced hypothermia model and in a rat developmental model. It is important to note that the advancement of TTBK1 inhibitors to clinical development may require some level of selectivity against TTBK2 given that mutations in this gene have been linked to the development of spinocerebellar ataxia type 11<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and knockout of TTBK2 in the postnatal mouse brain leads to progressive degeneration of the cerebellum.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Overall, we have demonstrated that inhibition of TTBK1 with the selective inhibitor <b>31</b> is a viable strategy to modulate the phosphorylation of tau at disease-relevant epitopes although additional studies are needed before a suitable TTBK inhibitor can be progressed to the clinic as a potential treatment of Alzheimer’s disease and related tauopathies.</div><figure id="fig9" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Summary of identification and optimization of novel TTBK1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03667" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03667" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All solvents and chemicals used were reagent grade. Anhydrous solvents were purchased from Sigma-Aldrich and used as received. Analytical thin layer chromatography (TLC) and silica gel column chromatography were performed on Merck silica gel 60 (230–400 mesh). Aqueous ammonium hydroxide (NH<sub>4</sub>OH) used for chromatography and TMT solution were purchased from Fisher (supplier item A669S500, 28–30% w/w ammonia). Removal of solvents was conducted by using a rotary evaporator, and residual solvents were removed from non-volatile compounds using a vacuum manifold maintained at approximately 1 Torr. NMR spectra were recorded on a Bruker Avance 400 MHz and 500 MHz NMR spectrometer. Chemical shifts (δ) are reported in parts per million (ppm) relative to a residual undeuterated solvent as an internal reference, and coupling constants (<i>J</i>) are reported in hertz (Hz). Splitting patterns are indicated as follows: s = singlet; d = doublet; t = triplet; q = quartet; qn = quintet; dd = doublet of doublets; dt = doublet of triplets; tt = triplet of triplets; m = multiplet; br = broad peak. All yields reported are isolated yields. All final compounds were purified to ≥95% purity as determined by LC/MS analysis using one of the following three methods. Method 1: using a linear gradient of elution: 90% water (containing 0.1% v/v of TFA)/10% MeCN (containing 0.1% v/v of TFA) to 10% water (containing 0.1% v/v of TFA)/90% MeCN (containing 0.1% v/v of TFA) for 2 min and then holding at 10% water (containing 0.1% v/v of TFA) and 90% MeCN (containing 0.1% v/v of TFA) up to 3 min at a flow rate of 3 mL/min (injection volume 5 μL and using a Waters Sunfire C18 4.6 × 20 mm × 3.5 μm IS column). MS mode: MS:ESI+ scan range 100–1000 daltons. PDA detection 210–400 nm. Method 2 (acidic condition): mobile phase prepared with 1.5 mL of TFA in 4 L of water (solvent A) and acetonitrile (solvent B), using the elution gradient 10–80% (solvent B) over 1.35 min and holding at 80% for 0.9 min at a flow rate of 0.8 mL/min; column: Xtimate C18 2.1 × 30 mm × 3 μm; detection wavelength: 220 nm and 254 nm; column temperature: 50 °C; MS mode: MS:ESI+. Method 3 (basic condition): mobile phase prepared with 0.8 mL of aq NH<sub>4</sub>OH in 4 L of water (solvent A) and acetonitrile (solvent B), using the elution gradient 10–80% (solvent B) over 2 min and holding at 80% for 0.48 min at a flow rate of 1.2 mL/min; column: Xbridge Shield RP-18 2.1 × 50 mm × 5 μm; detection wavelength: 220 and 254 nm; column temperature: 50 °C; MS mode: MS:ESI+. Trithiocyanuric acid (TMT) solution for sequestering palladium catalyst was prepared as follows: NaCl (14.0 g) was dissolved in water (250 mL), and then trithiocyanuric acid (1.80 g, CAS #638-16-4), EtOH (200 mL), and aq NH<sub>4</sub>OH (15 mL, to improve the solubility of TMT) were added. The mixture was sonicated for 15 min before further EtOH (240 mL) was added.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Procedure 1 for the Preparation of Compounds <b>4</b>–<b>19</b> and <b>28</b>–<b>32</b>: Heteroaryl Halide–Alkyne Cross-Coupling Reaction</h3><div class="NLM_p">Under an atmosphere of nitrogen, a mixture of heteroaryl halide <b>43–46</b>, <b>57–62</b>, <b>64</b>, <b>65</b>, or <b>85–89</b> (1 equiv), alkyne (2-methylbut-3-yn-2-ol or 3-methylpent-1-yn-3-ol, 1.00–10.0 equiv), Pd(PPh<sub>3</sub>)<sub>4</sub> (20.0 mol %), NaI (20.0 mol %), DBU (2.00 equiv, unless otherwise noted), triethylamine (2.00 equiv, unless otherwise noted), and Zn powder (20.0 mol %) in DMSO was stirred at 90 or 100 °C for an indicated period of time. The reaction suspension was cooled to room temperature, filtered, and purified by prep-HPLC or was subjected to an aqueous workup followed by prep-HPLC to provide the title compounds.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 4-(3-(2-Aminopyrimidin-4-yl)-1<i>H</i>-indol-5-yl)-2-methylbut-3-yn-2-ol (<b>4</b>)</h4><div class="NLM_p last">The reaction was carried out according to general procedure 1 using <b>43</b> (70.0 mg, 250 μmol) and 2-methylbut-3-yn-2-ol (48 μL, 500 μmol) in 3.0 mL of DMSO at 100 °C for 16 h. The reaction was filtered. Prep-HPLC purification (column: Xtimate C18 150 × 30 mm × 5 μm; gradient: MeCN/water (10 mM NaHCO<sub>3</sub>), 29–59%, 25 mL/min) afforded the title compound (45.0 mg, 64%) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 8.65 (s, 1H), 8.35 (s, 1H), 8.01 (d, <i>J</i> = 6.6 Hz, 1H), 7.44 (d, <i>J</i> = 8.6 Hz, 1H), 7.30 (dd, <i>J</i> = 8.4, 1.5 Hz, 1H), 7.24 (br d, <i>J</i> = 6.2 Hz, 1H), 1.60 (s, 6H). MS (ESI): 293.1 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>17</sub>H<sub>16</sub>N<sub>4</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 293.1397. Found: 293.1397.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 4-(3-(2-Aminopyrimidin-4-yl)-1<i>H</i>-indazol-5-yl)-2-methylbut-3-yn-2-ol (<b>5</b>)</h4><div class="NLM_p last">The reaction was carried out according to general procedure 1 using <b>44</b> (100 mg, 330 μmol) and 2-methylbut-3-yn-2-ol (64 μL, 660 μmol) in 3.0 mL of DMSO at 90 °C for 16 h. The reaction was filtered. Prep-HPLC purification (column: Xtimate C18 150 × 25 mm × 5 μm; gradient: MeCN/water (10 mM NH<sub>4</sub>HCO<sub>3</sub>), 24–54%, 25 mL/min) afforded the title compound (15.0 mg, 15%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.67 (dd, <i>J</i> = 1.4, 0.8 Hz, 1H), 8.29 (d, <i>J</i> = 5.1 Hz, 1H), 7.60 (dd, <i>J</i> = 8.7, 0.7 Hz, 1H), 7.39 (dd, <i>J</i> = 8.6, 1.5 Hz, 1H), 7.27 (d, <i>J</i> = 5.1 Hz, 1H), 6.79 (s, 2H), 6.05 (br s, 1H), 5.45 (br s, 1H), 1.52 (s, 6H). MS (ESI): 294.0 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>16</sub>H<sub>15</sub>N<sub>5</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 294.1350. Found: 294.1352.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 4-(3-(2-Aminopyrimidin-4-yl)-1-methyl-1<i>H</i>-indazol-5-yl)-2-methylbut-3-yn-2-ol (<b>6</b>)</h4><div class="NLM_p last">The reaction was carried out according to general procedure 1 using <b>45</b> (100 mg, 330 μmol) and 2-methylbut-3-yn-2-ol (64 μL, 660 μmol) in 3.0 mL of DMSO at 90 °C for 16 h. The reaction was filtered. Prep-HPLC purification (column: Xtimate C18 150 × 25 mm × 5 μm; gradient: MeCN/water (10 mM NH<sub>4</sub>HCO<sub>3</sub>), 27–57%, 25 mL/min) afforded the title compound (42.0 mg, 42%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.66 (d, <i>J</i> = 0.6 Hz, 1H), 8.28 (d, <i>J</i> = 5.1 Hz, 1H), 7.72 (dd, <i>J</i> = 8.7, 0.6 Hz, 1H), 7.44 (dd, <i>J</i> = 8.7, 1.6 Hz, 1H), 7.21 (d, <i>J</i> = 5.1 Hz, 1H), 6.79 (s, 2H), 6.05 (br s, 1H), 4.14 (s, 3H), 1.51 (s, 6H). MS (ESI): 308.1 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>17</sub>H<sub>17</sub>N<sub>5</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 308.1506. Found: 308.1505.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 4-(3-(2-Aminopyrimidin-4-yl)-1-methyl-1<i>H</i>-pyrazolo[3,4-<i>c</i>]pyridin-5-yl)-2-methylbut-3-yn-2-ol (<b>7</b>)</h4><div class="NLM_p last">The reaction was carried out according to general procedure 1 using <b>46</b> (27.0 mg, 100 μmol) and 2-methylbut-3-yn-2-ol (20 μL, 210 μmol) in 3.0 mL of DMSO at 100 °C for 16 h. Reaction was filtered. Prep-HPLC purification (column: Xtimate C18 150 × 25 mm × 5 μm; gradient: MeCN/water (10 mM NH<sub>4</sub>HCO<sub>3</sub>), 15–45%, 25 mL/min) afforded the title compound (8.0 mg, 76%) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 9.04 (d, <i>J</i> = 1.2 Hz, 1H), 8.71 (s, 1H), 8.28 (d, <i>J</i> = 5.2 Hz, 1H), 7.39 (d, <i>J</i> = 5.2 Hz, 1H), 4.28 (s, 3H), 1.62 (s, 6H). MS (ESI): 309.1 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>16</sub>H<sub>16</sub>N<sub>6</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 309.1459. Found: 309.1456.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 4-(1-(2-Aminopyrimidin-4-yl)-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-6-yl)-2-methylbut-3-yn-2-ol (<b>8</b>)</h4><div class="NLM_p last">The reaction was carried out according to general procedure 1 using <b>57</b> (65.0 mg, 250 μmol) and 2-methylbut-3-yn-2-ol (48 μL, 500 μmol) in 3.0 mL of DMSO at 100 °C for 16 h. Reaction was filtered. Prep-HPLC purification (column: Waters Xbridge Prep OBD C18 150 × 30 mm × 5 μm; gradient: MeCN/water (0.050 M NH<sub>4</sub>OH), 18–48%, 25 mL/min) afforded the title compound as a white solid (9.0 mg, 12%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 9.06 (d, <i>J</i> = 1.1 Hz, 1H), 8.93 (s, 1H), 8.51 (d, <i>J</i> = 0.9 Hz, 1H), 8.31 (d, <i>J</i> = 5.7 Hz, 1H), 7.27 (d, <i>J</i> = 5.5 Hz, 1H), 1.63 (s, 6H). MS (ESI): 295.0 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>15</sub>H<sub>14</sub>N<sub>6</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 295.1302. Found: 295.1305.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 4-(1-(2-Aminopyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-2-methylbut-3-yn-2-ol (<b>9</b>)</h4><div class="NLM_p last">The reaction was carried out according to general procedure 1 using <b>58</b> (50.0 mg, 204 μmol) and 2-methylbut-3-yn-2-ol (79 μL, 816 μmol) in 2.0 mL of DMSO at 100 °C for 12 h. EtOAc (20 mL) and water (20 mL) were added. The aqueous layer was separated and extracted with EtOAc (20 mL × 2). The combined organic layers were washed with brine (10 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The reaction was repeated (same scale), and the crude residues from the two reactions were combined and subjected to prep-HPLC purification (column: Xtimate C18 150 × 25 mm × 5 μm; gradient: MeCN/water (10 mM NH<sub>4</sub>HCO<sub>3</sub>), 20–50%, 25 mL/min) to afford the title compound (15.0 mg, 13%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.85 (d, <i>J</i> = 0.8 Hz, 1H), 8.64 (d, <i>J</i> = 0.8 Hz, 1H), 8.34 (d, <i>J</i> = 5.2 Hz, 1H), 8.21 (d, <i>J</i> = 3.6 Hz, 1H), 7.10–7.09 (m, 2H), 6.99 (d, <i>J</i> = 5.6 Hz, 1H), 6.95–6.93 (m, 1H), 5.53 (s, 1H) 1.52 (s, 6H). MS (ESI): 294.2 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>16</sub>H<sub>15</sub>N<sub>5</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 294.1350. Found: 294.1350.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 4-(1-(2-Aminopyrimidin-4-yl)-2,3-dihydro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-2-methylbut-3-yn-2-ol (<b>10</b>)</h4><div class="NLM_p last">The reaction was carried out according to general procedure 1 using <b>59</b> (100 mg, 410 μmol) and 2-methylbut-3-yn-2-ol (78 μL, 810 μmol) in 2.0 mL of DMSO at 100 °C for 17 h. The reaction was filtered. Prep-HPLC purification (column: Xtimate C18 150 × 25 mm × 5 μm; gradient: MeCN/water (10 mM NH<sub>4</sub>HCO<sub>3</sub>), 13–43%, 25 mL/min) afforded the title compound (42.0 mg, 36%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.31 (s, 1H), 8.21 (s, 1H), 8.06 (d, <i>J</i> = 5.6 Hz, 1H), 6.58 (s, 2H), 6.10 (d, <i>J</i> = 5.6 Hz, 1H), 5.52 (s, 1H), 4.02 (t, <i>J</i> = 8.4 Hz, 2H), 3.19 (t, <i>J</i> = 8.0 Hz, 2H), 1.49 (s, 6H). MS (ESI): 295.9 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>16</sub>H<sub>17</sub>N<sub>5</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 296.1506. Found: 296.1508.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 4-(1-(2-Aminopyrimidin-4-yl)-5-methoxy-1<i>H</i>-indol-6-yl)-2-methylbut-3-yn-2-ol (<b>11</b>)</h4><div class="NLM_p last">The reaction was carried out according to general procedure 1 using <b>60</b> (60.0 mg, 188 μmol) and 2-methylbut-3-yn-2-ol (37 μL, 380 μmol) in 2.0 mL of DMSO at 100 °C for 1 h. The mixture was diluted with water (5 mL) and extracted with EtOAc (10 mL × 3). The organic layers were combined and concentrated. The crude product was purified by prep-HPLC (column: Xtimate C18 150 × 25 mm × 5 μm; gradient: MeCN/water (10 mM NH<sub>4</sub>HCO<sub>3</sub>), 35–65%, 25 mL/min) to afford the title compound (7.3 mg, 12%) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 8.69 (s, 1H), 8.19 (d, <i>J</i> = 6.0 Hz, 1H), 7.88 (d, <i>J</i> = 3.5 Hz, 1H), 7.14 (s, 1H), 6.85 (d, <i>J</i> = 6.0 Hz, 1H), 6.68 (d, <i>J</i> = 3.5 Hz, 1H), 3.89 (s, 3H), 1.61 (s, 6H). MS (ESI): 323.1 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>18</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub> + H<sup>+</sup> [M + H]<sup>+</sup>: 323.1503. Found: 323.1506.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 4-(1-(2-Aminopyrimidin-4-yl)-5-fluoro-1<i>H</i>-indol-6-yl)-2-methylbut-3-yn-2-ol (<b>12</b>)</h4><div class="NLM_p last">The reaction was carried out according to general procedure 1 using <b>61</b> (50.0 mg, 163 μmol) and 2-methylbut-3-yn-2-ol (78 μL, 810 μmol) in 8.0 mL of DMSO at 100 °C for 5 h. The mixture was diluted with water (20 mL) and extracted with EtOAc (30 mL × 4). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude product was purified by prep-HPLC (column: Xtimate C18 150 × 25 mm × 5 μm; gradient: MeCN/water (10 mM NH<sub>4</sub>HCO<sub>3</sub>), 26–56%, 25 mL/min) to afford the title compound (6.0 mg, 12%) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.77 (d, <i>J</i> = 6.8 Hz, 1H), 8.28 (d, <i>J</i> = 5.6 Hz, 1H), 8.18 (d, <i>J</i> = 3.6 Hz, 1H), 7.48 (d, <i>J</i> = 9.6 Hz, 1H), 6.99 (s, 2H), 6.93 (d, <i>J</i> = 5.6 Hz, 1H), 6.77 (d, <i>J</i> = 3.6 Hz, 1H), 5.52 (s, 1H), 1.54 (s, 6H). MS (ESI): 311.0 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>17</sub>H<sub>15</sub>FN<sub>4</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 311.1303. Found: 311.1306.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 4-(1-(2-Aminopyrimidin-4-yl)-4-methoxy-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-2-methylbut-3-yn-2-ol (<b>13</b>)</h4><div class="NLM_p last">The reaction was carried out according to general procedure 1 using <b>62</b> (14.0 mg, 51.0 μmol) and 2-methylbut-3-yn-2-ol (25 μL, 263 μmol) in 500 μL of DMSO at 90 °C for 16 h. The reaction was filtered. Prep-HPLC purification (column: Waters XSelect CSH C18 OBD 100 × 50 mm × 5 μm; gradient: MeCN/water (0.2% v/v NH<sub>4</sub>OH), 5–70%, 25 mL/min) afforded the title compound (1.0 mg, 6.5%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 8.32 (s, 1H), 8.29 (d, <i>J</i> = 5.77 Hz, 1H), 7.87 (d, <i>J</i> = 3.51 Hz, 1H), 6.90 (d, <i>J</i> = 5.77 Hz, 1H), 6.79 (d, <i>J</i> = 3.51 Hz, 1H), 4.05 (s, 3H), 1.61 (s, 6H). MS (ESI): 324.2 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>17</sub>H<sub>17</sub>N<sub>5</sub>O<sub>2</sub> + H<sup>+</sup> [M + H]<sup>+</sup>: 324.1455. Found: 324.1457.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 4-(1-(2-Aminopyrimidin-4-yl)-4-morpholino-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-2-methylbut-3-yn-2-ol (<b>14</b>)</h4><div class="NLM_p last">The reaction was carried out according to general procedure 1 using <b>64</b> (37.0 mg, 112 μmol), 2-methylbut-3-yn-2-ol (44 μL, 450 μmol), DBU (67 μL, 450 μmol), and triethylamine (62 μL, 480 μmol) in 1.0 mL of DMSO at 90 °C for 12 h. The mixture was filtered through Celite and diluted with DCM (5 mL). The organic phase was washed with water (2 mL) and brine (2 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude product was purified by prep-HPLC (column: Waters XSelect CSH Prep C18 OBD 100 × 50 mm × 5 μm; gradient: MeCN/water (0.2% v/v NH<sub>4</sub>OH), 5–65%, 80 mL/min) to afford the title compound (20.0 mg, 47%) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 8.28 (d, <i>J</i> = 6.1 Hz, 1H), 8.21 (s, 1H), 7.85 (d, <i>J</i> = 4.3 Hz, 1H), 6.87 (d, <i>J</i> = 6.1 Hz, 1H), 6.84 (d, <i>J</i> = 3.7 Hz, 1H), 3.90–3.83 (m, 4H), 3.60–3.55 (m, 4H), 1.60 (s, 6H). MS (ESI): 379.2 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>20</sub>H<sub>22</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup> [M + H]<sup>+</sup>: 379.1877. Found: 379.1873.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 4-(1-(2-Aminopyrimidin-4-yl)-3-cyclopropyl-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-2-methylbut-3-yn-2-ol (<b>15</b>)</h4><div class="NLM_p last">The reaction was carried out according to general procedure 1 using <b>66</b> (20.0 mg, 70.0 μmol), 2-methylbut-3-yn-2-ol (27 μL, 280 μmol), DBU (42 μL, 280 μmol), and triethylamine (39 μL, 280 μmol) in 700 μL of DMSO at 90 °C for 16 h. The reaction was filtered. Prep-HPLC purification (column: Waters XSelect CSH Prep OBD C18 100 × 19 mm × 5 μm; gradient: MeCN/water (0.2% v/v NH<sub>4</sub>OH), 5–55%, 30 mL/min) afforded the title compound (8.0 mg, 34%) as a white solid. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ ppm 8.85 (s, 1H), 8.76 (s, 1H), 8.26 (d, <i>J</i> = 6.1 Hz, 1H), 7.73 (s, 1H), 6.89 (d, <i>J</i> = 6.1 Hz, 1H), 2.10–2.01 (m, 1H), 1.62 (s, 6H), 1.07–0.99 (m, 2H), 0.82–0.74 (m, 2H). MS (ESI): 334.3 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>19</sub>H<sub>19</sub>N<sub>5</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 334.1663. Found: 334.1661.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 4-(1-(2-Aminopyrimidin-4-yl)-3-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-2-methylbut-3-yn-2-ol (<b>16</b>)</h4><div class="NLM_p last">The reaction was carried out according to general procedure 1 using <b>75</b> (25.0 mg, 80.0 μmol), 2-methylbut-3-yn-2-ol (29 μL, 303 μmol), DBU (45 μL, 300 μmol), and triethylamine (29 μL, 300 μmol) in 760 μL of DMSO at 95 °C for 5 h. The reaction was filtered. Prep-HPLC purification (column: XSELECT CSH C18 100 × 50 mm × 5 μm; gradient: MeCN/water (0.2% v/v NH<sub>4</sub>OH), 5–60%, 25 mL/min) afforded the title compound (13.0 mg, 45%). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ ppm 8.86 (s, 1H), 8.78 (s, 1H), 8.29 (d, <i>J</i> = 6.1 Hz, 1H), 7.86 (s, 1H), 6.94 (d, <i>J</i> = 6.1 Hz, 1H), 4.08 (dd, <i>J</i> = 3.7, 10.4 Hz, 2H), 3.67 (dt, <i>J</i> = 1.8, 11.9 Hz, 2H), 3.23 (tt, <i>J</i> = 3.7, 11.6 Hz, 1H), 2.05–1.99 (m, 2H), 1.95–1.84 (m, 2H), 1.62 (s, 6H). MS (ESI): 378.2 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>21</sub>H<sub>23</sub>N<sub>5</sub>O<sub>2</sub> + H<sup>+</sup> [M + H]<sup>+</sup>: 378.1925. Found: 378.1922.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (<i>S</i>)-4-(1-(2-Aminopyrimidin-4-yl)-3-(1-methylpiperidin-3-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-2-methylbut-3-yn-2-ol (<b>17</b>)</h4><div class="NLM_p last">Step 1: The reaction was carried out according to general procedure 1 using <b>77</b> (120 mg, 350 μmol), 2-methylbut-3-yn-2-ol (338 μL, 3.50 mmol), and triethylamine (150 μL, 1.05 mmol) in 8.5 mL of DMSO at 95 °C for 20 h. The mixture was diluted with water (10 mL) and extracted with EtOAc (15 mL × 3). The combined organic layers were washed with brine (40 mL × 3), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude product was purified by prep-TLC (1:10 MeOH/DCM) to afford <i>rac</i>-4-(1-(2-aminopyrimidin-4-yl)-3-(1-methylpiperidin-3-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-2-methylbut-3-yn-2-ol as a brown oil (40.0 mg, 29%). MS (ESI): 391.0 [M + H]<sup>+</sup>. Step 2: Chiral separation of racemic product from step 1 was performed using the following column: DAICEL CHIRALPAK AD-H (250 × 30 mm × 5 μm); method: 40% EtOH with 0.1% NH<sub>4</sub>OH in CO<sub>2</sub> (flow rate: 50 mL/min). The first peak eluting off the column provided (<i>R</i>)-4-(1-(2-aminopyrimidin-4-yl)-3-(1-methylpiperidin-3-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-2-methylbut-3-yn-2-ol (the enantiomer of <b>17</b>) as an off-white solid in 100% ee (Rt = 6.050 min, 18.8 mg, 29%, <sup>1</sup>H NMR and MS identical to <b>17</b>). The second peak furnished (<i>S</i>)-4-(1-(2-aminopyrimidin-4-yl)-3-(1-methylpiperidin-3-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-2-methylbut-3-yn-2-ol <b>17</b> as an off-white solid in 99.5% ee (Rt = 6.749 min, 18.0 mg, 28%). The stereochemistry was arbitrarily assigned. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.89 (d, <i>J</i> = 0.8 Hz, 1H), 8.39 (d, <i>J</i> = 1.2 Hz, 1H), 8.35 (d, <i>J</i> = 5.2 Hz, 1H), 7.52 (s, 1H), 6.71 (d, <i>J</i> = 6.0 Hz, 1H), 5.25 (s, 2H), 3.25–3.18 (m, 1H), 3.14–3.11 (m, 1H), 2.91–2.88 (m, 1H), 2.34 (s, 3H), 2.11–2.08 (m, 2H), 2.02–2.01 (m, 1H), 1.85–1.80 (m, 2H), 1.68 (s, 6H), 1.54–1.50 (m, 1H). LCMS (ESI, m/z): 391.0 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>22</sub>H<sub>26</sub>N<sub>6</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 391.2241. Found: 391.2244.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (<i>S</i>)-1-(1-(2-Aminopyrimidin-4-yl)-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-6-yl)-3-methylpent-1-yn-3-ol (<b>18</b>)</h4><div class="NLM_p last">Step 1: The reaction was carried out according to general procedure 1 using <b>57</b> (1.40 g, 5.68 mmol), 3-methylpent-1-yn-3-ol (1.3 mL, 11.4 mmol), and triethylamine (2.4 mL, 17.0 mmol) in 15.0 mL of DMSO at 100 °C for 5 h. The mixture was diluted with water (50 mL) and extracted with EtOAc (15 mL × 3). The combined organic layers were concentrated under reduced pressure. The crude product was purified by column chromatography (SiO<sub>2</sub>, gradient: 20–50% EtOAc/petroleum ether) to afford <i>rac</i>-1-(1-(2-aminopyrimidin-4-yl)-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-6-yl)-3-methylpent-1-yn-3-ol as a yellow solid with some impurities (2.00 g). MS (ESI): 309.1 [M + H]<sup>+</sup>. Step 2: Chiral separation of racemic product from step 1 was performed using the following column<b>:</b> Phenomenex-Cellulose-2 (250 × 30 mm × 5 μm); method: 40% IPA with 0.1% NH<sub>4</sub>OH in CO<sub>2</sub> (flow rate: 60 mL/min). The first peak eluting off the column provided (<i>R</i>)-1-(1-(2-aminopyrimidin-4-yl)-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-6-yl)-3-methylpent-1-yn-3-ol (the enantiomer of <b>18</b>) as a yellow solid in 97.3% ee (Rt = 2.620 min, 656 mg, 37% over two steps. <sup>1</sup>H NMR and MS identical to <b>18</b>). The second peak furnished (<i>S</i>)-1-(1-(2-aminopyrimidin-4-yl)-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-6-yl)-3-methylpent-1-yn-3-ol <b>18</b> as a yellow solid in 100% ee (Rt = 3.455, 595 mg, 34% over two steps). Stereochemistry arbitrarily assigned. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 9.06 (d, <i>J</i> = 0.8 Hz, 1H), 8.92 (s, 1H), 8.51 (d, <i>J</i> = 0.8 Hz, 1H), 8.31 (d, <i>J</i> = 5.6 Hz, 1H), 7.27 (d, <i>J</i> = 5.6 Hz, 1H), 1.89–1.80 (m, 2H), 1.59 (s, 3H), 1.15 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (126 MHz, CD<sub>3</sub>OD) δ ppm 164.6, 161.8, 160.6, 146.3, 143.5, 140.4, 139.6, 123.9, 115.1, 99.6, 95.4, 83.3, 69.6, 37.5, 29.2, 9.4. LCMS (ESI, m/z): 309.1 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>16</sub>H<sub>16</sub>N<sub>6</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 309.1459. Found: 309.1462.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (<i>S</i>)-1-(1-(2-Aminopyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-3-methylpent-1-yn-3-ol (<b>19</b>)</h4><div class="NLM_p last">Step 1: The reaction was carried out according to general procedure 1 using <b>58</b> (100 mg, 407 μmol) and 3-methylpent-1-yn-3-ol (184 μL, 1.63 mmol) in 2.0 mL of DMSO at 100 °C for 18 h. TMT solution (1 mL) was added, the mixture was stirred at room temperature for 30 min and filtered. EtOAc (30 mL) and water (30 mL) were added. The aqueous layer was separated and extracted with EtOAc (20 mL × 2). The combined organic layers were concentrated under reduced pressure. The crude product was purified by prep-HPLC (column: Xtimate C18 150 × 25 mm × 5 μm; gradient: MeCN/water (10 mM NH<sub>4</sub>HCO<sub>3</sub>), 24–64%, 25 mL/min) to afford <i>rac</i>-1-(1-(2-aminopyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-3-methylpent-1-yn-3-ol as a white solid (50.0 mg, 40%). MS (ESI): 308.1 [M + H]<sup>+</sup>. Step 2: Chiral separation of racemic product from step 1 was performed using the following column<b>:</b> C2 (250 × 30 mm × 10 μm); method: 40% EtOH with 0.1% NH<sub>4</sub>OH in CO<sub>2</sub> (flow rate: 80 mL/min, detection wavelength: 220 nm). The first peak eluting off the column provided (<i>R</i>)-1-(1-(2-aminopyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-3-methylpent-1-yn-3-ol (the enantiomer of <b>19</b>) as a white solid in 100% ee (Rt = 6.637 min, 25.2 mg, 50%, <sup>1</sup>H NMR and MS identical to <b>19</b>). The second peak furnished (<i>S</i>)-1-(1-(2-aminopyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-3-methylpent-1-yn-3-ol <b>19</b> as a white solid in 99.5% ee (Rt = 6.433 min, 18.7 mg, 37%). Stereochemistry arbitrarily assigned. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.88 (d, <i>J</i> = 1.2 Hz, 1H), 8.44 (s, 1H), 8.37 (d, <i>J</i> = 5.6 Hz, 1H), 7.73 (d, <i>J</i> = 4.0 Hz, 1H), 6.80–6.78 (m, 1H), 6.74 (d, <i>J</i> = 5.6 Hz, 1H), 5.31 (s, 2H), 2.60 (s, 1H), 1.87–1.83 (m, 2H), 1.64 (s, 3H), 1.15 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ ppm 163.0, 160.2, 158.7, 144.1, 139.0, 136.2, 126.8, 126.6, 113.7, 106.3, 100.1, 91.4, 84.0, 69.1, 36.6, 29.2, 9.2. LCMS (ESI, m/z): 308.1 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>17</sub>H<sub>17</sub>N<sub>5</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 308.1506. Found: 308.1508.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (<i>E</i>)-4-(1-(2-Aminopyrimidin-4-yl)-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-6-yl)-2-methylbut-3-en-2-ol (<b>20</b>)</h4><div class="NLM_p last">To a solution of <b>8</b> (30.0 mg, 102 μmol) in THF (4.0 mL) was added Red-Al (204 μL, 408 μmol, 60% w/w in toluene) at 0 °C. The resulting mixture was stirred at 0 °C for 2 h and at 18 °C for 12 h. The mixture was quenched with sat. aq NaHCO<sub>3</sub> (10 mL). The aqueous layer was extracted with EtOAc (20 mL × 3). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude residue was purified by prep-HPLC (column: Waters Xbridge Prep OBD C18 150 × 30 mm × 5 μm; gradient: MeCN/water (0.05% v/v NH<sub>4</sub>OH), 15–45%, 25 mL/min) to afford the title compound as a white solid (5.2 mg, 16.7%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 9.05 (s, 1H), 8.49 (s, 1H), 8.37 (d, <i>J</i> = 5.6 Hz, 1H), 8.27 (s, 1H), 7.32 (d, <i>J</i> = 5.6 Hz, 1H), 7.10 (d, <i>J</i> = 15.6 Hz, 1H), 6.87 (d, <i>J</i> = 15.6 Hz, 1H), 5.21 (s, 2H), 1.49 (s, 6H). MS (ESI): 297.1 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>15</sub>H<sub>16</sub>N<sub>6</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 297.1459. Found: 297.1461.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 4-(1-(2-Aminopyrimidin-4-yl)-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-6-yl)-2-methylbutan-2-ol (<b>21</b>)</h4><div class="NLM_p last">To a solution of <b>8</b> (70.0 mg, 238 μmol) in MeOH (40 mL) was added Pd/C (25.0 mg, 23.8 μmol, 10% w/w). The resulting mixture was stirred under an atmosphere of hydrogen at 18 °C for 1 h. The mixture was filtered, and the filtrate was concentrated under reduced pressure. The reaction was repeated (same scale), and the crude residues from the two reactions were combined and purified by prep-HPLC (column: Waters Xbridge Prep OBD C18 150 × 30 mm × 5 μm; gradient: MeCN/water (0.05% v/v NH<sub>4</sub>OH), 20–50%, 30 mL/min) to afford the title compound as a white solid (40.0 mg, 57%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 9.02 (d, <i>J</i> = 0.8 Hz, 1H), 8.74 (s, 1H), 8.45 (d, <i>J</i> = 0.8 Hz, 1H), 8.29 (d, <i>J</i> = 6.0 Hz, 1H), 7.26 (d, <i>J</i> = 5.6 Hz, 1H), 3.09–3.05 (m, 2H), 1.96–1.91 (m, 2H), 1.31 (s, 6H). MS (ESI): 299.1 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>15</sub>H<sub>18</sub>N<sub>6</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 299.1615. Found: 299.1618.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 1-(1-(2-Aminopyrimidin-4-yl)-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-6-yl)-3-methylazetidin-3-ol (<b>22</b>)</h4><div class="NLM_p last">To a solution of <b>57</b> (50.0 mg, 203 μmol) in dioxane (2.0 mL) was added 3-methylazetidin-3-ol (50.1 mg, 405 μmol), SPhos-Pd-G3·DCM (15.8 mg, 20.3 μmol), and <i>t</i>-BuONa (58.4 mg, 608 μmol). The mixture was stirred at 90 °C for 17 h under an atmosphere of nitrogen. The mixture was filtered, and the filtrate was concentrated under reduced pressure. The reaction was repeated (same scale), and the crude residues from the two reactions were combined and purified by prep-HPLC (column: Xtimate C18 150 × 25 mm × 5 μm; gradient: MeCN/water (10 mM NH<sub>4</sub>HCO<sub>3</sub>), 11–41%, 25 mL/min) to afford the title compound as a white solid (9.7 mg, 8.1%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.70 (s, 1H), 8.37 (d, <i>J</i> = 0.8 Hz, 1H), 8.27 (d, <i>J</i> = 5.2 Hz, 1H), 7.46 (s, 1H), 7.01–6.98 (m, 3H), 5.63 (s, 1H), 3.97–3.95 (m, 2H), 3.89–3.87 (m, 2H), 1.48 (s, 3H). MS (ESI): 298.1 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>14</sub>H<sub>15</sub>N<sub>7</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 298.1411. Found: 298.1412.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 4-(1-(2-Aminopyrimidin-4-yl)-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-6-yl)phenol (<b>23</b>)</h4><div class="NLM_p last">To a solution of <b>57</b> (50.0 mg, 203 μmol) in dioxane/water (2.0 mL/0.5 mL) was added (4-hydroxyphenyl)boronic acid (41.9 mg, 304 μmol), K<sub>2</sub>CO<sub>3</sub> (56.0 mg, 405 μmol), and Pd(dppf)Cl<sub>2</sub> (14.8 mg, 20.3 μmol). The mixture was stirred at 90 °C for 17 h under an atmosphere of nitrogen. The mixture was concentrated under reduced pressure. The crude residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150 × 30 mm × 4 μm; gradient: MeCN/water (0.225% formic acid), 11–31%, 25 mL/min) to afford the title compound as a white solid (35.4 mg, 57%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.83 (br s, 1H), 9.23 (s, 1H), 9.05 (s, 1H), 8.68 (s, 1H), 8.37 (d, <i>J</i> = 6.0 Hz, 1H), 8.19–8.17 (m, 2H), 7.53 (br s, 2H), 7.18 (d, <i>J</i> = 6.0 Hz, 1H), 6.92–6.91 (m, 2H). MS (ESI): 305.0 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>16</sub>H<sub>12</sub>N<sub>6</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 305.1146. Found: 305.1146.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (<i>E</i>)-4-(1-(2-Aminopyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-2-methylbut-3-en-2-ol (<b>24</b>)</h4><div class="NLM_p last">To a solution of <b>9</b> (50.0 mg, 170 μmol) in THF (5.0 mL) was slowly added Red-Al (188 μL, 680 μmol, 70% w/w in toluene) at 0 °C, and the mixture was stirred at 20 °C for 16 h. After this time, the reaction was quenched by addition of sat. aq NaHCO<sub>3</sub> (5 mL) and diluted with water (10 mL). The aqueous layer was separated and extracted with EtOAc (20 mL × 3). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude was purified by prep-HPLC (column: Xtimate C18 150 × 30 mm × 5 μm; gradient: MeCN/water (10 mM NH<sub>4</sub>HCO<sub>3</sub>), 12–42%, 25 mL/min) to give the title compound (46.0 mg, 92%) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.86 (s, 1H), 8.37 (s, 1H), 8.22 (s, 1H), 7.65 (d, <i>J</i> = 3.5 Hz, 1H), 6.95 (d, <i>J</i> = 16.0 Hz, 1H), 6.81 (d, <i>J</i> = 16.0 Hz, 1H), 6.75–6.72 (m, 2H), 5.32 (s, 2H), 1.47 (m, 6H). LCMS (ESI, m/z): 295.9 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>16</sub>H<sub>17</sub>N<sub>5</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 296.1506. Found: 296.1507.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>rac</i>-<i>trans</i>-2-(2-(1-(2-Aminopyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)cyclopropyl)propan-2-ol (<b>25</b>)</h4><div class="NLM_p last">To a solution of <b>78</b> (28.0 mg, 86.6 μmol) in THF (2.0 mL) was added methyl lithium (1.1 mL, 1.70 mmol, 1.6 M in Et<sub>2</sub>O), and the mixture was stirred at −78 °C for 4 h under a nitrogen atmosphere. After this time, the mixture was diluted with water (30 mL) and extracted with EtOAc (20 mL × 3). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude residue was purified by prep-HPLC (column: Xtimate C18 150 × 25 mm × 5 μm; gradient: MeCN/water (10 mM NH<sub>4</sub>HCO<sub>3</sub>) as 17–47%, 25 mL/min) to afford the title compound (10.2 mg, 37%) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.68 (s, 1H), 8.57 (s, 1H), 8.29 (d, <i>J =</i> 5.5 Hz, 1H), 8.02 (d, <i>J =</i> 3.0 Hz, 1H), 7.03 (s, 2H), 6.96 (d, <i>J =</i> 5.5 Hz, 1H), 6.80 (d, <i>J =</i> 3.0 Hz, 1H), 4.20 (s, 1H), 2.28–2.25 (m, 1H), 1.56–1.53 (m, 1H), 1.19 (s, 3H), 1.16 (s, 3H), 1.04–1.02 (m, 1H), 0.95–0.93 (m, 1H). LCMS (ESI, m/z): 310.0 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>17</sub>H<sub>19</sub>N<sub>5</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 310.1663. Found: 310.1664.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 2-(3-(1-(2-Aminopyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)cyclobutyl)propan-2-ol (<b>26</b>)</h4><div class="NLM_p last">To a solution of <b>82</b> (30.0 mg, 93.0 μmol) in MeOH/EtOAc (12.0 mL/3.0 mL) was added Pd/C (20.0 mg, 19.0 μmol, 10% w/w), and the reaction mixture was stirred at 16 °C under an atmosphere of hydrogen (15 psi) for 4.5 h. After this time, the mixture was filtered through a pad of Celite and the filtrate was concentrated. The crude product was purified by prep-TLC (1:15 MeOH/DCM) to give the title compound (25.0 mg, 75%) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 8.72 (s, 1H), 8.62 (s, 1H), 8.29 (d, <i>J</i> = 6.0 Hz, 1H), 7.96 (d, <i>J</i> = 3.6 Hz, 1H), 6.92 (d, <i>J</i> = 6.0 Hz, 1H), 6.86 (d, <i>J</i> = 3.2 Hz, 1H), 3.58–3.53 (m, 1H), 2.45–2.39 (m, 4H), 2.31–2.26 (m, 2H), 1.16 (s, 6H). LCMS (ESI, m/z): 324.0 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>18</sub>H<sub>21</sub>N<sub>5</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 324.1819. Found: 324.1822. Purity: 92.5%.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 2-(3-(1-(2-Aminopyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)bicyclo[1.1.1]pentan-1-yl)propan-2-ol (<b>27</b>)</h4><div class="NLM_p last">To a solution of <b>84</b> (59.0 mg of equimolar mixture with <b>83</b>, ∼100 μmol of <b>84</b>) in THF (2.0 mL) was added dropwise via a syringe a solution of MeMgBr (3.0 M Et<sub>2</sub>O, 0.34 mL) at room temperature, and the resulting mixture was stirred for 1 h. After this time, the volatiles were removed under reduced pressure. The crude residue was purified by mass-directed HPLC (column: Waters XSelect CSH Prep C18 OBD 50 × 100 mm × 5 μm; gradient: MeCN/water (0.2% v/v NH<sub>4</sub>OH), 5–65%, 80 mL/min) to give the title compound (5.0 mg, 15%) as a pale yellow solid. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ ppm 8.77–8.73 (m, 1H), 8.38 (s, 1H), 8.30 (d, <i>J</i> = 5.5 Hz, 1H), 7.95 (d, <i>J</i> = 3.7 Hz, 1H), 6.91 (d, <i>J</i> = 6.1 Hz, 1H), 6.86 (d, <i>J</i> = 3.7 Hz, 1H), 2.10 (s, 6H), 1.24 (s, 6H). MS (ESI): 336.2 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>19</sub>H<sub>21</sub>N<sub>5</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 336.1819. Found: 336.1822.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 2-Methyl-4-(1-(2-(methylamino)pyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)but-3-yn-2-ol (<b>28</b>)</h4><div class="NLM_p last">The reaction was carried out according to general procedure 1 using a mixture of 4-(6-chloro-2,3-dihydro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-1-yl)-<i>N</i>-methylpyrimidin-2-amine and <b>85</b> (30.0 mg, 115 μmol), 2-methylbut-3-yn-2-ol (45 μL, 460 μmol), and triethylamine (48 μL, 345 μmol) in 2.0 mL of DMSO at 100 °C for 2 h. EtOAc (20 mL) and water (20 mL) were added, and the aqueous layer was separated and extracted with EtOAc (20 mL × 2). The combined organic layers were washed with brine (10 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude residue was purified by column chromatography (SiO<sub>2</sub>, gradient: 0–100% EtOAc/petroleum ether) to afford the title compound (15.0 mg, with impurities). The product was further purified by prep-HPLC (column: Phenomenex Synergy C18 150 × 30 mm × 4 μm; MeCN/water (0.225% formic acid), 15–35%, 25 mL/min) to afford the title compound as a white solid (2.7 mg, 1.7% over two steps). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 8.99 (s, 1H), 8.95 (s, 1H), 8.40–8.38 (m, 1H), 8.25 (d, <i>J</i> = 4.0 Hz, 1H), 7.08 (d, <i>J</i> = 3.2 Hz, 1H), 6.97 (d, <i>J</i> = 2.4 Hz, 1H), 3.06 (s, 3H), 1.63 (s, 6 H). MS (ESI): 308.1 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>17</sub>H<sub>17</sub>N<sub>5</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 308.1506. Found: 308.1507.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (<i>S</i>)-1-(1-(6-Aminopyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-3-methylpent-1-yn-3-ol (<b>29</b>)</h4><div class="NLM_p last">Step 1: The reaction was carried out according to general procedure 1 using <b>86</b> (100 mg, 407 μmol) and 3-methylpent-1-yn-3-ol (184 μL, 1.63 mmol) in 10.0 mL of DMSO at 100 °C for 10 h. The mixture was diluted with water (40 mL) and extracted with EtOAc (30 mL × 4). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude residue was purified by prep-HPLC (column: Xtimate C18 150 × 25 mm × 5 μm; gradient: MeCN/water (10 mM NH<sub>4</sub>HCO<sub>3</sub>), 15–55%, 25 mL/min) to afford the title compound as a yellow solid (41.6 mg, 26%). MS (ESI): 308.1 [M + H]<sup>+</sup>. Step 2: Chiral separation of racemic product from step 1 was performed using the following column: AD (250 × 30 mm × 5 μm); method: 40% IPA with 0.1% NH<sub>4</sub>OH in CO<sub>2</sub> (flow rate: 50 mL/min). The first peak eluting off the column provided (<i>S</i>)-1-(1-(6-aminopyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-3-methylpent-1-yn-3-ol <b>29</b> as a light yellow solid in 99.2% ee (Rt = 6.738 min, 8.2 mg, 20%). Stereochemistry arbitrarily assigned. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.88 (s, 1H), 8.44 (s, 1H), 8.40 (s, 1H), 8.08 (d, <i>J</i> = 3.6 Hz, 1H), 7.17 (s, 2H), 6.95–6.94 (m, 1H), 6.66 (d, <i>J</i> = 1.2 Hz, 1H), 5.45 (s, 1H), 1.72–1.65 (m, 2H), 1.45 (s, 3H), 1.02 (t, <i>J</i> = 7.2 Hz, 3H). MS (ESI): 308.1 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>17</sub>H<sub>17</sub>N<sub>5</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 308.1506. Found: 308.1514. The second peak furnished (<i>R</i>)-1-(1-(6-aminopyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-3-methylpent-1-yn-3-ol (the enantiomer of <b>29</b>) as a light yellow solid in 98.9% ee (Rt = 7.045 min, 9.8 mg, 24%, <sup>1</sup>H NMR and MS identical to <b>29</b>).</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (<i>S</i>)-1-(1-(2-Amino-6-methylpyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-3-methylpent-1-yn-3-ol (<b>30</b>)</h4><div class="NLM_p last">Step 1: The reaction was carried out according to general procedure 1 using <b>87</b> (150 mg, 575 μmol), 3-methylpent-1-yn-3-ol (259 μL, 2.30 mmol), and triethylamine (240 μL, 1.73 mmol) in 5.0 mL of DMSO at 100 °C for 3 h. TMT solution (1 mL) was added to the reaction mixture, and the mixture was filtered. The filtrate was concentrated under reduced pressure and purified by prep-HPLC (column: Agela ASB 150 × 25 mm × 5 μm; gradient: MeCN/water (0.1% TFA), 8–28%, 25 mL/min) to afford <i>rac</i>-1-(1-(2-amino-6-methylpyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-3-methylpent-1-yn-3-ol as a yellow solid (79.0 mg, 43%). MS (ESI): 322.1 [M + H]<sup>+</sup>. Step 2: Chiral separation of racemic product from step 1 was performed using the following column: C2 (250 × 30 mm × 10 μm); method: 40% EtOH with 0.1% NH<sub>4</sub>OH in CO<sub>2</sub> (flow rate: 70 mL/min). The first peak eluting off the column provided (<i>R</i>)-1-(1-(2-amino-6-methylpyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-3-methylpent-1-yn-3-ol (the enantiomer of <b>30</b>) as a light yellow solid in 100% ee (Rt = 6.136 min, 27.8 mg, 35%, <sup>1</sup>H NMR and MS identical to <b>30</b>). The second peak furnished (<i>S</i>)-1-(1-(2-amino-6-methylpyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-3-methylpent-1-yn-3-ol <b>30</b> as a white solid in 90% ee (Rt = 6.502 min, 37.7 mg, 48%). Stereochemistry arbitrarily assigned. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 9.02 (s, 1H), 8.97 (s, 1H), 8.29 (d, <i>J</i> = 3.6 Hz, 1H), 7.13 (d, <i>J</i> = 3.6 Hz, 1H), 7.04 (s, 1H), 2.47 (s, 3H), 1.88–1.82 (m, 2H), 1.60 (s, 3H), 1.14 (t, <i>J</i> = 7.6 Hz, 3H). MS (ESI): 322.0 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>18</sub>H<sub>19</sub>N<sub>5</sub>O + H<sup>+</sup> [M + H]<sup>+</sup>: 322.1663. Found: 322.1668.</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (<i>S</i>)-1-(1-(2-Amino-6-methoxypyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-3-methylpent-1-yn-3-ol (<b>31</b>)</h4><div class="NLM_p last">Step 1: The reaction was carried out according to general procedure 1 using <b>88</b> (120 mg, 435 μmol), 3-methylpent-1-yn-3-ol (196 μL, 1.74 mmol), and triethylamine (302 μL, 2.18 mmol) in 3.0 mL of DMSO at 100 °C for 14 h. The reaction was diluted with EtOAc (20 mL) and water (20 mL). The aqueous layer was separated and extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with brine (10 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude residue was purified by prep-HPLC (column: Xtimate C18 150 × 25 mm × 5 μm; gradient: MeCN/water (10 mM NH<sub>4</sub>HCO<sub>3</sub>), 25–55%, 25 mL/min) to afford <i>rac</i>-1-(1-(2-amino-6-methoxypyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-3-methylpent-1-yn-3-ol as a white solid (35.0 mg, 24%). MS (ESI): 338.1 [M + H]<sup>+</sup>. Step 2: Chiral separation of racemic product from step 1 was performed using the following column: C2 (250 × 30 mm × 10 μm); method: 45% IPA with 0.1% NH<sub>4</sub>OH in CO<sub>2</sub> (flow rate: 60 mL/min; detection wavelength: 220 nm). The first peak eluting off the column provided (<i>R</i>)-1-(1-(2-amino-6-methoxypyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-3-methylpent-1-yn-3-ol (the enantiomer of <b>31</b>) as a white solid in 98% ee (Rt = 6.727 min, 6.1 mg, 17%, <sup>1</sup>H NMR and MS identical to <b>31</b>). The second peak furnished (<i>S</i>)-1-(1-(2-amino-6-methoxypyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-3-methylpent-1-yn-3-ol <b>31</b> as a white solid in 98% ee (Rt = 7.333 min, 6.3 mg, 18%). Stereochemistry arbitrarily assigned. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.87–8.86 (m, 1H), 8.35 (s, 1H), 7.72 (d, <i>J</i> = 3.6 Hz, 1H), 6.75 (d, <i>J</i> = 2.8 Hz, 1H), 6.17 (s, 1H), 5.11 (s, 2H), 3.97 (s, 3H), 1.85 (q, <i>J</i> = 7.6 Hz, 2H), 1.63 (s, 3H), 1.14 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ ppm 172.3, 162.7, 159.3, 143.9, 138.9, 135.7, 127.3, 126.5, 113.2, 105.4, 91.4, 86.0, 84.0, 69.1, 54.0, 36.6, 29.2, 9.2. MS (ESI): 338.1 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>18</sub>H<sub>19</sub>N<sub>5</sub>O<sub>2</sub> + H<sup>+</sup> [M + H]<sup>+</sup>: 338.1612. Found: 338.1614.</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (<i>S</i>)-1-(1-(2-Amino-5-methoxypyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-3-methylpent-1-yn-3-ol (<b>32</b>)</h4><div class="NLM_p last">Step 1: The reaction was carried out according to general procedure 1 using <b>89</b> (15.0 mg, 43.5 μmol), 3-methylpent-1-yn-3-ol (5 μL, 43.5 μmol), and triethylamine (18 μL, 131 μmol) in 4.0 mL of DMSO at 100 °C for 12 h. The mixture was diluted with water (8 mL) and extracted with EtOAc (15 mL × 3). The combined organic layers were washed with brine (30 mL × 3), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The reaction was repeated three more times. The combined crude residue was purified by prep-TLC (1:10 MeOH/DCM), followed by prep-HPLC (column: YMC-Actus Pro C18 150 × 30 mm × 5 μm; gradient: MeCN/water (0.1% TFA), 15–45%, 40 mL/min) to afford <i>rac</i>-1-(1-(2-amino-5-methoxypyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-3-methylpent-1-yn-3-ol as a light brown oil (trifluoroacetate salt, 17.0 mg, 21%). MS (ESI): 338.1 [M + H]<sup>+</sup>. Step 2: Chiral separation of racemic product from step 1 was performed using the following column: DAICEL CHIRALCEL OJ-H (250 × 30 mm × 5 μm); method: 30% EtOH with 0.1% NH<sub>4</sub>OH in CO<sub>2</sub> (flow rate: 60 mL/min). The first peak eluting off the column provided (<i>R</i>)-1-(1-(2-amino-5-methoxypyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-3-methylpent-1-yn-3-ol (the enantiomer of <b>32</b>) as a white solid in 100% ee (Rt = 4.715 min, 1.8 mg, 11%, <sup>1</sup>H NMR and MS identical to <b>32</b>). The second peak furnished (<i>S</i>)-1-(1-(2-amino-5-methoxypyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-3-methylpent-1-yn-3-ol <b>32</b> as a white solid in 100% ee (Rt = 5.205 min, 1.8 mg, 11%). Stereochemistry arbitrarily assigned. <sup>1</sup>H NMR (400 MHz, CDC<sub>3</sub>OD) δ ppm 8.79 (s, 1H), 8.28–8.27 (m, 2H), 8.09 (d, <i>J</i> = 3.6 Hz, 1H), 6.88–6.86 (m, 1H), 3.86 (s, 3H), 1.84–1.79 (m, 2H), 1.56 (s, 3H), 1.13 (t, <i>J</i> = 7.2 Hz, 3H). MS (ESI): 338.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 1-(5-Bromo-1-tosyl-1<i>H</i>-indol-3-yl)ethan-1-one (<i>int</i>-<b>35</b>)</h4><div class="NLM_p last">To a solution of 1-(5-bromo-1<i>H</i>-indol-3-yl)ethan-1-one <b>33</b> (2.00 g, 10.0 mmol) in DCM (10.0 mL) was added TsCl (730 mg, 3.80 mmol) and triethylamine (970 μL, 7.0 mmol) at 26 °C and stirred at 26 °C for 16 h. The reaction solution was diluted with DCM (50 mL), washed with sat. aq NH<sub>4</sub>Cl solution, sat. aq NaHCO<sub>3</sub> solution, water, and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>. Evaporation of solvents afforded the title compound as a red solid which was used without purification (950 mg, 68%).</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 1-(5-Bromo-1-tosyl-1<i>H</i>-indazol-3-yl)ethan-1-one (<i>int</i>-<b>36</b>)</h4><div class="NLM_p last">To a solution of 1-(5-bromo-1<i>H</i>-indazol-3-yl)ethan-1-one <b>34</b> (240 mg, 1.00 mmol), DMAP (30.0 mg, 250 μmol), triethylamine (513 μL, 3.70 mmol) in DCM (15.0 mL) was added TsCl (270 mg, 1.50 mmol) at 16 °C and stirred at 16 °C for 2 h. The reaction solution was diluted with DCM (50 mL), washed with sat. aq NaHCO<sub>3</sub>, water, and brine. The organic layer was dried over Na<sub>2</sub>SO4. Evaporation of solvents afforded the title compound (300 mg, 75%) as a red solid which was used without purification.</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 1-(5-Bromo-1-methyl-1<i>H</i>-indazol-3-yl)ethan-1-one (<b>37</b>)</h4><div class="NLM_p last">To a suspension of 1-(5-bromo-1<i>H</i>-indazol-3-yl)ethan-1-one <b>34</b> (260 mg, 1.10 mmol) and NaOH (132 mg, 3.30 mmol) in THF (10.0 mL) was added MeI (137 μL, 2.20 mmol) at 16 °C and stirred at 16 °C for 3 h. The reaction solution was quenched with water (10 mL) and stirred at 16 °C for 2 h, then evaporated under reduced pressure. The aqueous layer was extracted with DCM (20 mL × 3). The combined organic phase was washed with water and brine and dried over Na<sub>2</sub>SO<sub>4</sub>. Evaporation of solvents afforded the title compound (250 mg, 91%) as a red solid. The product structure was confirmed by NOE. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.54 (d, <i>J</i> = 1.6 Hz, 1H), 7.53 (dd, <i>J</i> = 8.8, 1.6 Hz, 1H), 7.32 (d, <i>J</i> = 8.8 Hz, 1H), 4.14 (s, 3H), 2.70 (s, 3H).</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 1-(5-Chloro-1-methyl-1<i>H</i>-pyrazolo[3,4-<i>c</i>]pyridin-3-yl)ethan-1-one (<b>38</b>)</h4><div class="NLM_p last">To a solution of compound <b>48</b> (500 mg, 1.70 mmol) in DMF (15.0 mL) was added tributyl(1-ethoxyvinyl)stannane (677 mg, 1.87 mmol) and Pd(PPh<sub>3</sub>)<sub>4</sub> (197 mg, 170 μmol) with stirring at 30 °C under a nitrogen atmosphere. The mixture was heated to 80 °C with stirring for 4 h under a nitrogen atmosphere. The mixture was quenched with aq KF. HCl (aq, 3 M, 10 mL) was poured into the mixture with stirring at 30 °C for 30 min. The mixture was extracted with EtOAc (30 mL × 3), the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude product was purified by column chromatography (SiO<sub>2</sub>, gradient: 10–20% EtOAc/petroleum ether) to afford the title compound (320 mg, 90%) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 8.97 (s, 1H), 8.13 (s, 1H), 4.29 (s, 3H), 2.67 (s, 3H). MS (ESI): 210.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (<i>E</i>)-1-(5-Bromo-1-tosyl-1<i>H</i>-indol-3-yl)-3-(dimethylamino)prop-2-en-1-one (<i>int</i>-<b>39</b>)</h4><div class="NLM_p last">A mixture of <b>35</b> (950 mg, 2.42 mmol) and DMF–DMA (10.0 mL) was stirred at 100 °C for 3 h. The reaction solution was cooled to room temperature and evaporated under reduced pressure to afford the title compound (1.20 g, crude), which was used without purification. MS (ESI): 449.0 [M + H]<sup>+</sup> (<sup>81</sup>Br).</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (<i>E</i>)-1-(5-Bromo-1-tosyl-1<i>H</i>-indazol-3-yl)-3-(dimethylamino)prop-2-en-1-one (<i>int</i>-<b>40</b>)</h4><div class="NLM_p last">A solution of <b>36</b> (300 mg, 750 μmol) in DMF–DMA (5.0 mL) was stirred at 80 °C for 16 h. The reaction solution was evaporated under reduced pressure to afford the title compound (450 mg, crude) as a yellow solid, which was used without purification. MS (ESI): 448.0 [M + H]<sup>+</sup> (<sup>79</sup>Br).</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (<i>E</i>)-1-(5-Bromo-1-methyl-1<i>H</i>-indazol-3-yl)-3-(dimethylamino)prop-2-en-1-one (<i>int</i>-<b>41</b>)</h4><div class="NLM_p last">A solution of <b>37</b> (250 mg, 1.00 mmol) in DMF–DMA (5.0 mL) was stirred at 90 °C for 16 h. The reaction solution was evaporated under reduced pressure to afford the title compound as a brown solid (450 mg, crude), which was used without purification. MS (ESI): 307.9 [M + H]<sup>+</sup> (<sup>79</sup>Br).</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (<i>E</i>)-1-(5-Chloro-1-methyl-1<i>H</i>-pyrazolo[3,4-<i>c</i>]pyridin-3-yl)-3-(dimethylamino)prop-2-en-1-one (<i>int</i>-<b>42</b>)</h4><div class="NLM_p last">A solution of <b>38</b> (320 mg, 1.53 mmol) in DMF–DMA (20.0 mL) was stirred at 30 °C under a nitrogen atmosphere. The mixture was heated to 90 °C for 48 h. The mixture was concentrated to provide the title compound (404 mg, crude), which was used without purification. MS (ESI): 265.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 4-(5-Bromo-1<i>H</i>-indol-3-yl)pyrimidin-2-amine (<i>int</i>-<b>43</b>)</h4><div class="NLM_p last">Na (276 mg, 12.0 mmol) was dissolved in EtOH (10.0 mL). To this EtONa/EtOH solution was added <b>39</b> (1.20 g, 2.40 mmol) followed by addition of guanidine thiocyanate (700 mg, 7.50 mmol). The resulting mixture was heated to 90 °C for 16 h. The solvent was removed under reduced pressure, diluted with DCM (100 mL) and water (50 mL), and filtered through Celite. The organic phase was separated, washed with water and brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. Evaporation of solvents afforded crude product, which was purified by column chromatography (SiO<sub>2</sub>, 50% EtOAc/petroleum ether) to afford the title compound (380 mg, 55% over 2 steps) as an orange oil. MS (ESI): 289.0 [M + H]<sup>+</sup> (<sup>79</sup>Br).</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 4-(5-Bromo-1<i>H</i>-indazol-3-yl)pyrimidin-2-amine (<i>int</i>-<b>44</b>)</h4><div class="NLM_p last">Na (86.0 mg, 3.75 mmol) was dissolved in EtOH (10.0 mL). To this EtONa/EtOH solution was added <b>40</b> (330 mg, 750 μmol) and guanidine thiocyanate (220 mg, 2.25 mmol) at 16 °C and stirred at 80 °C for 20 h. Further guanidine thiocyanate (220 mg, 2.25 mmol) and EtONa (680 mg, 10.0 mmol) were added, and the reaction suspension was stirred at 90 °C for 20 h. The reaction suspension was evaporated under reduced pressure, and the product was purified by column chromatography (SiO<sub>2</sub>, 1:20 MeOH/DCM) to afford the title compound (20.0 mg, 56% over 2 steps) as a yellow solid. MS (ESI): 289.9 [M + H]<sup>+</sup> (<sup>79</sup>Br).</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 4-(5-Bromo-1-methyl-1<i>H</i>-indazol-3-yl)pyrimidin-2-amine (<i>int</i>-<b>45</b>)</h4><div class="NLM_p last">Na (345 mg, 15.0 mmol) was dissolved in EtOH (10.0 mL). To this EtONa/EtOH solution were added <b>41</b> (450 mg, 1.00 mmol) and guanidine thiocyanate (400 mg, 4.00 mmol). The resulting mixture was stirred at 80 °C for 3 h. Then the reaction suspension was evaporated under reduced pressure, and the product was purified by column chromatography (SiO<sub>2</sub>, gradient: from 1:1 EtOAc/petroleum ether to 1:20 MeOH/DCM) to afford the title compound (170 mg, 56% over 2 steps) as a red solid. MS (ESI): 303.9 [M + H]<sup>+</sup> (<sup>79</sup>Br).</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 4-(5-Chloro-1-methyl-1<i>H</i>-pyrazolo[3,4-<i>c</i>]pyridin-3-yl)pyrimidin-2-amine (<i>int</i>-<b>46</b>)</h4><div class="NLM_p last">Na (526 mg, 22.9 mmol) was dissolved into EtOH (25 mL). To this EtONa/EtOH solution were added <b>42</b> (404 mg, 1.53 mmol) and guanidine thiocyanate (367 mg, 6.10 mmol) at 30 °C. The resulting mixture was stirred at 80 °C for 3 h. The mixture was concentrated under reduced pressure, and then it was dissolved in EtOAc (30 mL) and washed with water (30 mL × 3). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude product was purified by prep-HPLC (column: Phenomenex Synergi C18 150 × 30 mm × 4 μm; gradient: MeCN/water (0.05% HCl), 4–24%, 25 mL/min) to afford the title compound (120 mg, 30%) as a yellow oil. MS (ESI): 261.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 5-Chloro-3-iodo-1-methyl-1<i>H</i>-pyrazolo[3,4-<i>c</i>]pyridine (<b>48</b>)</h4><div class="NLM_p last">To a solution of <b>47</b> (880 mg, 3.15 mmol) in DMF (8.0 mL) was added NaH (189 mg, 4.72 mmol), and the resulting mixture was stirred at 30 °C for 30 min after which time MeI (294 μL, 4.72 mmol) was added. The mixture was stirred for 2 h at 30 °C, quenched with water (10 mL), and concentrated. The product was purified by prep-HPLC (column: Waters Xbridge Prep OBD C18 150 × 30 × 5 μm; gradient: MeCN/water (0.05% v/v NH<sub>4</sub>OH), 26–56%, 25 mL/min) to afford the title compound (500 mg, 54%) as white solid and isomer 5-chloro-3-iodo-2-methyl-2<i>H</i>-pyrazolo[3,4-<i>c</i>]pyridine (100 mg, 10%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 8.86 (s, 1H), 7.46 (s, 1H), 4.21 (s, 3H). MS (ESI): 293.8 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 4-(6-Chloro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-1-yl)pyrimidin-2-amine (<i>int</i>-<b>57</b>)</h4><div class="NLM_p last">To a solution of <b>49</b> (118 mg, 770 μmol) in DMF (5.0 mL) at 10 °C was added NaH (63.7 mg, 1.55 mmol, 60% in mineral oil), and the resulting mixture was stirred at 10 °C for 30 min. After this time, 4-chloropyrimidin-2-amine (100 mg, 770 μmol) was added and the reaction suspension was stirred at 60 °C for 3 h. After this time, the reaction was concentrated, and the product was purified by column chromatography (SiO<sub>2</sub>, gradient: 0–100% EtOAc/petroleum ether) to afford the title compound (75.0 mg, 40%) as a yellow solid. MS (ESI): 247.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 4-(6-Chloro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-1-yl)pyrimidin-2-amine (<i>int</i>-<b>58</b>)</h4><div class="NLM_p last">To a suspension of NaH (197 mg, 4.92 mmol, 60% in mineral oil) in DMF (2.0 mL) was added <b>50</b> (500 mg, 3.28 mmol) dropwise in DMF (1.5 mL) at 0 °C under a nitrogen atmosphere, and the mixture was stirred at room temperature for 1.5 h. After this time, 4-chloropyrimidin-2-amine (637 mg, 4.92 mmol) was added and the reaction was stirred at 60 °C for 12 h. After this time, the mixture was quenched with water (3 mL), which led to the product precipitating out of solution. An additional amount of water (25 mL) was added, and the resulting mixture was filtered. The filter cake was then dried to give the title compound (850 mg, crude) as a yellow solid, which was used without further purification. MS (ESI): 246.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 4-(6-Chloro-2,3-dihydro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-1-yl)pyrimidin-2-amine (<i>int</i>-<b>59</b>)</h4><div class="NLM_p last">To <b>51</b> (500 mg, 3.23 mmol) in DMF (9.0 mL) was added NaH (194 mg, 4.85 mmol, 60% in mineral oil), and the mixture was stirred at 20 °C for 30 min. After this time, 4-chloropyrimidin-2-amine (419 mg, 3.23 mmol) was added to the mixture and the reaction was heated to 70 °C for 1 h. After this time, the mixture was poured into water (20 mL) and extracted with EtOAc (50 mL × 6). The combined the organic layers were concentrated, and the crude product was dissolved in petroleum ether/EtOAc (1:1, 10 mL) and filtered. The filtrate cake was dried to afford the title compound as a yellow solid (450 mg, 56%).</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 4-(6-Bromo-5-methoxy-1<i>H</i>-indol-1-yl)pyrimidin-2-amine (<i>int</i>-<b>60</b>)</h4><div class="NLM_p last">To a solution of <b>52</b> (150 mg, 660 μmol) in DMF (5.0 mL) was added NaH (26.0 mg, 660 μmol, 60% in mineral oil), and the mixture was stirred at 15 °C for 30 min. After this time, 4-chloropyrimidin-2-amine (103 mg, 796 μmol) was added and the reaction was heated to 80 °C for 18 h. After this time, the mixture was quenched with water (10 mL), stirred for 10 min, and filtered. The filter cake was washed with petroleum ether/EtOAc (10:1) to afford the title compound (200 mg, 94%) as a yellow solid. MS (ESI): 320.9 [M + H]<sup>+</sup> (<sup>81</sup>Br).</div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 4-(6-Bromo-5-fluoro-1<i>H</i>-indol-1-yl)pyrimidin-2-amine (<b>61</b>)</h4><div class="NLM_p last">To <b>53</b> (100 mg, 467 μmol) in DMF (5.0 mL) was added NaH (37.4 mg, 934 μmol, 60% in mineral oil) slowly at 0 °C, and the mixture was stirred at 30 °C for 30 min. After this time, 4-chloropyrimidin-2-amine (121 mg, 934 μmol) was added and the mixture was stirred at 60 °C for 16 h. After this time, the reaction was quenched with water (1 mL) and concentrated. The crude residue was triturated with petroleum ether/EtOAc (5:1, 20 mL) to give a yellow solid, which was purified by prep-HPLC (column: Xtimate C18 150 × 25 mm × 5 μm; gradient: MeCN/water (10 mM NH<sub>4</sub>HCO<sub>3</sub>), 36–66%, 25 mL/min) to afford the title compound as a white solid (72.0 mg, 50%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.11 (d, <i>J</i> = 6.4 Hz, 1H), 8.27 (d, <i>J</i> = 5.6 Hz, 1H), 8.18 (d, <i>J</i> = 3.6 Hz, 1H), 7.61 (d, <i>J</i> = 9.2 Hz, 1H), 7.03 (s, 2H), 6.95 (d, <i>J</i> = 6.0 Hz, 1H), 6.79 (d, <i>J</i> = 3.6 Hz, 1H). MS (ESI): 307.0 [M + H]<sup>+</sup> (<sup>79</sup>Br).</div></div><div id="sec4_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 4-(6-Chloro-4-methoxy-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-1-yl)pyrimidin-2-amine (<b>62</b>)</h4><div class="NLM_p last">To a solution of <b>54</b> (19.0 mg, 100 μmol) in DMF (300 μL) was added NaH (7.0 mg, 180 μmol, 60% in mineral oil), and the mixture was stirred at 25 °C for 30 min. After this time, 4-chloropyrimidin-2-amine (16.0 mg, 124 μmol) was added and the reaction mixture was stirred at 60 °C overnight. After this time, the mixture was quenched with water and concentrated under reduced pressure. The crude product was dissolved in DMSO, filtered, and purified by prep-HPLC (column: Waters XSelect CSH C18 OBD 100 × 50 mm × 5 μm; gradient: MeCN/water (0.2% v/v NH<sub>4</sub>OH), 5–60%, 25 mL/min) to afford the title compound (14.0 mg, 49%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 8.29–8.27 (m, 2H), 7.82 (d, <i>J</i> = 3.76 Hz, 1H), 6.88 (d, <i>J</i> = 5.77 Hz, 1H), 6.78 (d, <i>J</i> = 3.26 Hz, 1H), 4.05 (s, 3H). MS (ESI): 276.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 4-(4,6-Dichloro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-1-yl)pyrimidin-2-amine (<i>int</i>-<b>63</b>)</h4><div class="NLM_p last">A solution of 4-chloropyrimidin-2-amine (692 mg, 5.34 mmol), <b>55</b> (500 mg, 2.67 mmol), and DBU (800 μL, 5.34 mmol) in DMF (20.0 mL) was heated at 140 °C in a sealed microwave tube for 2 h. The volatiles were removed under reduced pressure, and the crude product was subjected to purification by column chromatography (24 g SiO<sub>2</sub>, gradient: 0–15% MeOH (5% v/v NH<sub>4</sub>OH)/DCM). The title compound was obtained as an equimolar mixture (1.13 g) with unreacted 4-chloropyrimidine-2-amine and was used as such in the next step. MS (ESI): 280.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 4-(6-Chloro-4-morpholino-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-1-yl)pyrimidin-2-amine (<b>64</b>)</h4><div class="NLM_p last">A solution of morpholine (38 μL, 430 μmol), <b>63</b> (100 mg, 360 μmol), and DBU (110 μL, 710 μmol) in DMF (2.0 mL) was heated in a microwave at 150 °C for 12 h. The resulting mixture was cooled to room temperature and purified by prep-HPLC (column: Waters XSelect CSH Prep C18 OBD 100 × 50 mm × 5 μm; gradient: MeCN/water (0.2% v/v NH<sub>4</sub>OH), 5–65%, 80 mL/min) to afford the title compound (37.0 mg, 31%) as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 8.26 (d, <i>J</i> = 5.5 Hz, 1H), 8.10 (s, 1H), 7.76 (d, <i>J</i> = 4.3 Hz, 1H), 6.88–6.80 (m, 2H), 3.87–3.82 (m, 4H), 3.66–3.59 (m, 4H). MS (ESI): 331.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 4-(6-Chloro-3-iodo-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-1-yl)pyrimidin-2-amine (<i>int</i>-<b>65</b>)</h4><div class="NLM_p last">4-Chloropyrimidin-2-amine (245 mg, 1.90 mmol), <b>56</b> (501 mg, 1.80 mmol), Cs<sub>2</sub>CO<sub>3</sub> (704 mg, 2.20 mmol), and DMF (6.0 mL) were combined in a 2–5 mL microwave vial. The reaction mixture was heated to 120 °C for 2 h in a microwave reactor. After this time, the reaction was diluted with water and the solid was collected by filtration. The filter cake was washed with water and ether and dried under reduced pressure to afford the title compound (528 mg, crude), which was used without purification. MS (ESI): 372.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 4-(6-Chloro-3-cyclopropyl-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-1-yl)pyrimidin-2-amine (<i>int</i>-<b>66</b>)</h4><div class="NLM_p last">To a mixture of <b>65</b> (200 mg, 540 μmol), cyclopropylboronic acid (69.0 mg, 810 μmol), Pd(dtbpf)Cl<sub>2</sub> (35.0 mg, 50.0 μmol), and K<sub>3</sub>PO<sub>4</sub> (343 mg, 1.61 mmol) was added dioxane (4.1 mL). The reaction mixture was sparged with nitrogen for 10 min, then heated to 140 °C for 1 h in a microwave reactor. The reaction was filtered and purified by prep- HPLC (column: Waters Sunfire C18 OBD 100 × 50 mm × 5 μm; gradient: MeCN/water (0.1% v/v TFA), 20–60%) to afford the title compound (80.0 mg, 52%). MS (ESI): 286.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 3-Bromo-6-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine (<b>68</b>)</h4><div class="NLM_p last">To <b>67</b> (1.50 g, 6.50 mmol) in DMF (16.2 mL) at 0 °C, NaH (363 mg, 9.10 mmol, 60% in mineral oil) was added portionwise. The reaction was stirred at 0 °C for 20 min and at room temperature for 40 min. After this time, the reaction was cooled to 0 °C and 2-(chloromethoxy)ethyl-trimethyl-silane (1.19 g, 7.10 mmol, 1.3 mL) was added dropwise. The reaction was stirred at 0 °C for 20 min and then at room temperature for 3 h. After this time, the reaction was diluted with water and Et<sub>2</sub>O. The aqueous layer was separated and extracted with Et<sub>2</sub>O (×2). The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. The crude product was purified by column chromatography (40 g SiO<sub>2</sub>, gradient: 5–20% EtOAc/heptane) to afford the title compound as a pale yellow oil (2.02 g, 86%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 8.65 (s, 1H), 7.44 (s, 1H), 7.30 (s, 1H), 5.43 (s, 2H), 3.51 (t, <i>J</i> = 7.9 Hz, 2H), 0.94 (t, <i>J</i> = 7.9 Hz, 2H), 0.00 (s, 9H). MS (ESI): 361.1 [M + H]<sup>+</sup> (<sup>79</sup>Br).</div></div><div id="sec4_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 6-Chloro-3-(3,6-dihydro-2<i>H</i>-pyran-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>] Pyridine (<i>Intermediate</i>-<b>69</b>)</h4><div class="NLM_p last">To <b>68</b> (499 mg, 1.38 mmol), 2-(3,6-dihydro-2<i>H</i>-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (290 mg, 1.40 mmol), K<sub>2</sub>CO<sub>3</sub> (668 mg, 4.80 mmol), Pd(dtbpf)Cl<sub>2</sub> (63.0 mg, 97.0 μmol) were added dioxane (6.8 mL) and water (2.4 mL). The reaction vial was sealed and heated to 110 °C for 1 h in a microwave. After this time, the reaction was concentrated, then diluted with water and EtOAc. The organic layer was removed via pipette, and the aqueous layer was separated and extracted with EtOAc (×2). The combined organic layers were concentrated, and the crude product was purified by column chromatography (24 g SiO<sub>2</sub>, gradient: 10–50% EtOAc/heptane) to afford the title compound as a pale yellow solid (450 mg, 89%). MS (ESI): 365.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> <i>tert</i>-Butyl 5-(6-Chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-3-yl)-3,6-di-hydropyridine-1(2<i>H</i>)-carboxylate (<b>70</b>)</h4><div class="NLM_p last">To a solution of <b>68</b> (5.00 g, 13.8 mmol) and <i>tert</i>-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate (4.30 g, 13.8 mmol) in water (14.0 mL) and DMSO (140 mL) was added K<sub>2</sub>CO<sub>3</sub> (4.20 g, 30.4 mmol) and Pd(dppf)Cl<sub>2</sub> (607 mg, 830 μmol). The mixture was stirred at 100 °C for 2 h under a nitrogen atmosphere. The mixture was diluted with water (400 mL) and extracted with EtOAc (160 mL × 5). The combined organic layers were washed with brine (120 mL × 3), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (SiO<sub>2</sub>, gradient: 0–6% EtOAc/petroleum ether) to afford the title compound as a white solid (3.37 g, 53%). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ ppm 8.80 (s, 1H), 7.63 (s, 1H), 7.53 (s, 1H), 6.38 (t, <i>J</i> = 4.0 Hz, 1H), 5.54 (s, 2H), 4.26 (s, 2H), 3.63–3.59 (m, 2H), 3.52 (t, <i>J</i> = 8.0 Hz, 2H), 2.39–2.37 (m, 2H), 1.51 (s, 9H), 0.87 (t, <i>J</i> = 8.0 Hz, 2H), −0.07 (s, 9H). MS (ESI): 464.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 6-Chloro-3-(tetrahydro-2<i>H</i>-pyran-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine (<b>71</b>)</h4><div class="NLM_p last">To a solution of <b>69</b> in EtOAc/EtOH (10.0 mL/10.0 mL) was added platinum dioxide (82.0 mg, 360 μmol). The headspace was purged with nitrogen, then hydrogen was bubbled through reaction solution for 10 min. The reaction was stirred under a balloon of hydrogen at room temperature for 3 h. After this time, the reaction was filtered through Celite, and the Celite plug was washed with EtOAc. The filtrate was concentrated and the crude product was purified by column chromatography (12 g SiO<sub>2</sub>, gradient: 10–50% EtOAc/heptane) to afford the title compound (405 mg, 91%) as a white solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 8.67 (s, 1H), 7.37 (s, 1H), 6.95 (s, 1H), 5.38 (s, 2H), 4.09 (dd, <i>J</i> = 3.4, 10.7 Hz, 2H), 3.61 (dt, <i>J</i> = 2.1, 11.8 Hz, 2H), 3.46 (t, <i>J</i> = 7.9 Hz, 2H), 3.08 (tt, <i>J</i> = 3.7, 11.8 Hz, 1H), 1.97 (br dd, <i>J</i> = 1.8, 13.4 Hz, 2H), 1.90–1.78 (m, 2H), 0.89 (t, <i>J</i> = 7.9 Hz, 2H), −0.05 (s, 9H). MS (ESI): 367.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> <i>tert</i>-Butyl 3-(6-Chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-3-yl)pi-peridine-1-carboxylate (<b>72</b>)</h4><div class="NLM_p last">To a solution of <b>70</b> (2.00 g, 4.30 mmol) in EtOH/EtOAc (100 mL/100 mL) was added platinum dioxide (294 mg, 1.30 mmol). The mixture was stirred at 25 °C for 4 h under an atmosphere of hydrogen (15 psi). After this time, the mixture was filtered and the filtrate was concentrated to afford the title compound (2.10 g, crude), which was used without purification. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 8.68 (s, 1H), 7.61 (s, 1H), 7.36 (s, 1H), 5.52 (s, 2H), 4.24 (d, <i>J</i> = 11.2 Hz, 1H), 4.03 (d, <i>J</i> = 12.4 Hz, 1H), 3.51 (t, <i>J</i> = 8.0 Hz, 2H), 3.07–2.96 (m, 3H), 2.19–2.17 (m, 1H), 1.82–1.79 (m, 2H), 1.66–1.62 (m, 1H), 1.48 (s, 9H), 0.85 (t, <i>J</i> = 8.0 Hz, 2H), −0.08 (s, 9H). MS (ESI): 466.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 6-Chloro-3-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine (<i>int</i>-<b>73</b>)</h4><div class="NLM_p last">A solution of <b>71</b> (405 mg, 1.10 mmol) in TBAF (1.0 M in THF, 3.8 mL) and ethylenediamine (450 μL, 6.70 mmol) was heated to 60 °C for 3 h. After this time, the reaction was diluted with brine and water and extracted with EtOAc (5 mL × 3). The combined organic layers were concentrated under reduced pressure. The crude product was purified by column chromatography (12 g SiO<sub>2</sub>, gradient: 25–100% EtOAc/heptane) to afford the title compound as a white solid (215 mg, 83%). MS (ESI): 237.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> <i>tert</i>-Butyl 3-(6-Chloro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-3-yl)piperidine-1-carboxylate (<i>int</i>-<b>74</b>)</h4><div class="NLM_p last">To a solution of <b>72</b> (2.10 g, 4.50 mmol) in THF (40.0 mL) was added TBAF (1.0 M, 13.5 mL) and ethylenediamine (1.8 mL, 27.1 mmol). The mixture was heated to 65 °C for 10 h. After this time, the mixture was diluted with water (100 mL) and extracted with EtOAc (40 mL x 5). The combined organic layers were dried over Na<sub>2</sub>SO4, filtered, and concentrated under reduced pressure to afford the title compound as a colorless oil (1.55 g, 86%), which was used without purification. MS (ESI): 336.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 4-(6-Chloro-3-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-1-yl)pyrimidin-2-amine (<i>int</i>-<b>75</b>)</h4><div class="NLM_p last">4-Chloropyrimidin-2-amine (60.0 mg, 460 μmol), <b>73</b> (100 mg, 420 μmol), NaH (22.0 mg, 550 μmol, 60% in mineral oil), and DMF (1.4 mL) were combined in a 2–5 mL microwave vial. The reaction mixture was heated to 110 °C for 40 min in a microwave reactor. After this time, the reaction was quenched with water (0.1 mL), diluted with DMSO until all solids dissolved (3.0 mL), filtered, and purified by prep-HPLC (column: Waters Sunfire C18 OBD 100 × 50 mm × 5 μm; gradient: MeCN/water (0.1 vol % TFA), 5–45%) to afford the title compound, and it was a white solid (137 mg, 73%, trifluoroacetate salt). MS (ESI): 330.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> <i>tert</i>-Butyl 3-(1-(2-Aminopyrimidin-4-yl)-6-chloro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-3-yl)piperidine-1-carboxylate (<b>76</b>)</h4><div class="NLM_p last">To a solution of <b>74</b> (900 mg, 2.70 mmol) in DMF (30.0 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (1.31 g, 4.02 mmol) and 4-chloropyrimidin-2-amine (347 mg, 2.68 mmol). The mixture was heated to 90 °C for 4 h. The mixture was cooled to room temperature, diluted with water (90 mL) and extracted with EtOAc (40 mL × 3). The combined organic layers were washed with brine (40 mL × 3), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude product was suspended in EtOAc/EtOH (30 mL/10 mL). The solid was collected by filtration. The filter cake was dried to afford the first batch of the title compound as white solid (625 mg, 54%). The filtrate was concentrated under reduced pressure and purified by column chromatography (SiO<sub>2</sub>, gradient: 0–75% EtOAc/petroleum ether) to afford the second batch of the title compound (300 mg, 26%) as a white solid (total amount isolated: 925 mg, 80%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.78–8.76 (m, 2H), 8.31 (d, <i>J</i> = 5.6 Hz, 1H), 8.02 (s, 1H), 7.08 (s, 2H), 7.00 (d, <i>J</i> = 5.2 Hz, 1H), 4.13–4.10 (m, 1H), 3.96–3.89 (m, 1H), 3.01–2.99 (m, 2H), 2.89–2.86 (m, 1H), 2.12–2.09 (m, 1H), 1.78–1.72 (m, 2H), 1.55–1.52 (m, 1H), 1.40 (s, 9H). MS (ESI): 429.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> 4-(6-Chloro-3-(1-methylpiperidin-3-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-1-yl)pyrimidin-2-amine (<b>77</b>)</h4><div class="NLM_p last">Step 1: To a solution of <b>76</b> (575 mg, 1.34 mmol) in MeOH (10.0 mL) was added HCl (4.0 M in EtOAc, 10.0 mL), and the mixture was stirred at room temperature for 2 h. The mixture was concentrated under reduced pressure to afford 4-(6-chloro-3-(piperidin-3-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-1-yl)pyrimidin-2-amine hydrochloride as a white solid (441 mg, crude), which was used in the next step without purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.46–9.43 (m, 1H), 9.16 (d, <i>J</i> = 8.4 Hz, 1H), 8.92 (s, 1H), 8.88 (s, 1H), 8.52 (d, <i>J</i> = 6.8 Hz, 1H), 8.31 (s, 1H), 7.47 (d, <i>J</i> = 6.8 Hz, 1H), 3.52–3.48 (m, 2H), 3.35–3.32 (m, 2H), 3.10–3.05 (m, 1H), 3.04–2.92 (m, 1H), 2.15–2.11 (m, 1H), 1.92–1.82 (m, 2H), 1.79–1.71 (m, 1H). MS (ESI): 329.0 [M + H]<sup>+</sup>. Step 2: To solution of the product from step 1 (441 mg, 1.34 mmol) in MeOH (15.0 mL) was added aq formaldehyde (678 μL, 8.04 mmol, 37% w/w) and NaCNBH<sub>3</sub> (421 mg, 6.70 mmol). The reaction was stirred at room temperature (26–29 °C) for 2 h. Sat. aq NaHCO<sub>3</sub> (25 mL) was added dropwise to the reaction mixture. The aqueous layer was separated and extracted with DCM (30 mL × 3). The combined organic layers were concentrated under reduced pressure. The crude product was purified by prep-TLC (1:8 MeOH/DCM) to afford the title compound (160 mg, 35%) as a white solid. MS (ESI): 343.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> <i>rac</i>-<i>trans</i>-Ethyl 2-(1-(2-Aminopyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)cyclopropane-1-carboxylate (<b>78</b>)</h4><div class="NLM_p">To a solution of <b>58</b> (50.0 mg, 200 μmol) and ethyl 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopropane-1-carboxylate (489 mg, 2.04 mmol) in DME (8.0 mL) and water (800 μL) was added K<sub>2</sub>CO<sub>3</sub> (84.0 mg, 610 μmol) and Pd(dtbpf)Cl<sub>2</sub> (14.0 mg, 20 μmol), and the mixture was stirred at 100 °C for 6 h. The mixture was filtered, and the filtrate was concentrated. The crude residue was purified by prep-HPLC (column: Xtimate C18 150 × 25 mm × 5 μm; gradient: MeCN/water (10 mM NH<sub>4</sub>HCO<sub>3</sub>), 15–45%, 25 mL/min) to give in order of elution: Isomer 1 (<i>cis</i>, racemic) (12.0 mg, 18%) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.71 (d, <i>J =</i> 1.0 Hz, 1H), 8.54 (d, <i>J =</i> 1.0 Hz, 1H), 8.29 (d, <i>J =</i> 5.5 Hz, 1H), 7.97 (d, <i>J =</i> 4.0 Hz, 1H), 6.93 (d, <i>J =</i> 6.0 Hz, 1H), 6.85 (dd, <i>J =</i> 0.5, 3.5 Hz, 1H), 3.86–3.81 (m, 2H), 2.93–2.87 (m, 1H), 2.27–2.23 (m, 1H), 1.93–1.89 (m, 1H), 1.55–1.51 (m, 1H), 0.91 (t, <i>J =</i> 7.0 Hz, 3H). LCMS (ESI, m/z): 324.1 [M + H]<sup>+</sup>.</div><div class="NLM_p">Isomer 2 (<i>trans</i>, racemic – desired diastereomer which was carried forward) (8.0 mg, 12%) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.70 (d, <i>J =</i> 1.0 Hz, 1H), 8.67 (s, 1H), 8.28 (d, <i>J =</i> 5.5 Hz, 1H), 7.95 (d, <i>J =</i> 4.0 Hz, 1H), 6.92 (d, <i>J =</i> 5.5 Hz, 1H), 6.85–6.84 (m, 1H), 4.20–4.15 (m, 2H), 2.84–2.80 (m, 1H), 2.24–2.20 (m, 1H), 1.69–1.67 (m, 1H), 1.61–1.58 (m, 1H), 1.28 (t, <i>J =</i> 7.0 Hz, 3H). LCMS (ESI, m/z): 324.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Relative stereochemistry was confirmed by 2D NMR.</div></div><div id="sec4_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> Methyl 3-(2-Tosylhydrazineylidene)cyclobutane-1-carboxylate (<b>80</b>)</h4><div class="NLM_p last">To a solution of methyl 3-oxocyclobutane-1-carboxylate 79 (60.0 g, 468 mmol) in MeOH (600 mL) was added <i>p</i>-toluenesulfonyl hydrazide (87.2 g, 468 mmol). The reaction mixture was stirred at 25 °C for 2 h, and a white suspension was formed. The mixture was filtered, and the solid was washed with MeOH (200 mL) to give the title compound as a white solid (120 g, 86%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 10.41 (s, 1H), 7.68 (d, <i>J</i> = 8.4 Hz, 2H), 7.38 (d, <i>J</i> = 8.0 Hz, 2H), 3.60 (s, 3H), 3.16–2.93 (m, 5H), 2.37 (s, 3H).</div></div><div id="sec4_1_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> Methyl 3-(1-(2-Aminopyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)cyclobut-2-ene-1-carboxylate (81)</h4><div class="NLM_p last">To a mixture of <b>58</b> (1.00 g, 4.07 mmol) and <b>80</b> (1.81 g, 6.11 mmol) in dioxane (160 mL) was added dppp (302 mg, 730 μmol), Cs<sub>2</sub>CO<sub>3</sub> (2.65 g, 8.14 mmol) and Pd(MeCN)<sub>2</sub>Cl<sub>2</sub> (95.0 mg, 370 μmol), and the reaction mixture was stirred at 95 °C under a nitrogen atmosphere for 20 h. The reaction was repeated two more times using 50.0 and 500 mg of <b>58</b>. The three reaction mixtures were combined and diluted with EtOAc (200 mL) and water (150 mL) and stirred vigorously for 5 min. The organic layer was separated, washed with brine (150 mL × 2), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude residue was purified by column chromatography (SiO<sub>2</sub>, gradient: 50–85% EtOAc/petroleum ether) to afford the title compound as a yellow solid (430 mg, 21%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 8.79 (s, 1H), 8.60 (s, 1H), 8.29 (d, <i>J</i> = 6.0 Hz, 1H), 8.01 (d, <i>J</i> = 3.6 Hz, 1H), 6.92 (d, <i>J</i> = 5.6 Hz, 1H), 6.89 (d, <i>J</i> = 3.6 Hz, 1H), 6.61 (d, <i>J</i> = 1.2 Hz, 1H), 3.74 (s, 3H), 3.30–3.23 (m, 2H), 3.15–3.11 (m, 1H). LCMS (ESI, m/z): 322.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> 2-(3-(1-(2-Aminopyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)cyclobut-2-en-1-yl)propan-2-ol (<b>82</b>)</h4><div class="NLM_p last">To a solution of <b>81</b> (150 mg, 470 μmol) in THF (8.0 mL) at 0 °C was added MeMgBr (1.56 mL, 4.67 mmol, 3.0 M in Et<sub>2</sub>O) dropwise over 3 min under a nitrogen atmosphere. After the addition was completed, the cooling bath was removed and the mixture was stirred at 17 °C for 1 h. The mixture was quenched with water (8 mL) and extracted with EtOAc (15 mL × 3). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude was purified by prep-TLC (1:15 MeOH/DCM) to give the title compound as a white solid (43.0 mg, 29%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 8.78 (s, 1H), 8.57 (s, 1H), 8.29 (d, <i>J</i> = 6.0 Hz, 1H), 8.00 (d, <i>J</i> = 3.6 Hz, 1H), 6.92 (d, <i>J</i> = 6.0 Hz, 1H), 6.89–6.88 (m, 1H), 6.69 (s, 1H), 2.95–2.89 (m, 2H), 2.80–2.76 (m, 1H), 1.29–1.27 (m, 6H). LCMS (ESI, m/z): 322.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> Methyl 3-(1-(2-Aminopyrimidin-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)bicyclo[1.1.1]pentane-1-carboxylate (<i>int</i>-<b>84</b>)</h4><div class="NLM_p last">Step 1: To a solution of <b>83</b> (100 mg, 410 μmol) in DMF (4.0 mL) and THF (2.0 mL) was added NaH (50.0 mg, 1.24 mmol, 60% dispersion in oil), and the reaction mixture was stirred at room temperature for 10 min. 4-Chloropyrimidin-2-amine (80.0 mg, 620 μmol) was then added, and the resulting suspension was heated to 140 °C in a microwave reactor for 30 min. After this time, the reaction mixture was cooled to room temperature, filtered through Celite and concentrated to give an equimolar mixture of 1-[1-(2-aminopyrimidin-4-yl)pyrrolo[3,2-<i>c</i>]pyridin-6-yl]bicyclo[1.1.1]pentane-3-carboxylic acid and 1-(1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)bicyclo[1.1.1]pentane-3-carboxylic acid as determined by <sup>1</sup>H NMR (75.0 mg). The mixture was used in the next step without purification. LCMS (ESI, m/z): 322.1 [M + H]<sup>+</sup>. Step 2: The mixture from step 1 (75.0 mg) in MeOH (2.0 mL) and DCM (1.0 mL) was added dropwise via a syringe trimethylsilyl diazomethane (0.68 mL, 2.0 M in hexanes) at room temperature, and the mixture was stirred for 1.5 h. After this time, the reaction mixture was diluted with DCM (3 mL) and washed with sat. aq NaHCO<sub>3</sub> (3 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford the title compound (59.0 mg, equimolar mixture with <b>83</b> as determined by NMR) which was used in the next step without purification. LCMS (ESI, m/z): 336.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> 4-(6-Chloro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-1-yl)-<i>N</i>-methylpyrimidin-2-amine (<i>int</i>-<b>85</b>)</h4><div class="NLM_p last">To a suspension of NaH (29.0 mg, 724 μmol, 60% in mineral oil) in DMF (2.0 mL) was added <b>51</b> (80.0 mg, 517 μmol) in DMF (1.0 mL). The mixture was stirred at room temperature (25–31 °C) for 40 min. Then 4-chloro-<i>N</i>-methylpyrimidin-2-amine (74.3 mg, 517 μmol) was added. The reaction was stirred at 60 °C for 4 h. The reaction was quenched with water (5 mL), the precipitated solid was collected by filtration. The filter cake was dried under vacuum to afford a mixture of 4-(6-chloro-2,3-dihydro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-1-yl)-<i>N</i>-methylpyrimidin-2-amine and title compound <b>85</b> (40.0 mg, crude) as a white solid, which was used in the next step without further purification. MS (ESI): 262.0 [M + H]<sup>+</sup> and 260.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> 6-(6-Chloro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-1-yl)pyrimidin-4-amine (<i>int</i>-<b>86</b>)</h4><div class="NLM_p last">To a solution of <b>50</b> (500 mg, 3.28 mmol) in DMF (10.0 mL) was added NaH (393 mg, 9.83 mmol, 60% in mineral oil) portionwise. The resulting mixture was stirred for 30 min. 6-Chloropyrimidin-4-amine (849 mg, 6.55 mmol) was then added, and the reaction was stirred at 60 °C for 16 h. The reaction mixture was concentrated, and the residue was triturated with petroleum ether/EtOAc (5:1, 40 mL) to give the crude residue. The reaction was repeated with 100 mg of <b>50</b>, and the crude residues from the two reactions were combined and subjected to prep-HPLC purification (column: Xtimate C18 150 × 30 mm × 5 μm; gradient: MeCN/water (10 mM NH<sub>4</sub>HCO<sub>3</sub>), 20–50%, 25 mL/min) to afford the title compound as a white solid (130 mg, 13%). MS (ESI): 246.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> 4-(6-Chloro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-1-yl)-6-methylpyrimidin-2-amine (<b>87</b>)</h4><div class="NLM_p last">To a solution of <b>50</b> (300 mg, 1.97 mmol) in DMF (5.0 mL) was added NaH (118 mg, 2.95 mmol, 60% in mineral oil). The reaction mixture was stirred at 30 °C for 30 min. Then, 4-chloro-6-methylpyrimidin-2-amine (565 mg, 3.93 mmol) was added. The reaction mixture was stirred at 60 °C for 12 h. The reaction was quenched with water (25 mL), and the aqueous layer was separated and extracted with EtOAc (25 mL × 3). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude residue was suspended in DCM (3 mL) and petroleum ether (45 mL), the resulting slurry was stirred at 30 °C for 1 h and filtered. The filter cake was washed with petroleum ether (15 mL × 3) and dried under reduced pressure to afford the title compound as a yellow solid (410 mg, crude). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.73(s, 1H), 8.71(s, 1H), 8.19 (d, <i>J</i> = 2.8 Hz, 1H), 6.99 (br s, 2H), 6.93 (s, 2H), 2.31 (s, 3H). MS (ESI): 260.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> 4-(6-Chloro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-1-yl)-6-methoxypyrimidin-2-amine (<i>int</i>-<b>88</b>)</h4><div class="NLM_p last">To a solution of <b>50</b> (300 mg, 1.97 mmol) in DMF (2.0 mL) was added to NaH (118 mg, 2.95 mmol, 60% in mineral oil) in DMF (2.0 mL) at room temperature. The resulting mixture was stirred at room temperature for 1 h. 4-Chloro-6-methoxypyrimidin-2-amine (377 mg, 2.36 mmol) was added. The reaction was stirred at 60 °C for 12 h, then at 90 °C for 12 h. The reaction was cooled to room temperature and quenched with water (3 mL). EtOAc (30 mL) and water (25 mL) were added, and the aqueous layer was separated and extracted with EtOAc (10 mL × 2). The combined organic layers were washed with brine (10 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150 × 30 mm × 4 μm; gradient: MeCN/water (0.05% HCl), 26–46%, 25 mL/min) to afford the title compound as a white solid (180 mg, 33%). MS (ESI): 276.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> 4-(6-Chloro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-1-yl)-5-methoxypyrimidin-2-amine (<i>int</i>-<b>89</b>)</h4><div class="NLM_p last">To a suspension of NaH (39.3 mg, 983 μmol, 60% in mineral oil) in DMF (6.0 mL) was added <b>50</b> (100 mg, 655 μmol). The resulting mixture was stirred at 18 °C for 30 min. 4-Chloro-5-methoxypyrimidin-2-amine (116 mg, 655 μmol) was added, and the reaction mixture was heated at 70 °C for 5 h. The mixture was cooled to room temperature and quenched with water (10 mL). The aqueous layer was separated and extracted with EtOAc (15 mL × 5). The combined organic layers were washed with brine (50 mL × 3), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude residue was purified by prep-TLC (1:10 MeOH/DCM) to afford the title compound (30.0 mg, 80% purity) and recovered <b>50</b> (20.0 mg). MS (ESI): 276.0 [M + H]<sup>+</sup>.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i94"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00382" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86280" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86280" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00382?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00382</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Description of biochemical and cellular assays; description of glutathione (GSH) experiments; experimental conditions for crystallization, collection, and refinement statistics for compounds <b>3</b> and <b>18</b>; description of cytotoxicity assay; selectivity profile of compounds <b>18</b>, <b>19</b>, and <b>31</b>; description of K<sub>p,uu</sub> studies; (Figure S1) unaltered western blots supporting quantification of tau phosphorylation summarized in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>; (Figure S2) basal Ser 422 levels in the developing rat brain; (Figure S3) unaltered western blots supporting quantification of tau phosphorylation summarized in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>; (Figure S4) neurotoxicity of lead compound <b>31</b> in primary mouse neurons; methods supporting in vivo pharmacology; general description of in vitro DMPK assays; and HPLC data for compounds <b>18</b>, <b>19</b>, and <b>31</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00382/suppl_file/jm1c00382_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00382/suppl_file/jm1c00382_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00382/suppl_file/jm1c00382_si_001.pdf">jm1c00382_si_001.pdf (3.13 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00382/suppl_file/jm1c00382_si_002.csv">jm1c00382_si_002.csv (2.33 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00382" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83444" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83444" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tamara Halkina</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e5918a8884cb8d84898e8c8b84a5878c8a82808bcb868a88"><span class="__cf_email__" data-cfemail="d5a1bab8b4fbbdb4b9bebcbbb495b7bcbab2b0bbfbb6bab8">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Felix Gonzalez-Lopez de Turiso</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9736-0907" title="Orcid link">http://orcid.org/0000-0001-9736-0907</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#147271787d6c3a737b7a6e7578716e787b64716e70716061667d677b54767d7b73717a3a777b79"><span class="__cf_email__" data-cfemail="c2a4a7aeabbaeca5adacb8a3aea7b8aeadb2a7b8a6a7b6b7b0abb1ad82a0abada5a7aceca1adaf">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jaclyn L. Henderson</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7097-1350" title="Orcid link">http://orcid.org/0000-0002-7097-1350</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Edward Y. Lin</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin K. Himmelbauer</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4960-4457" title="Orcid link">http://orcid.org/0000-0003-4960-4457</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">J. Howard Jones</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marta Nevalainen</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jun Feng</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kristopher King</span> - <span class="hlFld-Affiliation affiliation">Department
of Drug Metabolism and Pharmacokinetics, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Rooney</span> - <span class="hlFld-Affiliation affiliation">Department
of Drug Metabolism and Pharmacokinetics, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joshua L. Johnson</span> - <span class="hlFld-Affiliation affiliation">Department
of Drug Metabolism and Pharmacokinetics, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Douglas J. Marcotte</span> - <span class="hlFld-Affiliation affiliation">Department
of Physical Biochemistry and Molecular Design, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jayanth V. Chodaparambil</span> - <span class="hlFld-Affiliation affiliation">Department
of Physical Biochemistry and Molecular Design, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">P. Rajesh Kumar</span> - <span class="hlFld-Affiliation affiliation">Department
of Physical Biochemistry and Molecular Design, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas A. Patterson</span> - <span class="hlFld-Affiliation affiliation">Department
of Physical Biochemistry and Molecular Design, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paramasivam Murugan</span> - <span class="hlFld-Affiliation affiliation">Department
of Bioassays, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eli Schuman</span> - <span class="hlFld-Affiliation affiliation">Department
of Bioassays, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">LaiYee Wong</span> - <span class="hlFld-Affiliation affiliation">Department
of Bioassays, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas Hesson</span> - <span class="hlFld-Affiliation affiliation">Department
of Bioassays, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarah Lamore</span> - <span class="hlFld-Affiliation affiliation">Department
of Preclinical Safety, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Channa Bao</span> - <span class="hlFld-Affiliation affiliation">Department
of Emerging Neurosciences Research Unit, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Calhoun</span> - <span class="hlFld-Affiliation affiliation">Department
of Emerging Neurosciences Research Unit, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hannah Certo</span> - <span class="hlFld-Affiliation affiliation">Department
of Emerging Neurosciences Research Unit, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brenda Amaral</span> - <span class="hlFld-Affiliation affiliation">Department
of Emerging Neurosciences Research Unit, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gregory M. Dillon</span> - <span class="hlFld-Affiliation affiliation">Department
of Emerging Neurosciences Research Unit, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rab Gilfillan</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br><p class="inlineNote">Compound <b>3</b>: 7JXX; Compound <b>18</b>: 7JXX. Authors will release the atomic coordinates and experimental data upon article publication.</p><br /></br><p class="inlineNote">All in vivo studies were conducted in accordance with Biogen Institutional Animal Care and Use Committee (IACUC) guidelines.</p></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i97">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05688" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05688" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Kevin Barry for chiral separation support, Michael Dechantsreiter for parallel synthesis support, Sam Cziria for compound handling, and Jiasheng Huang for assistance with the collection of analytical data. We thank Xiaoping Wang, Hushan Zhang, and Wenkui Zhao for efforts coordinating the synthesis of some of the compounds included in this manuscript and Simone Sciabola and Claire Metrick for helpful discussions.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">ABBREVIATIONS Used</td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s disease</p></td></tr><tr><td class="NLM_term">aq</td><td class="NLM_def"><p class="first last">aqueous</p></td></tr><tr><td class="NLM_term">Cl</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">compd</td><td class="NLM_def"><p class="first last">compound</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">dppf</td><td class="NLM_def"><p class="first last">1,1′-bis(diphenylphosphino)ferrocene</p></td></tr><tr><td class="NLM_term">dtbpf</td><td class="NLM_def"><p class="first last">1,1′-bis(di-<i>tert</i>-butylphosphino)ferrocene</p></td></tr><tr><td class="NLM_term">equiv.</td><td class="NLM_def"><p class="first last">equivalent</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">efflux ratio</p></td></tr><tr><td class="NLM_term">ESI</td><td class="NLM_def"><p class="first last">electrospray ionization</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">HPPB</td><td class="NLM_def"><p class="first last">human plasma protein binding</p></td></tr><tr><td class="NLM_term">Int</td><td class="NLM_def"><p class="first last">intermediate</p></td></tr><tr><td class="NLM_term">IP</td><td class="NLM_def"><p class="first last">intraperitoneal</p></td></tr><tr><td class="NLM_term">MDCK</td><td class="NLM_def"><p class="first last">Madin–Darby canine kidney cells</p></td></tr><tr><td class="NLM_term">MDR1</td><td class="NLM_def"><p class="first last">multidrug resistance 1</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">NIK</td><td class="NLM_def"><p class="first last">NF-κB inducing kinase</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">PSA</td><td class="NLM_def"><p class="first last">polar surface area</p></td></tr><tr><td class="NLM_term">RLM</td><td class="NLM_def"><p class="first last">rat liver microsomes</p></td></tr><tr><td class="NLM_term">RPPB</td><td class="NLM_def"><p class="first last">rat plasma protein binding</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">satd.</td><td class="NLM_def"><p class="first last">saturated</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">standard error of the mean</p></td></tr><tr><td class="NLM_term">Ser</td><td class="NLM_def"><p class="first last">serine</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr><tr><td class="NLM_term">SPhos</td><td class="NLM_def"><p class="first last">2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin layer chromatography</p></td></tr><tr><td class="NLM_term">TTBK1</td><td class="NLM_def"><p class="first last">tau tubulin kinase 1</p></td></tr><tr><td class="NLM_term">TTBK2</td><td class="NLM_def"><p class="first last">tau tubulin kinase 2</p></td></tr><tr><td class="NLM_term">XPhos</td><td class="NLM_def"><p class="first last">2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i99">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83071" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83071" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 31 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlautman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciborowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikezu, T.</span></span> <span> </span><span class="NLM_article-title">Spatial learning impairment, enhanced CDK5/p35 activity, and downregulation of NMDA receptor expression in transgenic mice expressing tau-tubulin kinase 1</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">14511</span>– <span class="NLM_lpage">14521</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.3417-08.2008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1523%2FJNEUROSCI.3417-08.2008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=19118186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsF2nuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=14511-14521&author=S.+Satoauthor=J.+Xuauthor=S.+Okuyamaauthor=L.+B.+Martinezauthor=S.+M.+Walshauthor=M.+T.+Jacobsenauthor=R.+J.+Swanauthor=J.+D.+Schlautmanauthor=P.+Ciborowskiauthor=T.+Ikezu&title=Spatial+learning+impairment%2C+enhanced+CDK5%2Fp35+activity%2C+and+downregulation+of+NMDA+receptor+expression+in+transgenic+mice+expressing+tau-tubulin+kinase+1&doi=10.1523%2FJNEUROSCI.3417-08.2008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Spatial learning impairment, enhanced CDK5/p35 activity, and downregulation of NMDA receptor expression in transgenic mice expressing tau-tubulin kinase 1</span></div><div class="casAuthors">Sato, Shinji; Xu, Jiqing; Okuyama, Satoshi; Martinez, Lindsey B.; Walsh, Shannon M.; Jacobsen, Michael T.; Swan, Russell J.; Schlautman, Joshua D.; Ciborowski, Pawel; Ikezu, Tsuneya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">53</span>),
    <span class="NLM_cas:pages">14511-14521</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Tau-tubulin kinase-1 (TTBK1) is involved in phosphorylation of tau protein at specific Serine/Threonine residues found in paired helical filaments, suggesting its role in tauopathy pathogenesis.  We found that TTBK1 levels were upregulated in brains of human Alzheimer' disease (AD) patients compared with age-matched non-AD controls.  To understand the effects of TTBK1 activation in vivo, we developed transgenic mice harboring human full-length TTBK1 genomic DNA (TTBK1-Tg).  Transgenic TTBK1 is highly expressed in subiculum and cortical pyramidal layers, and induces phosphorylated neurofilament aggregation.  TTBK1-Tg mice show significant age-dependent memory impairment as detd. by radial arm water maze test, which is assocd. with enhancement of tau and neurofilament phosphorylation, increased levels of p25 and p35, both activators of cyclin-dependent protein kinase 5 (CDK5), enhanced calpain I activity, and reduced levels of hippocampal NMDA receptor types 2B (NR2B) and D.  Enhanced CDK5/p35 complex formation is strongly correlated with dissocn. of F-actin from p35, suggesting the inhibitory mechanism of CDK5/p35 complex formation by F-actin.  Expression of recombinant TTBK1 in primary mouse cortical neurons significantly downregulated NR2B in a CDK5- and calpain-dependent manner.  These data suggest that TTBK1 in AD brain may be one of the underlying mechanisms inducing CDK5 and calpain activation, NR2B downregulation, and subsequent memory dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZrV95H_8JCbVg90H21EOLACvtfcHk0lgJ1dopm9vyqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsF2nuw%253D%253D&md5=8a248e4807d46a31e1d49106bb66fc75</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.3417-08.2008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.3417-08.2008%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DOkuyama%26aufirst%3DS.%26aulast%3DMartinez%26aufirst%3DL.%2BB.%26aulast%3DWalsh%26aufirst%3DS.%2BM.%26aulast%3DJacobsen%26aufirst%3DM.%2BT.%26aulast%3DSwan%26aufirst%3DR.%2BJ.%26aulast%3DSchlautman%26aufirst%3DJ.%2BD.%26aulast%3DCiborowski%26aufirst%3DP.%26aulast%3DIkezu%26aufirst%3DT.%26atitle%3DSpatial%2520learning%2520impairment%252C%2520enhanced%2520CDK5%252Fp35%2520activity%252C%2520and%2520downregulation%2520of%2520NMDA%2520receptor%2520expression%2520in%2520transgenic%2520mice%2520expressing%2520tau-tubulin%2520kinase%25201%26jtitle%3DJ.%2520Neurosci.%26date%3D2008%26volume%3D28%26spage%3D14511%26epage%3D14521%26doi%3D10.1523%2FJNEUROSCI.3417-08.2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikezu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingraham Dixie, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaibuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikezu, T.</span></span> <span> </span><span class="NLM_article-title">Tau-tubulin kinase 1 and amyloid-β peptide induce phosphorylation of collapsin response mediator protein-2 and enhance neurite degeneration in Alzheimer disease mouse models</span>. <i>Acta Neuropathol. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">12</span>, <span class="refDoi"> DOI: 10.1186/s40478-020-0890-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1186%2Fs40478-020-0890-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=32019603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BB3cXltFemu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=12&author=S.+Ikezuauthor=K.+L.+Ingraham+Dixieauthor=L.+Koroauthor=T.+Watanabeauthor=K.+Kaibuchiauthor=T.+Ikezu&title=Tau-tubulin+kinase+1+and+amyloid-%CE%B2+peptide+induce+phosphorylation+of+collapsin+response+mediator+protein-2+and+enhance+neurite+degeneration+in+Alzheimer+disease+mouse+models&doi=10.1186%2Fs40478-020-0890-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Tau-tubulin kinase 1 and amyloid-β peptide induce phosphorylation of collapsin response mediator protein-2 and enhance neurite degeneration in Alzheimer disease mouse models</span></div><div class="casAuthors">Ikezu, Seiko; Ingraham Dixie, Kaitlin L.; Koro, Lacin; Watanabe, Takashi; Kaibuchi, Kozo; Ikezu, Tsuneya</div><div class="citationInfo"><span class="NLM_cas:title">Acta Neuropathologica Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12</span>CODEN:
                <span class="NLM_cas:coden">ANCCC9</span>;
        ISSN:<span class="NLM_cas:issn">2051-5960</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The accumulation of phosphorylated tau protein (pTau) in the entorhinal cortex (EC) is the earliest tau pathol. in Alzheimer's disease (AD).  Tau tubulin kinase-1 (TTBK1) is a neuron-specific tau kinase and expressed in the EC and hippocampal regions in both human and mouse brains.  Here we report that collapsin response mediator protein-2 (CRMP2), a crit. mediator of growth cone collapse, is a new downstream target of TTBK1 and is accumulated in the EC region of early stage AD brains.  TTBK1 transgenic mice show severe axonal degeneration in the perforant path, which is exacerbated by crossing with Tg2576 mice expressing Swedish familial AD mutant of amyloid precursor protein (APP).  TTBK1 mice show accumulation of phosphorylated CRMP2 (pCRMP2), in the EC at 10 mo of age, whereas age-matched APP/TTBK1 bigenic mice show pCRMP2 accumulation in both the EC and hippocampal regions.  Amyloid-β peptide (Aβ) and TTBK1 suppress the kinetics of microtubule polymn. and TTBK1 reduces the neurite length of primary cultured neurons in Rho kinase-dependent manner in vitro.  Silencing of TTBK1 or expression of dominant-neg. Rho kinase demonstrates that Aβ induces CRMP2 phosphorylation at threonine 514 in a TTBK1-dependent manner, and TTBK1 enhances Aβ-induced CRMP2 phosphorylation in Rho kinase-dependent manner in vitro.  Furthermore, TTBK1 expression induces pCRMP2 complex formation with pTau in vitro, which is enhanced upon Aβ stimulation in vitro.  Finally, pCRMP2 forms a complex with pTau in the EC tissue of TTBK1 mice in vivo, which is exacerbated in both the EC and hippocampal tissues in APP/TTBK1 mice.  These results suggest that TTBK1 and Aβ induce phosphorylation of CRMP2, which may be causative for the neurite degeneration and somal accumulation of pTau in the EC neurons, indicating crit. involvement of TTBK1 and pCRMP2 in the early AD pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmddVFBkzOn7Vg90H21EOLACvtfcHk0lh025XJUZUAcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXltFemu74%253D&md5=5e577e0834a2ec652556383dedd6400c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1186%2Fs40478-020-0890-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40478-020-0890-4%26sid%3Dliteratum%253Aachs%26aulast%3DIkezu%26aufirst%3DS.%26aulast%3DIngraham%2BDixie%26aufirst%3DK.%2BL.%26aulast%3DKoro%26aufirst%3DL.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DKaibuchi%26aufirst%3DK.%26aulast%3DIkezu%26aufirst%3DT.%26atitle%3DTau-tubulin%2520kinase%25201%2520and%2520amyloid-%25CE%25B2%2520peptide%2520induce%2520phosphorylation%2520of%2520collapsin%2520response%2520mediator%2520protein-2%2520and%2520enhance%2520neurite%2520degeneration%2520in%2520Alzheimer%2520disease%2520mouse%2520models%26jtitle%3DActa%2520Neuropathol.%2520Commun.%26date%3D2020%26volume%3D8%26spage%3D12%26doi%3D10.1186%2Fs40478-020-0890-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerny, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buescher, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikezu, T.</span></span> <span> </span><span class="NLM_article-title">Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">1573</span>– <span class="NLM_lpage">1584</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2006.04059.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1111%2Fj.1471-4159.2006.04059.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=16923168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVymtLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2006&pages=1573-1584&author=S.+Satoauthor=R.+L.+Cernyauthor=J.+L.+Buescherauthor=T.+Ikezu&title=Tau-tubulin+kinase+1+%28TTBK1%29%2C+a+neuron-specific+tau+kinase+candidate%2C+is+involved+in+tau+phosphorylation+and+aggregation&doi=10.1111%2Fj.1471-4159.2006.04059.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation</span></div><div class="casAuthors">Sato, Shinji; Cerny, Ronald L.; Buescher, James L.; Ikezu, Tsuneya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1573-1584</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Neurofibrillary tangles, which are major pathol. hallmarks of Alzheimer's disease (AD), are composed of paired helical filaments (PHFs) contg. hyper-phosphorylated tau.  Specific kinases regulate tau phosphorylation and are closely linked to the pathogenesis of AD.  We have characterized a human tau-tubulin kinase 1 (TTBK1) gene located on chromosome 6p21.1.  TTBK1 is a serine/threonine/tyrosine kinase that is conserved among species and belongs to the casein kinase 1 superfamily.  It is specifically expressed in the brain, esp. in the cytoplasm of cortical and hippocampal neurons.  TTBK1 phosphorylates tau proteins in both a Mg2+- and a Mn2+-dependent manner.  Phosphopeptide mapping and immunoblotting anal. confirmed a direct tau phosphorylation by TTBK1 at Ser198, Ser199, Ser202 and Ser422, which are also phosphorylated in PHFs.  TTBK1 also induces tau aggregation in human neuronal cells in a dose-dependent manner.  We conclude that TTBK1 is a neuron-specific dual kinase involved in tau phosphorylation at AD-related sites and is also assocd. with tau aggregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPnxUboOe6fLVg90H21EOLACvtfcHk0lh025XJUZUAcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVymtLnL&md5=cacb0fef484676a20567bed3ef90c3a5</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2006.04059.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2006.04059.x%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DS.%26aulast%3DCerny%26aufirst%3DR.%2BL.%26aulast%3DBuescher%26aufirst%3DJ.%2BL.%26aulast%3DIkezu%26aufirst%3DT.%26atitle%3DTau-tubulin%2520kinase%25201%2520%2528TTBK1%2529%252C%2520a%2520neuron-specific%2520tau%2520kinase%2520candidate%252C%2520is%2520involved%2520in%2520tau%2520phosphorylation%2520and%2520aggregation%26jtitle%3DJ.%2520Neurochem.%26date%3D2006%26volume%3D98%26spage%3D1573%26epage%3D1584%26doi%3D10.1111%2Fj.1471-4159.2006.04059.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calhoun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaral, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajrami, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabah, D.</span></span> <span> </span><span class="NLM_article-title">Acute inhibition of the CNS-specific kinase TTBK1 significantly lowers tau phosphorylation at several disease relevant sites</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span>, <span class="NLM_elocation-id">e0228771</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0228771</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1371%2Fjournal.pone.0228771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=32255788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvVGlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&author=G.+M.+Dillonauthor=J.+L.+Hendersonauthor=C.+Baoauthor=J.+A.+Joyceauthor=M.+Calhounauthor=B.+Amaralauthor=K.+W.+Kingauthor=B.+Bajramiauthor=D.+Rabah&title=Acute+inhibition+of+the+CNS-specific+kinase+TTBK1+significantly+lowers+tau+phosphorylation+at+several+disease+relevant+sites&doi=10.1371%2Fjournal.pone.0228771"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Acute inhibition of the CNS-specific kinase TTBK1 significantly lowers tau phosphorylation at several disease relevant sites</span></div><div class="casAuthors">Dillon, Gregory M.; Henderson, Jaclyn L.; Bao, Channa; Joyce, John A.; Calhoun, Michael; Amaral, Brenda; King, Kristopher W.; Bajrami, Bekim; Rabah, Dania</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e0228771</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Hyperphosphorylated tau protein is a pathol. hallmark of numerous neurodegenerative diseases and the level of tau pathol. is correlated with the degree of cognitive impairment.  Tau hyper-phosphorylation is thought to be an early initiating event in the cascade leading to tau toxicity and neuronal death.  Inhibition of tau phosphorylation therefore represents an attractive therapeutic strategy.  However, the widespread expression of most kinases and promiscuity of their substrates, along with poor selectivity of most kinase inhibitors, have resulted in systemic toxicities that have limited the advancement of tau kinase inhibitors into the clinic.  We therefore focused on the CNS-specific tau kinase, TTBK1, and investigated whether selective inhibition of this kinase could represent a viable approach to targeting tau phosphorylation in disease.  In the current study, we demonstrate that TTBK1 regulates tau phosphorylation using overexpression or knockdown of this kinase in heterologous cells and primary neurons.  Importantly, we find that TTBK1-specific phosphorylation of tau leads to a loss of normal protein function including a decrease in tau-tubulin binding and deficits in tubulin polymn.  We demonstrate substantial lowering of tau phosphorylation at multiple sites implicated in disease, suggesting that TTBK1 inhibitors may represent an exciting new approach in the search for neurodegenerative disease therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5IbKU-F7Em7Vg90H21EOLACvtfcHk0lhkVvFD3xVdaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvVGlt7s%253D&md5=d8f8a6bdcec11c32359472f657434826</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0228771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0228771%26sid%3Dliteratum%253Aachs%26aulast%3DDillon%26aufirst%3DG.%2BM.%26aulast%3DHenderson%26aufirst%3DJ.%2BL.%26aulast%3DBao%26aufirst%3DC.%26aulast%3DJoyce%26aufirst%3DJ.%2BA.%26aulast%3DCalhoun%26aufirst%3DM.%26aulast%3DAmaral%26aufirst%3DB.%26aulast%3DKing%26aufirst%3DK.%2BW.%26aulast%3DBajrami%26aufirst%3DB.%26aulast%3DRabah%26aufirst%3DD.%26atitle%3DAcute%2520inhibition%2520of%2520the%2520CNS-specific%2520kinase%2520TTBK1%2520significantly%2520lowers%2520tau%2520phosphorylation%2520at%2520several%2520disease%2520relevant%2520sites%26jtitle%3DPLoS%2520One%26date%3D2020%26volume%3D15%26doi%3D10.1371%2Fjournal.pone.0228771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballatore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, V. M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojanowski, J. Q.</span></span> <span> </span><span class="NLM_article-title">Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">663</span>– <span class="NLM_lpage">672</span>, <span class="refDoi"> DOI: 10.1038/nrn2194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1038%2Fnrn2194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=17684513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpt1Crt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=663-672&author=C.+Ballatoreauthor=V.+M.-Y.+Leeauthor=J.+Q.+Trojanowski&title=Tau-mediated+neurodegeneration+in+Alzheimer%E2%80%99s+disease+and+related+disorders&doi=10.1038%2Fnrn2194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Tau-mediated neurodegeneration in Alzheimer's disease and related disorders</span></div><div class="casAuthors">Ballatore, Carlo; Lee, Virginia M.-Y.; Trojanowski, John Q.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">663-672</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Advances in the understanding of the mechanisms of tau-mediated neurodegeneration in Alzheimer's disease (AD) and related tauopathies, which are characterized by prominent CNS accumulations of fibrillar tau inclusions, are rapidly moving this previously underexplored disease pathway to center stage for disease-modifying drug discovery efforts.  However, controversies abound concerning whether or not the deleterious effects of tau pathologies result from toxic gains-of-function by pathol. tau or from crit. losses of normal tau function in the disease state.  This review summarizes the most recent advances in the authors' knowledge of the mechanisms of tau-mediated neurodegeneration to forge an integrated concept of those tau-linked disease processes that drive the onset and progression of AD and related tauopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8-k_a3SnV7bVg90H21EOLACvtfcHk0lhkVvFD3xVdaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpt1Crt78%253D&md5=eef3cc99033075b3215b739521d672f6</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrn2194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn2194%26sid%3Dliteratum%253Aachs%26aulast%3DBallatore%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DV.%2BM.-Y.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26atitle%3DTau-mediated%2520neurodegeneration%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520and%2520related%2520disorders%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2007%26volume%3D8%26spage%3D663%26epage%3D672%26doi%3D10.1038%2Fnrn2194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelkow, E.</span></span> <span> </span><span class="NLM_article-title">Tau in physiology and pathology</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1038/nrn.2015.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1038%2Fnrn.2015.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=26631930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A280%3ADC%252BC28vnsVGhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=5-21&author=Y.+Wangauthor=E.+Mandelkow&title=Tau+in+physiology+and+pathology&doi=10.1038%2Fnrn.2015.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tau in physiology and pathology</span></div><div class="casAuthors">Wang Yipeng; Mandelkow Eckhard; Wang Yipeng; Mandelkow Eckhard; Mandelkow Eckhard</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tau is a microtubule-associated protein that has a role in stabilizing neuronal microtubules and thus in promoting axonal outgrowth.  Structurally, tau is a natively unfolded protein, is highly soluble and shows little tendency for aggregation.  However, tau aggregation is characteristic of several neurodegenerative diseases known as tauopathies.  The mechanisms underlying tau pathology and tau-mediated neurodegeneration are debated, but considerable progress has been made in the field of tau research in recent years, including the identification of new physiological roles for tau in the brain.  Here, we review the expression, post-translational modifications and functions of tau in physiology and in pathophysiology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRryzboeQaGukdrW1FkXG-fW6udTcc2eadodCixAuE3bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vnsVGhtg%253D%253D&md5=7f0fda5812709bc043731f34a45fb24e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrn.2015.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn.2015.1%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMandelkow%26aufirst%3DE.%26atitle%3DTau%2520in%2520physiology%2520and%2520pathology%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2016%26volume%3D17%26spage%3D5%26epage%3D21%26doi%3D10.1038%2Fnrn.2015.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaidi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundke-Iqbal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, K.</span></span> <span> </span><span class="NLM_article-title">Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">5562</span>– <span class="NLM_lpage">5566</span>, <span class="refDoi"> DOI: 10.1073/pnas.91.12.5562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1073%2Fpnas.91.12.5562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=8202528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A280%3ADyaK2c3mtFKhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=5562-5566&author=A.+C.+Alonsoauthor=T.+Zaidiauthor=I.+Grundke-Iqbalauthor=K.+Iqbal&title=Role+of+abnormally+phosphorylated+tau+in+the+breakdown+of+microtubules+in+Alzheimer+disease&doi=10.1073%2Fpnas.91.12.5562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease</span></div><div class="casAuthors">Alonso A C; Zaidi T; Grundke-Iqbal I; Iqbal K</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5562-6</span>
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The microtubule assembly-promoting activity of different pools of tau protein isolated from Alzheimer disease (AD) and control brains and the effect of dephosphorylation on this activity were studied.  Tau isolated from a 2.5% perchloric extract of AD brain had almost the same activity as that obtained from control brain, and this activity did not change significantly on dephosphorylation.  Abnormally phosphorylated tau (AD P-tau) isolated from brain homogenate of AD patients had little activity, and upon dephosphorylation with alkaline phosphatase, its activity increased to approximately the same level as the acid-soluble tau.  Addition of AD P-tau to a mixture of normal tau and tubulin inhibited microtubule assembly.  AD P-tau bound to normal tau but not to tubulin.  These studies suggest that the abnormal phosphorylation of tau might be responsible for the breakdown of microtubules in affected neurons in AD not only because the altered protein has little microtubule-promoting activity but also because it interacts with normal tau, making the latter unavailable for promoting the assembly of tubulin into microtubules.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5nJ1wCLFdwrZpSb_XWfMrfW6udTcc2eZQm4NKzSSy5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c3mtFKhtA%253D%253D&md5=4b73493ac98f48a1d5b6976104bd5ca3</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.12.5562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.12.5562%26sid%3Dliteratum%253Aachs%26aulast%3DAlonso%26aufirst%3DA.%2BC.%26aulast%3DZaidi%26aufirst%3DT.%26aulast%3DGrundke-Iqbal%26aufirst%3DI.%26aulast%3DIqbal%26aufirst%3DK.%26atitle%3DRole%2520of%2520abnormally%2520phosphorylated%2520tau%2520in%2520the%2520breakdown%2520of%2520microtubules%2520in%2520Alzheimer%2520disease%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1994%26volume%3D91%26spage%3D5562%26epage%3D5566%26doi%3D10.1073%2Fpnas.91.12.5562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murayama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshiike, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyasaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murayama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takashima, A.</span></span> <span> </span><span class="NLM_article-title">Granular tau oligomers as intermediates of tau filaments</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">3856</span>– <span class="NLM_lpage">3861</span>, <span class="refDoi"> DOI: 10.1021/bi061359o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi061359o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisVGlsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=3856-3861&author=S.+Maedaauthor=N.+Saharaauthor=Y.+Saitoauthor=M.+Murayamaauthor=Y.+Yoshiikeauthor=H.+Kimauthor=T.+Miyasakaauthor=S.+Murayamaauthor=A.+Ikaiauthor=A.+Takashima&title=Granular+tau+oligomers+as+intermediates+of+tau+filaments&doi=10.1021%2Fbi061359o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Granular Tau Oligomers as Intermediates of Tau Filaments</span></div><div class="casAuthors">Maeda, Sumihiro; Sahara, Naruhiko; Saito, Yuko; Murayama, Miyuki; Yoshiike, Yuji; Kim, Hyonchol; Miyasaka, Tomohiro; Murayama, Shigeo; Ikai, Atsushi; Takashima, Akihiko</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3856-3861</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Neurofibrillary tangles (NFTs) are pathol. hallmarks of several neurodegenerative disorders, including Alzheimer's disease (AD).  NFTs are composed of microtubule-binding protein tau, which assembles to form paired helical filaments (PHFs) and straight filaments.  Here we show by at. force microscopy that AD brain tissue and in vitro tau form granular and fibrillar tau aggregates.  CD spectral anal. and immunostaining with conformation-dependent antibodies indicated that tau may undergo conformational changes during fibril formation.  Enriched granules generated filaments, suggesting that granular tau aggregates may be an intermediate form of tau fibrils.  The amt. of granular tau aggregates was elevated in prefrontal cortex of Braak stage I cases compared to that of Braak stage 0 cases, suggesting that granular tau aggregation precedes PHF formation.  Thus, granular tau aggregates may be a relevant marker for the early diagnosis of tauopathy.  Reducing the level of these aggregates may be a promising therapy for tauopathies and for promoting healthy brain aging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjmRXwd4jCY7Vg90H21EOLACvtfcHk0libMIi9-bCMyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisVGlsr4%253D&md5=b1570ec3e4a3d218c50d59ded5b27e5b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fbi061359o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi061359o%26sid%3Dliteratum%253Aachs%26aulast%3DMaeda%26aufirst%3DS.%26aulast%3DSahara%26aufirst%3DN.%26aulast%3DSaito%26aufirst%3DY.%26aulast%3DMurayama%26aufirst%3DM.%26aulast%3DYoshiike%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DMiyasaka%26aufirst%3DT.%26aulast%3DMurayama%26aufirst%3DS.%26aulast%3DIkai%26aufirst%3DA.%26aulast%3DTakashima%26aufirst%3DA.%26atitle%3DGranular%2520tau%2520oligomers%2520as%2520intermediates%2520of%2520tau%2520filaments%26jtitle%3DBiochemistry%26date%3D2007%26volume%3D46%26spage%3D3856%26epage%3D3861%26doi%3D10.1021%2Fbi061359o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orr, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, B.</span></span> <span> </span><span class="NLM_article-title">A Brief overview of tauopathy: causes, consequences, and therapeutic strategies</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">648</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2017.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1016%2Fj.tips.2017.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=28455089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtFOiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=637-648&author=M.+E.+Orrauthor=A.+C.+Sullivanauthor=B.+Frost&title=A+Brief+overview+of+tauopathy%3A+causes%2C+consequences%2C+and+therapeutic+strategies&doi=10.1016%2Fj.tips.2017.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies</span></div><div class="casAuthors">Orr, Miranda E.; Sullivan, A. Campbell; Frost, Bess</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">637-648</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">There are currently no disease-modifying therapies for the treatment of tauopathies, a group of progressive neurodegenerative disorders that are pathol. defined by the presence of tau protein aggregates in the brain.  Current challenges for the treatment of tauopathies include the inability to diagnose early and to confidently discriminate between distinct tauopathies in patients, alongside an incomplete understanding of the cellular mechanisms involved in pathogenic tau-induced neuronal death and dysfunction.  In this review, we describe current diagnostic and therapeutic strategies, known drivers of pathogenic tau formation, recent contributions to our current mechanistic understanding of how pathogenic tau induces neuronal death, and potential diagnostic and therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo67tWmxH7Qa7Vg90H21EOLACvtfcHk0lg9CH7z_5djkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtFOiu7g%253D&md5=7529288546143a87ce13f2168884046a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2017.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2017.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DOrr%26aufirst%3DM.%2BE.%26aulast%3DSullivan%26aufirst%3DA.%2BC.%26aulast%3DFrost%26aufirst%3DB.%26atitle%3DA%2520Brief%2520overview%2520of%2520tauopathy%253A%2520causes%252C%2520consequences%252C%2520and%2520therapeutic%2520strategies%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2017%26volume%3D38%26spage%3D637%26epage%3D648%26doi%3D10.1016%2Fj.tips.2017.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knerr, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundgren-Andersson, A. K.</span></span> <span> </span><span class="NLM_article-title">The conundrum of GSK3 inhibitors: is it the dawn of a new beginning?</span>. <i>J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">S547</span>– <span class="NLM_lpage">S554</span>, <span class="refDoi"> DOI: 10.3233/JAD-179934.</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.3233%2FJAD-179934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=29758944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFGgsL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2018&pages=S547-S554&author=R.+V.+Bhatauthor=U.+Anderssonauthor=S.+Anderssonauthor=L.+Knerrauthor=U.+Bauerauthor=A.+K.+Sundgren-Andersson&title=The+conundrum+of+GSK3+inhibitors%3A+is+it+the+dawn+of+a+new+beginning%3F&doi=10.3233%2FJAD-179934."target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The Conundrum of GSK3 Inhibitors: Is it the Dawn of a New Beginning?</span></div><div class="casAuthors">Bhat, Ratan V.; Andersson, Ulf; Andersson, Shalini; Knerr, Laurent; Bauer, Udo; Sundgren-Andersson, Anna K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">s1</span>),
    <span class="NLM_cas:pages">S547-S554</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">Spanning over three decades of extensive drug discovery research, the efforts to develop a potent and selective GSK3 inhibitor as a therapeutic for the treatment of type 2 diabetes, Alzheimer's disease (AD), bipolar disorders and cancer have been futile.  Since its initial discovery in 1980 and subsequent decades of research, one cannot underscore the importance of the target and the promise of a game changing disease modifier.  Several pharmaceutical companies, biotech companies, and academic institutions raged in a quest to unravel the biol. and discover potent and selective GSK3 inhibitors, some of which went through clin. trials.  However, the conundrum of what happened to the fate of the AstraZeneca's GSK3 inhibitors and the undertaking to find a therapeutic that could control glycogen metab. and aberrant tau hyperphosphorylation in the brain, and rescue synaptic dysfunction has largely been untold.  AstraZeneca was in the forefront of GSK3 drug discovery research with six GSK3 drug candidates, one of which progressed up to Phase II clin. trials in the quest to untangle the tau hypothesis for AD.  Anal. of key toxicity issues, serendipitous findings and efficacy, and biomarker considerations in relation to safety margins have limited the potential of small mol. therapeutics as a way forward.  To guide future innovation of this important target, we reveal the roller coaster journey comprising of two decades of preclin. and clin. GSK3 drug discovery at AstraZeneca; the understanding of which could lead to improved GSK3 therapies for disease.  These learnings in combination with advances in achieving kinase selectivity, different modes of action as well as the recent discovery of novel conjugated peptide technol. targeting specific tissues have potentially provided a venue for scientific innovation and a new beginning for GSK3 drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLP9jk6RTw_7Vg90H21EOLACvtfcHk0lg9CH7z_5djkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFGgsL7E&md5=4ee97abb934c85d809591e6a4caf8356</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3233%2FJAD-179934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-179934%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DR.%2BV.%26aulast%3DAndersson%26aufirst%3DU.%26aulast%3DAndersson%26aufirst%3DS.%26aulast%3DKnerr%26aufirst%3DL.%26aulast%3DBauer%26aufirst%3DU.%26aulast%3DSundgren-Andersson%26aufirst%3DA.%2BK.%26atitle%3DThe%2520conundrum%2520of%2520GSK3%2520inhibitors%253A%2520is%2520it%2520the%2520dawn%2520of%2520a%2520new%2520beginning%253F%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2018%26volume%3D64%26spage%3DS547%26epage%3DS554%26doi%3D10.3233%2FJAD-179934." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">and references therein.</p></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wadhwa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, H. R.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase 3 (GSK3): its role and inhibitors</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1522</span>– <span class="NLM_lpage">1534</span>, <span class="refDoi"> DOI: 10.2174/1568026620666200516153136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.2174%2F1568026620666200516153136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=32416693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslKisr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=1522-1534&author=P.+Wadhwaauthor=P.+Jainauthor=H.+R.+Jadhav&title=Glycogen+synthase+kinase+3+%28GSK3%29%3A+its+role+and+inhibitors&doi=10.2174%2F1568026620666200516153136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen Synthase Kinase 3 (GSK3): Its Role and Inhibitors</span></div><div class="casAuthors">Wadhwa, Pankaj; Jain, Priti; Jadhav, Hemant R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1522-1534</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Glycogen Synthase Kinase 3 (GSK3) is one of the Serine/Threonine protein kinases, which has gained a lot of attention for its role in a variety of pathways.  It has two isoforms, GSK3α and GSK3β.  However, GSK3β is highly expressed in different areas of the brain and has been implicated in Alzheimers disease as it is involved in tau phosphorylation.  Due to its high specificity concerning substrate recognition, GSK3 has been considered as an important target.  In the last decade, several GSK3 inhibitors have been reported and two mols. are in clin. trials.  This review collates the information published in the last decade about the role of GSK3 in Alzheimers disease and progress in the development of its inhibitors.  Using this collated information medicinal chemists can strategize and design novel GSK3 inhibitors that could be useful in the treatment of Alzheimers disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxZmZdyp3j-7Vg90H21EOLACvtfcHk0liD65jm1gOIsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslKisr7E&md5=e1f9fbad989f694f6f76c65fb5530bd6</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F1568026620666200516153136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026620666200516153136%26sid%3Dliteratum%253Aachs%26aulast%3DWadhwa%26aufirst%3DP.%26aulast%3DJain%26aufirst%3DP.%26aulast%3DJadhav%26aufirst%3DH.%2BR.%26atitle%3DGlycogen%2520synthase%2520kinase%25203%2520%2528GSK3%2529%253A%2520its%2520role%2520and%2520inhibitors%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2020%26volume%3D20%26spage%3D1522%26epage%3D1534%26doi%3D10.2174%2F1568026620666200516153136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goetz, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liem, K. F.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. V.</span></span> <span> </span><span class="NLM_article-title">The spinocerebellar ataxia-associated gene tau tubulin kinase 2 controls the initiation of ciliogenesis</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">847</span>– <span class="NLM_lpage">858</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2012.10.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1016%2Fj.cell.2012.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=23141541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Kjsr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2012&pages=847-858&author=S.+C.+Goetzauthor=K.+F.+Liemauthor=K.+V.+Anderson&title=The+spinocerebellar+ataxia-associated+gene+tau+tubulin+kinase+2+controls+the+initiation+of+ciliogenesis&doi=10.1016%2Fj.cell.2012.10.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The Spinocerebellar Ataxia-Associated Gene Tau Tubulin Kinase 2 Controls the Initiation of Ciliogenesis</span></div><div class="casAuthors">Goetz, Sarah C.; Liem, Karel F.; Anderson, Kathryn V.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">847-858</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The primary cilium has crit. roles in human development and disease, but the mechanisms that regulate ciliogenesis are not understood.  Here, we show that Tau tubulin kinase 2 (TTBK2) is a dedicated regulator of the initiation of ciliogenesis in vivo.  We identified a null allele of mouse Ttbk2 based on loss of Sonic hedgehog activity, a signaling pathway that requires the primary cilium.  Despite a normal basal body template, Ttbk2 mutants lack cilia.  TTBK2 acts at the distal end of the basal body, where it promotes the removal of CP110, which caps the mother centriole, and promotes recruitment of IFT proteins, which build the ciliary axoneme.  Dominant truncating mutations in human TTBK2 cause spinocerebellar ataxia type 11 (SCA11); these mutant proteins do not promote ciliogenesis and inhibit ciliogenesis in wild-type cells.  We propose that cell-cycle regulators target TTBK2 to the basal body, where it modifies specific targets to initiate ciliogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHV3kLyiUXQLVg90H21EOLACvtfcHk0liA4GH9Vb625g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Kjsr%252FK&md5=6de9e5f8875a2ac5b6fd4d6fc20320e1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DGoetz%26aufirst%3DS.%2BC.%26aulast%3DLiem%26aufirst%3DK.%2BF.%26aulast%3DAnderson%26aufirst%3DK.%2BV.%26atitle%3DThe%2520spinocerebellar%2520ataxia-associated%2520gene%2520tau%2520tubulin%2520kinase%25202%2520controls%2520the%2520initiation%2520of%2520ciliogenesis%26jtitle%3DCell%26date%3D2012%26volume%3D151%26spage%3D847%26epage%3D858%26doi%3D10.1016%2Fj.cell.2012.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-W.</span></span> <span> </span><span class="NLM_article-title">TTBK2: A tau protein kinase beyond tau phosphorylation</span>. <i>BioMed Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">575170</span>, <span class="refDoi"> DOI: 10.1155/2015/575170</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1155%2F2015%2F575170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=25950000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A280%3ADC%252BC2Mbgs1aktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=575170&author=J.-C.+Liaoauthor=T.+T.+Yangauthor=R.+R.+Wengauthor=C.-T.+Kuoauthor=C.-W.+Chang&title=TTBK2%3A+A+tau+protein+kinase+beyond+tau+phosphorylation&doi=10.1155%2F2015%2F575170"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">TTBK2: a tau protein kinase beyond tau phosphorylation</span></div><div class="casAuthors">Liao Jung-Chi; Yang T Tony; Weng Rueyhung Roc; Kuo Ching-Te; Chang Chih-Wei</div><div class="citationInfo"><span class="NLM_cas:title">BioMed research international</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">575170</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tau tubulin kinase 2 (TTBK2) is a kinase known to phosphorylate tau and tubulin.  It has recently drawn much attention due to its involvement in multiple important cellular processes.  Here, we review the current understanding of TTBK2, including its sequence, structure, binding sites, phosphorylation substrates, and cellular processes involved.  TTBK2 possesses a casein kinase 1 (CK1) kinase domain followed by a ~900 amino acid segment, potentially responsible for its localization and substrate recruitment.  It is known to bind to CEP164, a centriolar protein, and EB1, a microtubule plus-end tracking protein.  In addition to autophosphorylation, known phosphorylation substrates of TTBK2 include tau, tubulin, CEP164, CEP97, and TDP-43, a neurodegeneration-associated protein.  Mutations of TTBK2 are associated with spinocerebellar ataxia type 11.  In addition, TTBK2 is essential for regulating the growth of axonemal microtubules in ciliogenesis.  It also plays roles in resistance of cancer target therapies and in regulating glucose and GABA transport.  Reported sites of TTBK2 localization include the centriole/basal body, the midbody, and possibly the mitotic spindles.  Together, TTBK2 is a multifunctional kinase involved in important cellular processes and demands augmented efforts in investigating its functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSK5qjjP0gzDrGbPKh4T9eAfW6udTcc2eb9zpRjqPknTbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mbgs1aktA%253D%253D&md5=853d9f1c78eeb2c003cc427f04405f05</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1155%2F2015%2F575170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F575170%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DJ.-C.%26aulast%3DYang%26aufirst%3DT.%2BT.%26aulast%3DWeng%26aufirst%3DR.%2BR.%26aulast%3DKuo%26aufirst%3DC.-T.%26aulast%3DChang%26aufirst%3DC.-W.%26atitle%3DTTBK2%253A%2520A%2520tau%2520protein%2520kinase%2520beyond%2520tau%2520phosphorylation%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2015%26volume%3D2015%26spage%3D575170%26doi%3D10.1155%2F2015%2F575170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcotte, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spilker, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chodaparambil, J. V.</span></span> <span> </span><span class="NLM_article-title">The crystal structure of the catalytic domain of tau tubulin kinase 2 in complex with a small-molecule inhibitor</span>. <i>Acta Crystallogr., Sect. F: Struct. Biol. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1107/S2053230X2000031X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1107%2FS2053230X2000031X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=32133995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktlenu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2020&pages=103-108&author=D.+J.+Marcotteauthor=K.+A.+Spilkerauthor=D.+Wenauthor=T.+Hessonauthor=T.+A.+Pattersonauthor=P.+R.+Kumarauthor=J.+V.+Chodaparambil&title=The+crystal+structure+of+the+catalytic+domain+of+tau+tubulin+kinase+2+in+complex+with+a+small-molecule+inhibitor&doi=10.1107%2FS2053230X2000031X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The crystal structure of the catalytic domain of tau tubulin kinase 2 in complex with a small-molecule inhibitor</span></div><div class="casAuthors">Marcotte, Douglas J.; Spilker, Kerri A.; Wen, Dingyi; Hesson, Thomas; Patterson, Thomas A.; Kumar, P. Rajesh; Chodaparambil, Jayanth V.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section F: Structural Biology Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">103-108</span>CODEN:
                <span class="NLM_cas:coden">ACSFEN</span>;
        ISSN:<span class="NLM_cas:issn">2053-230X</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Tau proteins play an important role in the proper assembly and function of neurons.  Hyperphosphorylation of tau by kinases such as tau tubulin kinase (TTBK) has been hypothesized to cause the aggregation of tau and the formation of neurofibrillary tangles (NFTs) that lead to the destabilization of microtubules, thereby contributing to neurodegenerative diseases such as Alzheimer's disease (AD).  There are two TTBK isoforms with highly homologous catalytic sites but with distinct tissue distributions, tau phosphorylation patterns and loss-of-function effects.  Inhibition of TTBK1 reduces the levels of NFT formation involved in neurodegenerative diseases such as AD, whereas inhibition of TTBK2 may lead to the movement disorder spinocerebellar ataxia type 11 (SCA11).  Hence, it is crit. to obtain isoform-selective inhibitors.  Structure-based drug design (SBDD) has been used to design highly potent and exquisitely selective inhibitors.  While structures of TTBK1 have been reported in the literature, TTBK2 has evaded structural characterization.  Here, the first crystal structure of the TTBK2 kinase domain is described.  Furthermore, the crystal structure of human TTBK2 in complex with a small-mol. inhibitor has successfully been detd. to elucidate the structural differences in protein conformations between the two TTBK isoforms that could aid in SBDD for the design of inhibitors that selectively target TTBK1 over TTBK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrqhRtU3UmrLVg90H21EOLACvtfcHk0liA4GH9Vb625g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktlenu7o%253D&md5=bff94b403224841ba31becae4dba1661</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1107%2FS2053230X2000031X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053230X2000031X%26sid%3Dliteratum%253Aachs%26aulast%3DMarcotte%26aufirst%3DD.%2BJ.%26aulast%3DSpilker%26aufirst%3DK.%2BA.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DHesson%26aufirst%3DT.%26aulast%3DPatterson%26aufirst%3DT.%2BA.%26aulast%3DKumar%26aufirst%3DP.%2BR.%26aulast%3DChodaparambil%26aufirst%3DJ.%2BV.%26atitle%3DThe%2520crystal%2520structure%2520of%2520the%2520catalytic%2520domain%2520of%2520tau%2520tubulin%2520kinase%25202%2520in%2520complex%2520with%2520a%2520small-molecule%2520inhibitor%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520F%253A%2520Struct.%2520Biol.%2520Commun.%26date%3D2020%26volume%3D76%26spage%3D103%26epage%3D108%26doi%3D10.1107%2FS2053230X2000031X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span>Some of our findings
in this area have been recently reported; see ref <a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Some+of+our+findings%0Ain+this+area+have+been+recently+reported%3B+see+ref+%284%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="note"><p class="first last">See:</p></div><div class="NLM_citation" id="cit16"><span> <i>List of Kinase Targets
at US Facility</i>; .</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+List+of+Kinase+Targets%0Aat+US+Facility%3B+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DList%2520of%2520Kinase%2520Targets%250Aat%2520US%2520Facility" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">(accessed Mar 30, 2021)</p></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillertz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweikart, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wissler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dekker, N.</span></span> <span> </span><span class="NLM_article-title">X-ray Structural analysis of tau-tubulin kinase 1 and its interactions with small molecular inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1846</span>– <span class="NLM_lpage">1854</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201300274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1002%2Fcmdc.201300274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=24039150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVeqsL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1846-1854&author=Y.+Xueauthor=P.+T.+Wanauthor=P.+Hillertzauthor=F.+Schweikartauthor=Y.+Zhaoauthor=L.+Wisslerauthor=N.+Dekker&title=X-ray+Structural+analysis+of+tau-tubulin+kinase+1+and+its+interactions+with+small+molecular+inhibitors&doi=10.1002%2Fcmdc.201300274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">X-ray structural analysis of tau-tubulin kinase 1 and its interactions with small molecular inhibitors</span></div><div class="casAuthors">Xue, Yafeng; Wan, Paul T.; Hillertz, Per; Schweikart, Fritz; Zhao, Yanlong; Wissler, Lisa; Dekker, Niek</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1846-1854</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Tau-tubulin kinase 1 (I) is a serine/threonine/tyrosine kinase that putatively phosphorylates residues including Ser-422 in tau protein.  Hyperphosphorylation of tau protein is the primary cause of tau pathol. and neuronal death assocd. with Alzheimer's disease.  Here, a library of 12 truncation variants comprising the I kinase domain was screened for expression in Escherichia coli and insect cells.  One variant (residues 14-313) could be purified, but mass spectrometric anal. revealed extensive phosphorylation of the protein.  Co-expression with phage λ phosphatase in Escherichia coli resulted in the prodn. of homogeneous, nonphosphorylated I.  The binding of ATP and several compds. to I was characterized by surface plasmon resonance.  Crystal structures of I in the unliganded form and in complex with ATP, and 2 high-affinity ATP-competitive inhibitors, 3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol and Me 2-bromo-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)benzoate (II), were elucidated.  The structure revealed 2 clear basic patches near the ATP pocket providing an explanation of I for phosphorylation-primed substrates.  Interestingly, II displayed slow binding kinetics with I and the structure of I in complex with this compd. revealed a reorganization of the Lue-199-Asp-200 peptide backbone conformation together with altered H-bonding with II.  These conformational changes necessary for the binding of II are likely the basis of the slow kinetics.  This 1st I structure can assist the discovery of novel inhibitors for the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_Z_a4ZEZKz7Vg90H21EOLACvtfcHk0lhfRjVwewiqFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVeqsL%252FE&md5=467e2009dc3d5b8a5bf662048d5c6d8e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300274%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DY.%26aulast%3DWan%26aufirst%3DP.%2BT.%26aulast%3DHillertz%26aufirst%3DP.%26aulast%3DSchweikart%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DWissler%26aufirst%3DL.%26aulast%3DDekker%26aufirst%3DN.%26atitle%3DX-ray%2520Structural%2520analysis%2520of%2520tau-tubulin%2520kinase%25201%2520and%2520its%2520interactions%2520with%2520small%2520molecular%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D1846%26epage%3D1854%26doi%3D10.1002%2Fcmdc.201300274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastalerz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cacace, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheriff, S.</span></span> <span> </span><span class="NLM_article-title">The structure of human tau-tubulin kinase 1 both in the apo form and in complex with an inhibitor</span>. <i>Acta Crystallogr., Sect. F: Struct. Biol. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1107/S2053230X14000144</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1107%2FS2053230X14000144" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=24637750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVejsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2014&pages=173-181&author=S.+E.+Kieferauthor=C.+J.+Changauthor=S.+R.+Kimuraauthor=M.+Gaoauthor=D.+Xieauthor=Y.+Zhangauthor=G.+Zhangauthor=M.+B.+Gillauthor=H.+Mastalerzauthor=L.+A.+Thompsonauthor=A.+M.+Cacaceauthor=S.+Sheriff&title=The+structure+of+human+tau-tubulin+kinase+1+both+in+the+apo+form+and+in+complex+with+an+inhibitor&doi=10.1107%2FS2053230X14000144"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The structure of human tau-tubulin kinase 1 both in the apo form and in complex with an inhibitor</span></div><div class="casAuthors">Kiefer, Susan E.; Chang, Chieh Ying J.; Kimura, S. Roy; Gao, Mian; Xie, Dianlin; Zhang, Yaqun; Zhang, Guifen; Gill, Martin B.; Mastalerz, Harold; Thompson, Lorin A.; Cacace, Angela M.; Sheriff, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section F: Structural Biology Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">173-181</span>CODEN:
                <span class="NLM_cas:coden">ACSFEN</span>;
        ISSN:<span class="NLM_cas:issn">2053-230X</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Tau-tubulin kinase 1 (TTBK1) is a dual-specificity (serine/threonine and tyrosine) kinase belonging to the casein kinase 1 superfamily.  TTBK1 is a neuron-specific kinase that regulates tau phosphorylation.  Hyperphosphorylation of tau is implicated in the pathogenesis of Alzheimer's disease.  Two kinase-domain constructs of TTBK1 were expressed in a baculovirus-infected insect-cell system and purified.  The purified TTBK1 kinase-domain proteins were crystd. using the hanging-drop vapor-diffusion method.  X-ray diffraction data were collected and the structure of TTBK1 was detd. by mol. replacement both as an apo structure and in complex with a kinase inhibitor (I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKB-lyYNRRVbVg90H21EOLACvtfcHk0lhfRjVwewiqFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVejsrY%253D&md5=f37ee6f58921bb5ac72877888129bc0b</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1107%2FS2053230X14000144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053230X14000144%26sid%3Dliteratum%253Aachs%26aulast%3DKiefer%26aufirst%3DS.%2BE.%26aulast%3DChang%26aufirst%3DC.%2BJ.%26aulast%3DKimura%26aufirst%3DS.%2BR.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DGill%26aufirst%3DM.%2BB.%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DThompson%26aufirst%3DL.%2BA.%26aulast%3DCacace%26aufirst%3DA.%2BM.%26aulast%3DSheriff%26aufirst%3DS.%26atitle%3DThe%2520structure%2520of%2520human%2520tau-tubulin%2520kinase%25201%2520both%2520in%2520the%2520apo%2520form%2520and%2520in%2520complex%2520with%2520an%2520inhibitor%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520F%253A%2520Struct.%2520Biol.%2520Commun.%26date%3D2014%26volume%3D70%26spage%3D173%26epage%3D181%26doi%3D10.1107%2FS2053230X14000144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span> <i>The biochemical potency was determined at Reaction Biology</i>: see: <a href="https://www.reactionbiology.com/list-kinase-targets-us-facility" class="extLink">https://www.reactionbiology.com/list-kinase-targets-us-facility</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+The+biochemical+potency+was+determined+at+Reaction+Biology%3A+see%3A+https%3A%2F%2Fwww.reactionbiology.com%2Flist-kinase-targets-us-facility."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520biochemical%2520potency%2520was%2520determined%2520at%2520Reaction%2520Biology" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">(accessed Mar 30, 2021)</p></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span> <i>MRC
PPU International Centre for Kinase Profiling</i> .</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+MRC%0APPU+International+Centre+for+Kinase+Profiling+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DMRC%250APPU%2520International%2520Centre%2520for%2520Kinase%2520Profiling" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">(accessed Mar 30, 2021)</p></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="note"><p class="first last">Compound <b>3</b> was first disclosed by:</p></div><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubenstein, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Answer, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waszkowycz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plotnikova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrelly, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Inhibiting NF-κB-inducing kinase (NIK): discovery, structure-based design, synthesis, structure–activity relationship, and co-crystal structures</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1238</span>– <span class="NLM_lpage">1244</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1016%2Fj.bmcl.2013.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=23374866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=1238-1244&author=K.+Liauthor=L.+R.+McGeeauthor=B.+Fisherauthor=A.+Sudomauthor=J.+Liuauthor=S.+M.+Rubensteinauthor=M.+K.+Answerauthor=T.+D.+Cushingauthor=Y.+Shinauthor=M.+Ayresauthor=F.+Leeauthor=J.+Eksterowiczauthor=P.+Faulderauthor=B.+Waszkowyczauthor=O.+Plotnikovaauthor=E.+Farrellyauthor=S.-H.+Xiaoauthor=G.+Chenauthor=Z.+Wang&title=Inhibiting+NF-%CE%BAB-inducing+kinase+%28NIK%29%3A+discovery%2C+structure-based+design%2C+synthesis%2C+structure%E2%80%93activity+relationship%2C+and+co-crystal+structures&doi=10.1016%2Fj.bmcl.2013.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting NF-κB-inducing kinase (NIK): Discovery, structure-based design, synthesis, structure-activity relationship, and co-crystal structures</span></div><div class="casAuthors">Li, Kexue; McGee, Lawrence R.; Fisher, Ben; Sudom, Athena; Liu, Jinsong; Rubenstein, Steven M.; Anwer, Mohmed K.; Cushing, Timothy D.; Shin, Youngsook; Ayres, Merrill; Lee, Fei; Eksterowicz, John; Faulder, Paul; Waszkowycz, Bohdan; Plotnikova, Olga; Farrelly, Ellyn; Xiao, Shou-Hua; Chen, Guoqing; Wang, Zhulun</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1238-1244</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery, structure-based design, synthesis, and optimization of NIK inhibitors are described.  Our work began with an HTS hit, imidazopyridinyl pyrimidinamine I.  We utilized homol. modeling and conformational anal. to optimize the indole scaffold leading to the discovery of novel and potent conformationally constrained inhibitors such as compds. II [R1 = Br, C≡CCMe2OH].  Compds. II [R1 = Br] and III were co-crystd. with NIK kinase domain to provide structural insights.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm5WqvTIrBqrVg90H21EOLACvtfcHk0ljzmNmZHASAtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGmt7s%253D&md5=a382078cf3bf84a41749783be33a5988</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DK.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DSudom%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DRubenstein%26aufirst%3DS.%2BM.%26aulast%3DAnswer%26aufirst%3DM.%2BK.%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DF.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DFaulder%26aufirst%3DP.%26aulast%3DWaszkowycz%26aufirst%3DB.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DFarrelly%26aufirst%3DE.%26aulast%3DXiao%26aufirst%3DS.-H.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DInhibiting%2520NF-%25CE%25BAB-inducing%2520kinase%2520%2528NIK%2529%253A%2520discovery%252C%2520structure-based%2520design%252C%2520synthesis%252C%2520structure%25E2%2580%2593activity%2520relationship%252C%2520and%2520co-crystal%2520structures%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D1238%26epage%3D1244%26doi%3D10.1016%2Fj.bmcl.2013.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Morais, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalvass, J. C.</span></span> <span> </span><span class="NLM_article-title">In vitro P-glycoprotein efflux ratio can predict the in vivo brain penetration regardless of biopharmaceutics drug disposition classification system class</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">2012</span>– <span class="NLM_lpage">2017</span>, <span class="refDoi"> DOI: 10.1124/dmd.113.053868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1124%2Fdmd.113.053868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=24009309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVCjtbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=2012-2017&author=R.+Kikuchiauthor=S.+M.+de+Moraisauthor=J.+C.+Kalvass&title=In+vitro+P-glycoprotein+efflux+ratio+can+predict+the+in+vivo+brain+penetration+regardless+of+biopharmaceutics+drug+disposition+classification+system+class&doi=10.1124%2Fdmd.113.053868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro P-glycoprotein efflux ratio can predict the in vivo brain penetration regardless of biopharmaceutics drug disposition classification system class</span></div><div class="casAuthors">Kikuchi, Ryota; de Morais, Sonia M.; Kalvass, J. Cory</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2012-2017</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">P-glycoprotein (P-gp) is expressed at the blood-brain barrier (BBB) and restricts the penetration of its substrates into the central nervous system (CNS).  In vitro substrate assessment for P-gp is frequently used to predict the in vivo relevance of P-gp-mediated efflux at the BBB.  We have conducted a comprehensive review of literature focusing on the in vitro-in vivo correlation of P-gp efflux ratio (ER), and demonstrated that in vitro substrates of P-gp are also in vivo substrates at the BBB.  It was of note that the in vitro ER in the MDCK-MDR1 cell line from National Institutes of Health was found to be a better predictor of in vivo ER than that from Netherlands Cancer Institute, with r2 values of 0.813 and 0.531, resp.  Recently, a research group proposed that 98% of Biopharmaceutics Drug Disposition Classification System (BDDCS) class 1 drugs can penetrate the brain even when those compds. are shown as P-gp substrates in vitro.  However, our data anal. suggested that in vitro ER can predict the in vivo brain penetration regardless of the class in BDDCS.  Considering that very few marketed CNS drugs are in vivo substrates for P-gp, the in vitro substrate assessment of P-gp should be used in the early stages of drug discovery to select compds. that are most likely to penetrate the CNS to exert their pharmacol. action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFQtEu5USc2LVg90H21EOLACvtfcHk0ljkFvbzxRjbAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVCjtbvO&md5=f4e32455375b1bd684ba38174a71657c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1124%2Fdmd.113.053868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.113.053868%26sid%3Dliteratum%253Aachs%26aulast%3DKikuchi%26aufirst%3DR.%26aulast%3Dde%2BMorais%26aufirst%3DS.%2BM.%26aulast%3DKalvass%26aufirst%3DJ.%2BC.%26atitle%3DIn%2520vitro%2520P-glycoprotein%2520efflux%2520ratio%2520can%2520predict%2520the%2520in%2520vivo%2520brain%2520penetration%2520regardless%2520of%2520biopharmaceutics%2520drug%2520disposition%2520classification%2520system%2520class%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2013%26volume%3D41%26spage%3D2012%26epage%3D2017%26doi%3D10.1124%2Fdmd.113.053868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moustakas, D. T.</span></span> <span> </span><span class="NLM_article-title">The necessary nitrogen atom: a versatile high-impact design element for multiparameter optimization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">3552</span>– <span class="NLM_lpage">3579</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01807</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01807" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BC2sXit1yit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3552-3579&author=L.+D.+Penningtonauthor=D.+T.+Moustakas&title=The+necessary+nitrogen+atom%3A+a+versatile+high-impact+design+element+for+multiparameter+optimization&doi=10.1021%2Facs.jmedchem.6b01807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The Necessary Nitrogen Atom: A Versatile High-Impact Design Element for Multiparameter Optimization</span></div><div class="casAuthors">Pennington, Lewis D.; Moustakas, Demetri T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3552-3579</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  There is a continued desire in biomedical research to reduce the no. and duration of design cycles required to optimize lead compds. into high-quality chem. probes or safe and efficacious drug candidates.  The insightful application of impactful mol. design elements is one approach toward achieving this goal.  The replacement of a CH group with a N atom in arom. and heteroarom. ring systems can have many important effects on mol. and physicochem. properties and intra- and intermol. interactions that can translate to improved pharmacol. profiles.  In this Perspective, the "necessary nitrogen atom" is shown to be a versatile high-impact design element for multiparameter optimization, wherein ≥10-, 100-, or 1000-fold improvement in a variety of key pharmacol. parameters can be realized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8ZLKZMgt6IbVg90H21EOLACvtfcHk0ljkFvbzxRjbAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXit1yit74%253D&md5=002aaee48995e7954647a1f75183db4d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01807%26sid%3Dliteratum%253Aachs%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DMoustakas%26aufirst%3DD.%2BT.%26atitle%3DThe%2520necessary%2520nitrogen%2520atom%253A%2520a%2520versatile%2520high-impact%2520design%2520element%2520for%2520multiparameter%2520optimization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D3552%26epage%3D3579%26doi%3D10.1021%2Facs.jmedchem.6b01807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grootenhuis, P. D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayada, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delbressine, L. P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploemen, J.-P.</span></span> <span> </span><span class="NLM_article-title">Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1514</span>– <span class="NLM_lpage">1519</span>, <span class="refDoi"> DOI: 10.1023/A:1015040217741</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1023%2FA%3A1015040217741" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10554091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADyaK1MXntVOhtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1999&pages=1514-1519&author=J.+Kelderauthor=P.+D.+J.+Grootenhuisauthor=D.+M.+Bayadaauthor=L.+P.+C.+Delbressineauthor=J.-P.+Ploemen&title=Polar+molecular+surface+as+a+dominating+determinant+for+oral+absorption+and+brain+penetration+of+drugs&doi=10.1023%2FA%3A1015040217741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs</span></div><div class="casAuthors">Kelder, Jan; Grootenhuis, Peter D. J.; Bayada, Denis M.; Delbressine, Leon P. C.; Ploemen, Jan-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1514-1519</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic/Plenum Publishers</span>)
        </div><div class="casAbstract">Purpose: To study oral absorption and brain penetration as a function of polar mol. surface area.  Methods: Measured brain penetration data of 45 drug mols. were investigated.  The dynamic polar surface areas were calcd. and correlated with the brain penetration data.  Also the static polar surface areas of 776 orally administered CNS drugs that have reached at least Phase II efficacy studies were calcd.  The same was done for a series of 1590 orally administered non-CNS drugs that have reached at least Phase II efficacy studies.  Results: A linear relationship between brain penetration and dynamic polar surface area (A2) was found (n = 45, R = 0.917, F1,43 = 229).  Brain penetration decreases with increasing polar surface area.  A clear difference between the distribution of the polar surface area of the 776 CNS and 1590 non-CNS drugs was found.  It was deduced that orally active drugs that are transported passively by the transcellular route should not exceed a polar surface area of about 120 A2.  They can be tailored to brain penetration by decreasing the polar surface to <60-70 A2.  This conclusion is supported by the inverse linear relationship between exptl. brain penetration data and the dynamic polar surface area of 45 drug mols.  Conclusions: The polar mol. surface area is a dominating determinant for oral absorption and brain penetration of drugs that are transported by the transcellular route.  This property should be considered in the early phase of drug screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmc3v7TzWM4LVg90H21EOLACvtfcHk0ljkFvbzxRjbAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntVOhtb8%253D&md5=868fe1e9491dd3b8b92b326d28ee48f9</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1023%2FA%3A1015040217741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1015040217741%26sid%3Dliteratum%253Aachs%26aulast%3DKelder%26aufirst%3DJ.%26aulast%3DGrootenhuis%26aufirst%3DP.%2BD.%2BJ.%26aulast%3DBayada%26aufirst%3DD.%2BM.%26aulast%3DDelbressine%26aufirst%3DL.%2BP.%2BC.%26aulast%3DPloemen%26aufirst%3DJ.-P.%26atitle%3DPolar%2520molecular%2520surface%2520as%2520a%2520dominating%2520determinant%2520for%2520oral%2520absorption%2520and%2520brain%2520penetration%2520of%2520drugs%26jtitle%3DPharm.%2520Res.%26date%3D1999%26volume%3D16%26spage%3D1514%26epage%3D1519%26doi%3D10.1023%2FA%3A1015040217741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makarov, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brocklehurst, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaghiosoff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knochel, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis of bicyclo[1.1.1]pentane bioisosteres of internal alkynes and <i>para</i>-disubstituted benzenes from [1.1.1]propellane</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">12774</span>– <span class="NLM_lpage">12777</span>, <span class="refDoi"> DOI: 10.1002/anie.201706799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1002%2Fanie.201706799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVansrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=12774-12777&author=I.+S.+Makarovauthor=C.+E.+Brocklehurstauthor=K.+Karaghiosoffauthor=G.+Kochauthor=P.+Knochel&title=Synthesis+of+bicyclo%5B1.1.1%5Dpentane+bioisosteres+of+internal+alkynes+and+para-disubstituted+benzenes+from+%5B1.1.1%5Dpropellane&doi=10.1002%2Fanie.201706799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Bicyclo[1.1.1]pentane Bioisosteres of Internal Alkynes and para-Disubstituted Benzenes from [1.1.1]Propellane</span></div><div class="casAuthors">Makarov, Ilya S.; Brocklehurst, Cara E.; Karaghiosoff, Konstantin; Koch, Guido; Knochel, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">12774-12777</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A general prepn. of arylated bicyclo[1.1.1]pentanes through the opening of [1.1.1]propellane with various arylmagnesium halides is reported.  After transmetalation with ZnCl2 and Negishi cross-coupling with aryl and heteroaryl halides, bis-arylated bicyclo[1.1.1]pentanes are obtained.  These bis-arylated bicyclo[1.1.1]pentanes may be considered as bioisosteres of internal alkynes.  Bioisosteres I and II of tazarotene and the metabotropic glutamate receptor 5 (mGluR5) antagonist 2-methyl-6-(phenylethynyl)pyridine, resp., were prepd. and their physicochem. properties were evaluated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouj5jm5mNiTbVg90H21EOLACvtfcHk0ljLiY6qvwTfAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVansrvF&md5=4a7c5dcb5de7763fc410151aa653a502</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fanie.201706799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201706799%26sid%3Dliteratum%253Aachs%26aulast%3DMakarov%26aufirst%3DI.%2BS.%26aulast%3DBrocklehurst%26aufirst%3DC.%2BE.%26aulast%3DKaraghiosoff%26aufirst%3DK.%26aulast%3DKoch%26aufirst%3DG.%26aulast%3DKnochel%26aufirst%3DP.%26atitle%3DSynthesis%2520of%2520bicyclo%255B1.1.1%255Dpentane%2520bioisosteres%2520of%2520internal%2520alkynes%2520and%2520para-disubstituted%2520benzenes%2520from%2520%255B1.1.1%255Dpropellane%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D12774%26epage%3D12777%26doi%3D10.1002%2Fanie.201706799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span> <span> </span><span class="NLM_article-title">Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1410</span>, <span class="refDoi"> DOI: 10.1021/tx200168d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx200168d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1345-1410&author=A.+F.+Stepanauthor=D.+P.+Walkerauthor=J.+Baumanauthor=D.+A.+Priceauthor=T.+A.+Baillieauthor=A.+S.+Kalgutkarauthor=M.+D.+Aleo&title=Structural+alert%2Freactive+metabolite+concept+as+applied+in+medicinal+chemistry+to+mitigate+the+risk+of+idiosyncratic+drug+toxicity%3A+a+perspective+based+on+the+critical+examination+of+trends+in+the+top+200+drugs+marketed+in+the+United+States&doi=10.1021%2Ftx200168d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Ftx200168d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200168d%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DBauman%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26atitle%3DStructural%2520alert%252Freactive%2520metabolite%2520concept%2520as%2520applied%2520in%2520medicinal%2520chemistry%2520to%2520mitigate%2520the%2520risk%2520of%2520idiosyncratic%2520drug%2520toxicity%253A%2520a%2520perspective%2520based%2520on%2520the%2520critical%2520examination%2520of%2520trends%2520in%2520the%2520top%2520200%2520drugs%2520marketed%2520in%2520the%2520United%2520States%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D24%26spage%3D1345%26epage%3D1410%26doi%3D10.1021%2Ftx200168d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talele, T. T.</span></span> <span> </span><span class="NLM_article-title">Acetylene group, friend or foe in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">5625</span>– <span class="NLM_lpage">5663</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01617</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01617" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisVygsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=5625-5663&author=T.+T.+Talele&title=Acetylene+group%2C+friend+or+foe+in+medicinal+chemistry&doi=10.1021%2Facs.jmedchem.9b01617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Acetylene Group, Friend or Foe in Medicinal Chemistry</span></div><div class="casAuthors">Talele, Tanaji T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5625-5663</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The use of an acetylene (ethynyl) group in medicinal chem. coincides with the launch of the Journal of Medicinal Chem. in 1959.  Since then, the acetylene group has been broadly exploited in drug discovery and development.  As a result, it has become recognized as a privileged structural feature for targeting a wide range of therapeutic target proteins, including MAO, tyrosine kinases, BACE1, steroid receptors, mGlu5 receptors, FFA1/GPR40, and HIV-1 RT.  Furthermore, a terminal alkyne functionality is frequently introduced in chem. biol. probes as a click handle to identify mol. targets and to assess target engagement.  This Perspective is divided into three parts encompassing: (1) the physicochem. properties of the ethynyl group, (2) the advantages and disadvantages of the ethynyl group in medicinal chem., and (3) the impact of the ethynyl group on chem. biol. approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotTcNwOy0swrVg90H21EOLACvtfcHk0ljLiY6qvwTfAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisVygsr8%253D&md5=199e9f0139337753617b6718e95de5ec</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01617%26sid%3Dliteratum%253Aachs%26aulast%3DTalele%26aufirst%3DT.%2BT.%26atitle%3DAcetylene%2520group%252C%2520friend%2520or%2520foe%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D5625%26epage%3D5663%26doi%3D10.1021%2Facs.jmedchem.9b01617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Planel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyasaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Launey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chui, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanemura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murayama, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishiguro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatebayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takashima, A.</span></span> <span> </span><span class="NLM_article-title">Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer’s disease</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2401</span>– <span class="NLM_lpage">2411</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.5561-03.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1523%2FJNEUROSCI.5561-03.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=15014115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisVKhsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=2401-2411&author=E.+Planelauthor=T.+Miyasakaauthor=T.+Launeyauthor=D.+H.+Chuiauthor=K.+Tanemuraauthor=S.+Satoauthor=O.+Murayamaauthor=K.+Ishiguroauthor=Y.+Tatebayashiauthor=A.+Takashima&title=Alterations+in+glucose+metabolism+induce+hypothermia+leading+to+tau+hyperphosphorylation+through+differential+inhibition+of+kinase+and+phosphatase+activities%3A+implications+for+Alzheimer%E2%80%99s+disease&doi=10.1523%2FJNEUROSCI.5561-03.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease</span></div><div class="casAuthors">Planel, Emmanuel; Miyasaka, Tomohiro; Launey, Thomas; Chui, De-Hua; Tanemura, Kentaro; Sato, Shinji; Murayama, Ohoshi; Ishiguro, Koichi; Tatebayashi, Yoshitaka; Takashima, Akihiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2401-2411</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) brains contain neurofibrillary tangles (NFTs) composed of abnormally hyperphosphorylated tau protein.  Regional redns. in cerebral glucose metab. correlating to NFT densities were reported in AD brains.  Assuming that reduced glucose metab. might cause abnormal tau hyperphosphorylation, the authors induced in vivo alterations of glucose metab. in mice by starvation or i.p. injections of either insulin or deoxyglucose.  We found that the treatments led to abnormal tau hyperphosphorylation with patterns resembling those in early AD brains and also resulted in hypothermia.  Surprisingly, tau hyperphosphorylation could be traced down to a differential effect of low temps. on kinase and phosphatase activities.  These data indicate that abnormal tau hyperphosphorylation is assocd. with altered glucose metab. through hypothermia.  These results imply that serine-threonine protein phosphatase 2A plays a major role in regulating tau phosphorylation in the adult brain and provide in vivo evidence for its crucial role in abnormal tau hyperphosphorylation in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmIJmL4o2h97Vg90H21EOLACvtfcHk0ljLiY6qvwTfAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisVKhsLk%253D&md5=9b55d8d0df1b56ff2bd04c2eeffe4b96</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.5561-03.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.5561-03.2004%26sid%3Dliteratum%253Aachs%26aulast%3DPlanel%26aufirst%3DE.%26aulast%3DMiyasaka%26aufirst%3DT.%26aulast%3DLauney%26aufirst%3DT.%26aulast%3DChui%26aufirst%3DD.%2BH.%26aulast%3DTanemura%26aufirst%3DK.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DMurayama%26aufirst%3DO.%26aulast%3DIshiguro%26aufirst%3DK.%26aulast%3DTatebayashi%26aufirst%3DY.%26aulast%3DTakashima%26aufirst%3DA.%26atitle%3DAlterations%2520in%2520glucose%2520metabolism%2520induce%2520hypothermia%2520leading%2520to%2520tau%2520hyperphosphorylation%2520through%2520differential%2520inhibition%2520of%2520kinase%2520and%2520phosphatase%2520activities%253A%2520implications%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurosci.%26date%3D2004%26volume%3D24%26spage%3D2401%26epage%3D2411%26doi%3D10.1523%2FJNEUROSCI.5561-03.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guillozet-Bongaarts, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cahill, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cryns, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binder, L. I.</span></span> <span> </span><span class="NLM_article-title">Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1014</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2006.03784.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1111%2Fj.1471-4159.2006.03784.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=16606369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsVOntro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2006&pages=1005-1014&author=A.+L.+Guillozet-Bongaartsauthor=M.+E.+Cahillauthor=V.+L.+Crynsauthor=M.+R.+Reynoldsauthor=R.+W.+Berryauthor=L.+I.+Binder&title=Pseudophosphorylation+of+tau+at+serine+422+inhibits+caspase+cleavage%3A+in+vitro+evidence+and+implications+for+tangle+formation+in+vivo&doi=10.1111%2Fj.1471-4159.2006.03784.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo</span></div><div class="casAuthors">Guillozet-Bongaarts, Angela L.; Cahill, Michael E.; Cryns, Vincent L.; Reynolds, Matthew R.; Berry, Robert W.; Binder, Lester I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1005-1014</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The tangles of Alzheimer's disease (AD) are comprised of the tau protein displaying numerous alterations, including phosphorylation at serine 422 (S422) and truncation at aspartic acid 421 (D421).  Truncation at the latter site appears to result from activation of caspases, a class of proteases that cleave specifically at aspartic acid residues.  It has been proposed that phosphorylation at or near caspase cleavage sites could regulate the ability of the protease to cleave at those sites.  Here, we use tau pseudophosphorylated at S422 (S422E) to examine the effects of tau phosphorylation on its cleavage by caspase 3.  We find that S422E tau is more resistant to proteolysis by caspase 3 than non-pseudophosphorylated tau.  Addnl., we use antibodies directed against the phosphorylation site and against the truncation epitope to assess the presence of these epitopes in neurofibrillary tangles in the aged human brain.  We show that phosphorylation precedes truncation during tangle maturation.  Moreover, the distribution of the two epitopes suggests that a significant length of time (perhaps as much as two decades) elapses between S422 phosphorylation and cleavage at D421.  We further conclude that tau phosphorylation at S422 may be a protective mechanism that inhibits cleavage in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8FRMpyiZv4bVg90H21EOLACvtfcHk0lj7nouIlMBmlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsVOntro%253D&md5=6124e371597607c8482e7e046e782b3e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2006.03784.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2006.03784.x%26sid%3Dliteratum%253Aachs%26aulast%3DGuillozet-Bongaarts%26aufirst%3DA.%2BL.%26aulast%3DCahill%26aufirst%3DM.%2BE.%26aulast%3DCryns%26aufirst%3DV.%2BL.%26aulast%3DReynolds%26aufirst%3DM.%2BR.%26aulast%3DBerry%26aufirst%3DR.%2BW.%26aulast%3DBinder%26aufirst%3DL.%2BI.%26atitle%3DPseudophosphorylation%2520of%2520tau%2520at%2520serine%2520422%2520inhibits%2520caspase%2520cleavage%253A%2520in%2520vitro%2520evidence%2520and%2520implications%2520for%2520tangle%2520formation%2520in%2520vivo%26jtitle%3DJ.%2520Neurochem.%26date%3D2006%26volume%3D97%26spage%3D1005%26epage%3D1014%26doi%3D10.1111%2Fj.1471-4159.2006.03784.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vana, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanaan, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugwu, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mufson, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binder, L. I.</span></span> <span> </span><span class="NLM_article-title">Progression of tau pathology in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer’s disease</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">2533</span>– <span class="NLM_lpage">2550</span>, <span class="refDoi"> DOI: 10.1016/j.ajpath.2011.07.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1016%2Fj.ajpath.2011.07.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=21945902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCmu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2011&pages=2533-2550&author=L.+Vanaauthor=N.+M.+Kanaanauthor=I.+C.+Ugwuauthor=J.+Wuuauthor=E.+J.+Mufsonauthor=L.+I.+Binder&title=Progression+of+tau+pathology+in+cholinergic+basal+forebrain+neurons+in+mild+cognitive+impairment+and+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.ajpath.2011.07.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Progression of Tau pathology in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease</span></div><div class="casAuthors">Vana, Laurel; Kanaan, Nicholas M.; Ugwu, Isabella C.; Wuu, Joanne; Mufson, Elliott J.; Binder, Lester I.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2533-2550</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Tau is a microtubule-assocd. protein that forms neurofibrillary tangles (NFTs) in the selective vulnerable long projection neurons of the cholinergic basal forebrain (CBF) in Alzheimer's disease (AD).  Although CBF neurodegeneration correlates with cognitive decline during AD progression, little is known about the temporal changes of tau accumulation in this region.  We investigated tau posttranslational modifications during NFT evolution within the CBF neurons of the nucleus basalis (NB) using tissue from subjects with no cognitive impairment, mild cognitive impairment, and AD.  The pS422 antibody was used as an early tau pathol. marker that labels tau phosphorylated at Ser422; the TauC3 antibody was used to detect later stage tau pathol.  Stereol. evaluation of NB tissue immunostained for pS422 and TauC3 revealed an increase in neurons expressing these tau epitopes during disease progression.  We also investigated the occurrence of pretangle tau events within cholinergic NB neurons by dual staining for the cholinergic cell marker, p75NTR, which displays a phenotypic down-regulation within CBF perikarya in AD.  As pS422+ neurons increased in no., p75NTR+ neurons decreased, and these changes correlated with both AD neuropathol. and cognitive decline.  Also, NFTs developed slower in the CBF compared with previously examd. cortical regions.  Taken together, these results suggest that changes in cognition are assocd. with pretangle events within NB cholinergic neurons before frank NFT deposition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonBSJihBY7h7Vg90H21EOLACvtfcHk0lj7nouIlMBmlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCmu7jI&md5=87c73eff0b88ec1c724a101704d33cbb</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.ajpath.2011.07.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajpath.2011.07.044%26sid%3Dliteratum%253Aachs%26aulast%3DVana%26aufirst%3DL.%26aulast%3DKanaan%26aufirst%3DN.%2BM.%26aulast%3DUgwu%26aufirst%3DI.%2BC.%26aulast%3DWuu%26aufirst%3DJ.%26aulast%3DMufson%26aufirst%3DE.%2BJ.%26aulast%3DBinder%26aufirst%3DL.%2BI.%26atitle%3DProgression%2520of%2520tau%2520pathology%2520in%2520cholinergic%2520basal%2520forebrain%2520neurons%2520in%2520mild%2520cognitive%2520impairment%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2011%26volume%3D179%26spage%3D2533%26epage%3D2550%26doi%3D10.1016%2Fj.ajpath.2011.07.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowie, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetz, S. C.</span></span> <span> </span><span class="NLM_article-title">TTBK2 and primary cilia are essential for the connectivity and survival of cerebellar Purkinje neurons</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e511166</span> <span class="refDoi"> DOI: 10.7554/eLife.51166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.7554%2FeLife.51166" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&author=E.+Bowieauthor=S.+C.+Goetz&title=TTBK2+and+primary+cilia+are+essential+for+the+connectivity+and+survival+of+cerebellar+Purkinje+neurons&doi=10.7554%2FeLife.51166"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.7554%2FeLife.51166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.51166%26sid%3Dliteratum%253Aachs%26aulast%3DBowie%26aufirst%3DE.%26aulast%3DGoetz%26aufirst%3DS.%2BC.%26atitle%3DTTBK2%2520and%2520primary%2520cilia%2520are%2520essential%2520for%2520the%2520connectivity%2520and%2520survival%2520of%2520cerebellar%2520Purkinje%2520neurons%26jtitle%3DeLife%26date%3D2020%26volume%3D9%26doi%3D10.7554%2FeLife.51166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Profile of TTBK1 inhibitors reported in the literature.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Cocrystal structure of <b>3</b> (magenta) with the human kinase domain of TTBK1 highlighting key interactions in the active site (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JXX">7JXX</a>). (b) Surface view illustrating key elements of tertiary kinase structure and showcasing the narrow entrance to the back pocket. A water molecule in the lipophilic back pocket is displayed as a red sphere. (c) Schematic representation of the binding mode of <b>3</b> in the kinase domain of TTBK1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Initial simplification of the TTBK1 pharmacophore.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Identification of azaindazole TTBK1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Optimization of alkyne substitution in the back pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) Overlay of the cocrystal structures of <b>3</b> (magenta) and <b>18</b> (cyan) in the human kinase domain of TTBK1 highlighting key interactions of <b>18</b> with the hinge and Lys 63 (only cartoon for the protein from the X-ray cocrystal structure of <b>18</b> is shown for clarity, PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JXY">7JXY</a>). (b) Protein surface view of the cocrystal structure of <b>18</b> (cyan) with the human kinase domain of TTBK1 showing interactions in the back pocket. (c) Schematic representation of the binding mode of <b>18</b> in the kinase domain of TTBK1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Inhibitor <b>31</b> was administered at 2.5, 7, 20, 60, and 180 mg/kg to 2 month-old, male C57Bl/6 mice (<i>n</i> = 4–6 per group) 5 min prior to isoflurane-induced hypothermia. At the 20, 60, and 180 mg/kg groups, tau phosphorylation at Ser 422 was attenuated relative to non-hypothermic controls. Phosphorylation signal at Ser 422 was normalized to the level of total tau in each sample. Data are represented as the mean +/– SEM. (*<i>p</i> = 0.0236; **<i>p</i> = 0.0039 relative to vehicle). The level of tau phosphorylation at Ser 422 was normalized to the amount of total tau within a sample. To determine the effect of hypothermia on tau phosphorylation levels, an unpaired <i>t</i>-test was run directly comparing animals with or without isoflurane treatment. To determine drug treatment effects, an ordinary one-way ANOVA was used across all groups that underwent hypothermia. A Tukey’s multiple comparisons test was used to look for effects between groups using the vehicle-treated hypothermia group as the control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Inhibitor <b>31</b> was administered at 80 mg/kg (I.P.) to post-natal day 10 rats. Tau phosphorylation at Ser 422 was attenuated at 0.5, 1, 3, and 6 h timepoints. Phosphorylation signal at Ser 422 was normalized to the level of total tau in each sample. Data are represented as the mean +/– SEM. (<i>p</i> = 0.0525, <i>t</i> = 0.5 h; <i>p</i> = 0.004, <i>t</i> = 1 h; <i>p</i> = 0.0019, <i>t</i> = 3 h; <i>p</i> = 0.0021, <i>t</i> = 6 h; <i>p</i> = 0.1552, <i>t</i> = 24 h). A one-way ANOVA was used to look for significance across timepoints. A Tukey’s multiple comparisons test was used to look for effects between groups, using the level of phosphorylation at Ser 422 present at the 0 h timepoint as the control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>4</b>–<b>7</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>33</b>, TsCl, NEt<sub>3</sub>, DCM, 16 h, 68%; (b) <b>34</b>, TsCl, NEt<sub>3</sub>, DMAP, DCM, 2 h, 75%; (c) <b>34</b>, NaOH, MeI, THF, 3 h, 91%; (d) NaH, MeI, DMF, 30 °C, 2.5 h, 54%; (e) Tributyl(1-ethoxyvinyl)stannane, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 80 °C, 4 h, 90%; (f) DMF–DMA, 80–100 °C, 3–48 h; (g) Guanidine thiocyanate, NaOEt, EtOH, 80–90 °C, 3–40 h, 55–56% over two steps; (h) 2-Methylbut-3-yn-2-ol, Pd(PPh<sub>3</sub>)<sub>4</sub>, NaI, Zn, NEt<sub>3</sub>, DBU, DMSO, 90 or 100 °C, 16 h, 15–76%.</p></p></figure><figure data-id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>8</b>–<b>15</b> and <b>18</b>–<b>19</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>57–62</b>, 4-Chloropyrimidin-2-amine, NaH, DMF, 60–80 °C, 1–18 h, 40–94%; (b) <b>63</b>, 4-Chloropyrimidin-2-amine, DBU, DMF, 140 °C, 2 h; (c) <b>65</b>, 4-Chloropyrimidin-2-amine, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 120 °C, 2 h; (d) Morpholine, DBU, DMF, 150 °C, 12 h, 31%; (e) Cyclopropylboronic acid, Pd(dtbpf)Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, dioxane, 140 °C, 1 h, 52%; (f) 2-Methylbut-3-yn-2-ol, Pd(PPh<sub>3</sub>)<sub>4</sub>, NaI, Zn, NEt<sub>3</sub>, DBU, DMSO, 90 or 100 °C, 1–24 h, 6.5–47%; (g) 3-Methylpent-1-yn-3-ol, NaI, Pd(PPh<sub>3</sub>)<sub>4</sub>, Zn, DBU, Et<sub>3</sub>N, DMSO, 90 or 100 °C; (h) Chiral separation, 34% from <b>57</b>, 15% from <b>58</b>.</p></p></figure><figure data-id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>16</b> and <b>17</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) SEM-Cl, NaH, DMF, 0 °C to rt, 4.5 h, 86%; (b) 2-(3,6-Dihydro-2<i>H</i>-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, Pd(dtbpf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane/water, 110 °C, 1 h, 89%; (c) <i>tert</i>-Butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate, Pd(dppf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane/water, 100 °C, 2 h, 53%; (d) PtO<sub>2</sub>, H<sub>2</sub> (1 atm), EtOAc/EtOH, rt, 3–4 h, 91%; (e) TBAF, ethylene diamine, THF, 60–65 °C, 3 h, 83–86%; (f) <b>73</b>, 4-Chloropyrimidin-2-amine, NaH, DMF, 110 °C, 40 min, 73%; (g) <b>74</b>, 4-Chloropyrimidin-2-amine, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 90 °C, 4 h, 80%; (h) HCl, EtOAc, rt, 2 h; (i) Formaldehyde, NaCNBH<sub>3</sub>, MeOH, rt, 2 h, 35% over 2 steps; (j) 2-Methyl-3-yn-2-ol, Pd(PPh<sub>3</sub>)<sub>4</sub>, NaI, Zn, Et<sub>3</sub>N, DBU, DMSO, 95 °C, 5–20 h, 29–45%; (k) Chiral separation.</p></p></figure><figure data-id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0014.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>18</b>–<b>21</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Red-Al, THF, 0 °C to rt, 14 h, 16.7%; (b) H<sub>2</sub>, Pd/C, MeOH, 1 h, 57%; (c) 3-Methylazetidin-3-ol, SPhos-Pd-G3, <i>t</i>-BuONa, dioxane, 90 °C, 17 h, 8%; (d) (4-Hydroxyphenyl)boronic acid, Pd(dppf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane/water, 90 °C, 17 h, 57%.</p></p></figure><figure data-id="sch5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0015.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>24</b>–<b>27</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Red-Al, THF, 0 °C to rt, 16 h, 92%; (b) Ethyl 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopropane-1-carboxylate, Pd(dtbpf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 100 °C, 6 h, 18%; (c) MeLi, THF, −78 °C, 4 h, 37%; (d) 4-Methylbenzenesulfonohydrazide, MeOH, 2 h, 86%; (e) <b>80</b>, Pd(MeCN)<sub>2</sub>Cl<sub>2</sub>, dppp, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 95 °C, 20 h, 21%; (f) MeMgBr, THF, 1 h, 29%; (g) H<sub>2</sub>, Pd/C, MeOH, EtOAc, 16 h, 75%; (h) 4-Chloropyrimidin-2-amine, NaH, DMF; (i) TMSCHN<sub>2</sub>, MeOH, DCM, 1.5 h; (j) MeMgBr, THF, 1 h, 15% from <b>83</b>.</p></p></figure><figure data-id="sch6" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0016.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>28</b>–<b>32</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, DMF, rt to 70 °C, 13–87%; (b) NaI, Pd(PPh<sub>3</sub>)<sub>4</sub>, Zn, DBU, NEt<sub>3</sub>, DMSO, 100 °C, 2–14 h; (c) Chiral separation, 1.7–48%.</p></p></figure><figure data-id="fig9" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/medium/jm1c00382_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Summary of identification and optimization of novel TTBK1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00382/20210506/images/large/jm1c00382_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00382&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i99">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37357" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37357" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 31 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlautman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciborowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikezu, T.</span></span> <span> </span><span class="NLM_article-title">Spatial learning impairment, enhanced CDK5/p35 activity, and downregulation of NMDA receptor expression in transgenic mice expressing tau-tubulin kinase 1</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">14511</span>– <span class="NLM_lpage">14521</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.3417-08.2008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1523%2FJNEUROSCI.3417-08.2008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=19118186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsF2nuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=14511-14521&author=S.+Satoauthor=J.+Xuauthor=S.+Okuyamaauthor=L.+B.+Martinezauthor=S.+M.+Walshauthor=M.+T.+Jacobsenauthor=R.+J.+Swanauthor=J.+D.+Schlautmanauthor=P.+Ciborowskiauthor=T.+Ikezu&title=Spatial+learning+impairment%2C+enhanced+CDK5%2Fp35+activity%2C+and+downregulation+of+NMDA+receptor+expression+in+transgenic+mice+expressing+tau-tubulin+kinase+1&doi=10.1523%2FJNEUROSCI.3417-08.2008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Spatial learning impairment, enhanced CDK5/p35 activity, and downregulation of NMDA receptor expression in transgenic mice expressing tau-tubulin kinase 1</span></div><div class="casAuthors">Sato, Shinji; Xu, Jiqing; Okuyama, Satoshi; Martinez, Lindsey B.; Walsh, Shannon M.; Jacobsen, Michael T.; Swan, Russell J.; Schlautman, Joshua D.; Ciborowski, Pawel; Ikezu, Tsuneya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">53</span>),
    <span class="NLM_cas:pages">14511-14521</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Tau-tubulin kinase-1 (TTBK1) is involved in phosphorylation of tau protein at specific Serine/Threonine residues found in paired helical filaments, suggesting its role in tauopathy pathogenesis.  We found that TTBK1 levels were upregulated in brains of human Alzheimer' disease (AD) patients compared with age-matched non-AD controls.  To understand the effects of TTBK1 activation in vivo, we developed transgenic mice harboring human full-length TTBK1 genomic DNA (TTBK1-Tg).  Transgenic TTBK1 is highly expressed in subiculum and cortical pyramidal layers, and induces phosphorylated neurofilament aggregation.  TTBK1-Tg mice show significant age-dependent memory impairment as detd. by radial arm water maze test, which is assocd. with enhancement of tau and neurofilament phosphorylation, increased levels of p25 and p35, both activators of cyclin-dependent protein kinase 5 (CDK5), enhanced calpain I activity, and reduced levels of hippocampal NMDA receptor types 2B (NR2B) and D.  Enhanced CDK5/p35 complex formation is strongly correlated with dissocn. of F-actin from p35, suggesting the inhibitory mechanism of CDK5/p35 complex formation by F-actin.  Expression of recombinant TTBK1 in primary mouse cortical neurons significantly downregulated NR2B in a CDK5- and calpain-dependent manner.  These data suggest that TTBK1 in AD brain may be one of the underlying mechanisms inducing CDK5 and calpain activation, NR2B downregulation, and subsequent memory dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZrV95H_8JCbVg90H21EOLACvtfcHk0lhmNrONZdIilg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsF2nuw%253D%253D&md5=8a248e4807d46a31e1d49106bb66fc75</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.3417-08.2008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.3417-08.2008%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DOkuyama%26aufirst%3DS.%26aulast%3DMartinez%26aufirst%3DL.%2BB.%26aulast%3DWalsh%26aufirst%3DS.%2BM.%26aulast%3DJacobsen%26aufirst%3DM.%2BT.%26aulast%3DSwan%26aufirst%3DR.%2BJ.%26aulast%3DSchlautman%26aufirst%3DJ.%2BD.%26aulast%3DCiborowski%26aufirst%3DP.%26aulast%3DIkezu%26aufirst%3DT.%26atitle%3DSpatial%2520learning%2520impairment%252C%2520enhanced%2520CDK5%252Fp35%2520activity%252C%2520and%2520downregulation%2520of%2520NMDA%2520receptor%2520expression%2520in%2520transgenic%2520mice%2520expressing%2520tau-tubulin%2520kinase%25201%26jtitle%3DJ.%2520Neurosci.%26date%3D2008%26volume%3D28%26spage%3D14511%26epage%3D14521%26doi%3D10.1523%2FJNEUROSCI.3417-08.2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikezu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingraham Dixie, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaibuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikezu, T.</span></span> <span> </span><span class="NLM_article-title">Tau-tubulin kinase 1 and amyloid-β peptide induce phosphorylation of collapsin response mediator protein-2 and enhance neurite degeneration in Alzheimer disease mouse models</span>. <i>Acta Neuropathol. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">12</span>, <span class="refDoi"> DOI: 10.1186/s40478-020-0890-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1186%2Fs40478-020-0890-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=32019603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BB3cXltFemu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=12&author=S.+Ikezuauthor=K.+L.+Ingraham+Dixieauthor=L.+Koroauthor=T.+Watanabeauthor=K.+Kaibuchiauthor=T.+Ikezu&title=Tau-tubulin+kinase+1+and+amyloid-%CE%B2+peptide+induce+phosphorylation+of+collapsin+response+mediator+protein-2+and+enhance+neurite+degeneration+in+Alzheimer+disease+mouse+models&doi=10.1186%2Fs40478-020-0890-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Tau-tubulin kinase 1 and amyloid-β peptide induce phosphorylation of collapsin response mediator protein-2 and enhance neurite degeneration in Alzheimer disease mouse models</span></div><div class="casAuthors">Ikezu, Seiko; Ingraham Dixie, Kaitlin L.; Koro, Lacin; Watanabe, Takashi; Kaibuchi, Kozo; Ikezu, Tsuneya</div><div class="citationInfo"><span class="NLM_cas:title">Acta Neuropathologica Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12</span>CODEN:
                <span class="NLM_cas:coden">ANCCC9</span>;
        ISSN:<span class="NLM_cas:issn">2051-5960</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The accumulation of phosphorylated tau protein (pTau) in the entorhinal cortex (EC) is the earliest tau pathol. in Alzheimer's disease (AD).  Tau tubulin kinase-1 (TTBK1) is a neuron-specific tau kinase and expressed in the EC and hippocampal regions in both human and mouse brains.  Here we report that collapsin response mediator protein-2 (CRMP2), a crit. mediator of growth cone collapse, is a new downstream target of TTBK1 and is accumulated in the EC region of early stage AD brains.  TTBK1 transgenic mice show severe axonal degeneration in the perforant path, which is exacerbated by crossing with Tg2576 mice expressing Swedish familial AD mutant of amyloid precursor protein (APP).  TTBK1 mice show accumulation of phosphorylated CRMP2 (pCRMP2), in the EC at 10 mo of age, whereas age-matched APP/TTBK1 bigenic mice show pCRMP2 accumulation in both the EC and hippocampal regions.  Amyloid-β peptide (Aβ) and TTBK1 suppress the kinetics of microtubule polymn. and TTBK1 reduces the neurite length of primary cultured neurons in Rho kinase-dependent manner in vitro.  Silencing of TTBK1 or expression of dominant-neg. Rho kinase demonstrates that Aβ induces CRMP2 phosphorylation at threonine 514 in a TTBK1-dependent manner, and TTBK1 enhances Aβ-induced CRMP2 phosphorylation in Rho kinase-dependent manner in vitro.  Furthermore, TTBK1 expression induces pCRMP2 complex formation with pTau in vitro, which is enhanced upon Aβ stimulation in vitro.  Finally, pCRMP2 forms a complex with pTau in the EC tissue of TTBK1 mice in vivo, which is exacerbated in both the EC and hippocampal tissues in APP/TTBK1 mice.  These results suggest that TTBK1 and Aβ induce phosphorylation of CRMP2, which may be causative for the neurite degeneration and somal accumulation of pTau in the EC neurons, indicating crit. involvement of TTBK1 and pCRMP2 in the early AD pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmddVFBkzOn7Vg90H21EOLACvtfcHk0lhmNrONZdIilg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXltFemu74%253D&md5=5e577e0834a2ec652556383dedd6400c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1186%2Fs40478-020-0890-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40478-020-0890-4%26sid%3Dliteratum%253Aachs%26aulast%3DIkezu%26aufirst%3DS.%26aulast%3DIngraham%2BDixie%26aufirst%3DK.%2BL.%26aulast%3DKoro%26aufirst%3DL.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DKaibuchi%26aufirst%3DK.%26aulast%3DIkezu%26aufirst%3DT.%26atitle%3DTau-tubulin%2520kinase%25201%2520and%2520amyloid-%25CE%25B2%2520peptide%2520induce%2520phosphorylation%2520of%2520collapsin%2520response%2520mediator%2520protein-2%2520and%2520enhance%2520neurite%2520degeneration%2520in%2520Alzheimer%2520disease%2520mouse%2520models%26jtitle%3DActa%2520Neuropathol.%2520Commun.%26date%3D2020%26volume%3D8%26spage%3D12%26doi%3D10.1186%2Fs40478-020-0890-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerny, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buescher, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikezu, T.</span></span> <span> </span><span class="NLM_article-title">Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">1573</span>– <span class="NLM_lpage">1584</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2006.04059.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1111%2Fj.1471-4159.2006.04059.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=16923168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVymtLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2006&pages=1573-1584&author=S.+Satoauthor=R.+L.+Cernyauthor=J.+L.+Buescherauthor=T.+Ikezu&title=Tau-tubulin+kinase+1+%28TTBK1%29%2C+a+neuron-specific+tau+kinase+candidate%2C+is+involved+in+tau+phosphorylation+and+aggregation&doi=10.1111%2Fj.1471-4159.2006.04059.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation</span></div><div class="casAuthors">Sato, Shinji; Cerny, Ronald L.; Buescher, James L.; Ikezu, Tsuneya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1573-1584</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Neurofibrillary tangles, which are major pathol. hallmarks of Alzheimer's disease (AD), are composed of paired helical filaments (PHFs) contg. hyper-phosphorylated tau.  Specific kinases regulate tau phosphorylation and are closely linked to the pathogenesis of AD.  We have characterized a human tau-tubulin kinase 1 (TTBK1) gene located on chromosome 6p21.1.  TTBK1 is a serine/threonine/tyrosine kinase that is conserved among species and belongs to the casein kinase 1 superfamily.  It is specifically expressed in the brain, esp. in the cytoplasm of cortical and hippocampal neurons.  TTBK1 phosphorylates tau proteins in both a Mg2+- and a Mn2+-dependent manner.  Phosphopeptide mapping and immunoblotting anal. confirmed a direct tau phosphorylation by TTBK1 at Ser198, Ser199, Ser202 and Ser422, which are also phosphorylated in PHFs.  TTBK1 also induces tau aggregation in human neuronal cells in a dose-dependent manner.  We conclude that TTBK1 is a neuron-specific dual kinase involved in tau phosphorylation at AD-related sites and is also assocd. with tau aggregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPnxUboOe6fLVg90H21EOLACvtfcHk0lil8qYB1u1zhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVymtLnL&md5=cacb0fef484676a20567bed3ef90c3a5</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2006.04059.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2006.04059.x%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DS.%26aulast%3DCerny%26aufirst%3DR.%2BL.%26aulast%3DBuescher%26aufirst%3DJ.%2BL.%26aulast%3DIkezu%26aufirst%3DT.%26atitle%3DTau-tubulin%2520kinase%25201%2520%2528TTBK1%2529%252C%2520a%2520neuron-specific%2520tau%2520kinase%2520candidate%252C%2520is%2520involved%2520in%2520tau%2520phosphorylation%2520and%2520aggregation%26jtitle%3DJ.%2520Neurochem.%26date%3D2006%26volume%3D98%26spage%3D1573%26epage%3D1584%26doi%3D10.1111%2Fj.1471-4159.2006.04059.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calhoun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaral, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajrami, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabah, D.</span></span> <span> </span><span class="NLM_article-title">Acute inhibition of the CNS-specific kinase TTBK1 significantly lowers tau phosphorylation at several disease relevant sites</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span>, <span class="NLM_elocation-id">e0228771</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0228771</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1371%2Fjournal.pone.0228771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=32255788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvVGlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&author=G.+M.+Dillonauthor=J.+L.+Hendersonauthor=C.+Baoauthor=J.+A.+Joyceauthor=M.+Calhounauthor=B.+Amaralauthor=K.+W.+Kingauthor=B.+Bajramiauthor=D.+Rabah&title=Acute+inhibition+of+the+CNS-specific+kinase+TTBK1+significantly+lowers+tau+phosphorylation+at+several+disease+relevant+sites&doi=10.1371%2Fjournal.pone.0228771"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Acute inhibition of the CNS-specific kinase TTBK1 significantly lowers tau phosphorylation at several disease relevant sites</span></div><div class="casAuthors">Dillon, Gregory M.; Henderson, Jaclyn L.; Bao, Channa; Joyce, John A.; Calhoun, Michael; Amaral, Brenda; King, Kristopher W.; Bajrami, Bekim; Rabah, Dania</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e0228771</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Hyperphosphorylated tau protein is a pathol. hallmark of numerous neurodegenerative diseases and the level of tau pathol. is correlated with the degree of cognitive impairment.  Tau hyper-phosphorylation is thought to be an early initiating event in the cascade leading to tau toxicity and neuronal death.  Inhibition of tau phosphorylation therefore represents an attractive therapeutic strategy.  However, the widespread expression of most kinases and promiscuity of their substrates, along with poor selectivity of most kinase inhibitors, have resulted in systemic toxicities that have limited the advancement of tau kinase inhibitors into the clinic.  We therefore focused on the CNS-specific tau kinase, TTBK1, and investigated whether selective inhibition of this kinase could represent a viable approach to targeting tau phosphorylation in disease.  In the current study, we demonstrate that TTBK1 regulates tau phosphorylation using overexpression or knockdown of this kinase in heterologous cells and primary neurons.  Importantly, we find that TTBK1-specific phosphorylation of tau leads to a loss of normal protein function including a decrease in tau-tubulin binding and deficits in tubulin polymn.  We demonstrate substantial lowering of tau phosphorylation at multiple sites implicated in disease, suggesting that TTBK1 inhibitors may represent an exciting new approach in the search for neurodegenerative disease therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5IbKU-F7Em7Vg90H21EOLACvtfcHk0lil8qYB1u1zhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvVGlt7s%253D&md5=d8f8a6bdcec11c32359472f657434826</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0228771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0228771%26sid%3Dliteratum%253Aachs%26aulast%3DDillon%26aufirst%3DG.%2BM.%26aulast%3DHenderson%26aufirst%3DJ.%2BL.%26aulast%3DBao%26aufirst%3DC.%26aulast%3DJoyce%26aufirst%3DJ.%2BA.%26aulast%3DCalhoun%26aufirst%3DM.%26aulast%3DAmaral%26aufirst%3DB.%26aulast%3DKing%26aufirst%3DK.%2BW.%26aulast%3DBajrami%26aufirst%3DB.%26aulast%3DRabah%26aufirst%3DD.%26atitle%3DAcute%2520inhibition%2520of%2520the%2520CNS-specific%2520kinase%2520TTBK1%2520significantly%2520lowers%2520tau%2520phosphorylation%2520at%2520several%2520disease%2520relevant%2520sites%26jtitle%3DPLoS%2520One%26date%3D2020%26volume%3D15%26doi%3D10.1371%2Fjournal.pone.0228771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballatore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, V. M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojanowski, J. Q.</span></span> <span> </span><span class="NLM_article-title">Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">663</span>– <span class="NLM_lpage">672</span>, <span class="refDoi"> DOI: 10.1038/nrn2194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1038%2Fnrn2194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=17684513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpt1Crt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=663-672&author=C.+Ballatoreauthor=V.+M.-Y.+Leeauthor=J.+Q.+Trojanowski&title=Tau-mediated+neurodegeneration+in+Alzheimer%E2%80%99s+disease+and+related+disorders&doi=10.1038%2Fnrn2194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Tau-mediated neurodegeneration in Alzheimer's disease and related disorders</span></div><div class="casAuthors">Ballatore, Carlo; Lee, Virginia M.-Y.; Trojanowski, John Q.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">663-672</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Advances in the understanding of the mechanisms of tau-mediated neurodegeneration in Alzheimer's disease (AD) and related tauopathies, which are characterized by prominent CNS accumulations of fibrillar tau inclusions, are rapidly moving this previously underexplored disease pathway to center stage for disease-modifying drug discovery efforts.  However, controversies abound concerning whether or not the deleterious effects of tau pathologies result from toxic gains-of-function by pathol. tau or from crit. losses of normal tau function in the disease state.  This review summarizes the most recent advances in the authors' knowledge of the mechanisms of tau-mediated neurodegeneration to forge an integrated concept of those tau-linked disease processes that drive the onset and progression of AD and related tauopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8-k_a3SnV7bVg90H21EOLACvtfcHk0lil8qYB1u1zhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpt1Crt78%253D&md5=eef3cc99033075b3215b739521d672f6</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrn2194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn2194%26sid%3Dliteratum%253Aachs%26aulast%3DBallatore%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DV.%2BM.-Y.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26atitle%3DTau-mediated%2520neurodegeneration%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520and%2520related%2520disorders%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2007%26volume%3D8%26spage%3D663%26epage%3D672%26doi%3D10.1038%2Fnrn2194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelkow, E.</span></span> <span> </span><span class="NLM_article-title">Tau in physiology and pathology</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1038/nrn.2015.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1038%2Fnrn.2015.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=26631930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A280%3ADC%252BC28vnsVGhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=5-21&author=Y.+Wangauthor=E.+Mandelkow&title=Tau+in+physiology+and+pathology&doi=10.1038%2Fnrn.2015.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tau in physiology and pathology</span></div><div class="casAuthors">Wang Yipeng; Mandelkow Eckhard; Wang Yipeng; Mandelkow Eckhard; Mandelkow Eckhard</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tau is a microtubule-associated protein that has a role in stabilizing neuronal microtubules and thus in promoting axonal outgrowth.  Structurally, tau is a natively unfolded protein, is highly soluble and shows little tendency for aggregation.  However, tau aggregation is characteristic of several neurodegenerative diseases known as tauopathies.  The mechanisms underlying tau pathology and tau-mediated neurodegeneration are debated, but considerable progress has been made in the field of tau research in recent years, including the identification of new physiological roles for tau in the brain.  Here, we review the expression, post-translational modifications and functions of tau in physiology and in pathophysiology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRryzboeQaGukdrW1FkXG-fW6udTcc2eZ5td9S2q6Ih7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vnsVGhtg%253D%253D&md5=7f0fda5812709bc043731f34a45fb24e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrn.2015.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn.2015.1%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMandelkow%26aufirst%3DE.%26atitle%3DTau%2520in%2520physiology%2520and%2520pathology%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2016%26volume%3D17%26spage%3D5%26epage%3D21%26doi%3D10.1038%2Fnrn.2015.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaidi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundke-Iqbal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, K.</span></span> <span> </span><span class="NLM_article-title">Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">5562</span>– <span class="NLM_lpage">5566</span>, <span class="refDoi"> DOI: 10.1073/pnas.91.12.5562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1073%2Fpnas.91.12.5562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=8202528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A280%3ADyaK2c3mtFKhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=5562-5566&author=A.+C.+Alonsoauthor=T.+Zaidiauthor=I.+Grundke-Iqbalauthor=K.+Iqbal&title=Role+of+abnormally+phosphorylated+tau+in+the+breakdown+of+microtubules+in+Alzheimer+disease&doi=10.1073%2Fpnas.91.12.5562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease</span></div><div class="casAuthors">Alonso A C; Zaidi T; Grundke-Iqbal I; Iqbal K</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5562-6</span>
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The microtubule assembly-promoting activity of different pools of tau protein isolated from Alzheimer disease (AD) and control brains and the effect of dephosphorylation on this activity were studied.  Tau isolated from a 2.5% perchloric extract of AD brain had almost the same activity as that obtained from control brain, and this activity did not change significantly on dephosphorylation.  Abnormally phosphorylated tau (AD P-tau) isolated from brain homogenate of AD patients had little activity, and upon dephosphorylation with alkaline phosphatase, its activity increased to approximately the same level as the acid-soluble tau.  Addition of AD P-tau to a mixture of normal tau and tubulin inhibited microtubule assembly.  AD P-tau bound to normal tau but not to tubulin.  These studies suggest that the abnormal phosphorylation of tau might be responsible for the breakdown of microtubules in affected neurons in AD not only because the altered protein has little microtubule-promoting activity but also because it interacts with normal tau, making the latter unavailable for promoting the assembly of tubulin into microtubules.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5nJ1wCLFdwrZpSb_XWfMrfW6udTcc2eZ5td9S2q6Ih7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c3mtFKhtA%253D%253D&md5=4b73493ac98f48a1d5b6976104bd5ca3</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.12.5562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.12.5562%26sid%3Dliteratum%253Aachs%26aulast%3DAlonso%26aufirst%3DA.%2BC.%26aulast%3DZaidi%26aufirst%3DT.%26aulast%3DGrundke-Iqbal%26aufirst%3DI.%26aulast%3DIqbal%26aufirst%3DK.%26atitle%3DRole%2520of%2520abnormally%2520phosphorylated%2520tau%2520in%2520the%2520breakdown%2520of%2520microtubules%2520in%2520Alzheimer%2520disease%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1994%26volume%3D91%26spage%3D5562%26epage%3D5566%26doi%3D10.1073%2Fpnas.91.12.5562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murayama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshiike, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyasaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murayama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takashima, A.</span></span> <span> </span><span class="NLM_article-title">Granular tau oligomers as intermediates of tau filaments</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">3856</span>– <span class="NLM_lpage">3861</span>, <span class="refDoi"> DOI: 10.1021/bi061359o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi061359o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisVGlsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=3856-3861&author=S.+Maedaauthor=N.+Saharaauthor=Y.+Saitoauthor=M.+Murayamaauthor=Y.+Yoshiikeauthor=H.+Kimauthor=T.+Miyasakaauthor=S.+Murayamaauthor=A.+Ikaiauthor=A.+Takashima&title=Granular+tau+oligomers+as+intermediates+of+tau+filaments&doi=10.1021%2Fbi061359o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Granular Tau Oligomers as Intermediates of Tau Filaments</span></div><div class="casAuthors">Maeda, Sumihiro; Sahara, Naruhiko; Saito, Yuko; Murayama, Miyuki; Yoshiike, Yuji; Kim, Hyonchol; Miyasaka, Tomohiro; Murayama, Shigeo; Ikai, Atsushi; Takashima, Akihiko</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3856-3861</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Neurofibrillary tangles (NFTs) are pathol. hallmarks of several neurodegenerative disorders, including Alzheimer's disease (AD).  NFTs are composed of microtubule-binding protein tau, which assembles to form paired helical filaments (PHFs) and straight filaments.  Here we show by at. force microscopy that AD brain tissue and in vitro tau form granular and fibrillar tau aggregates.  CD spectral anal. and immunostaining with conformation-dependent antibodies indicated that tau may undergo conformational changes during fibril formation.  Enriched granules generated filaments, suggesting that granular tau aggregates may be an intermediate form of tau fibrils.  The amt. of granular tau aggregates was elevated in prefrontal cortex of Braak stage I cases compared to that of Braak stage 0 cases, suggesting that granular tau aggregation precedes PHF formation.  Thus, granular tau aggregates may be a relevant marker for the early diagnosis of tauopathy.  Reducing the level of these aggregates may be a promising therapy for tauopathies and for promoting healthy brain aging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjmRXwd4jCY7Vg90H21EOLACvtfcHk0liupBnDkVeQ3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisVGlsr4%253D&md5=b1570ec3e4a3d218c50d59ded5b27e5b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fbi061359o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi061359o%26sid%3Dliteratum%253Aachs%26aulast%3DMaeda%26aufirst%3DS.%26aulast%3DSahara%26aufirst%3DN.%26aulast%3DSaito%26aufirst%3DY.%26aulast%3DMurayama%26aufirst%3DM.%26aulast%3DYoshiike%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DMiyasaka%26aufirst%3DT.%26aulast%3DMurayama%26aufirst%3DS.%26aulast%3DIkai%26aufirst%3DA.%26aulast%3DTakashima%26aufirst%3DA.%26atitle%3DGranular%2520tau%2520oligomers%2520as%2520intermediates%2520of%2520tau%2520filaments%26jtitle%3DBiochemistry%26date%3D2007%26volume%3D46%26spage%3D3856%26epage%3D3861%26doi%3D10.1021%2Fbi061359o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orr, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, B.</span></span> <span> </span><span class="NLM_article-title">A Brief overview of tauopathy: causes, consequences, and therapeutic strategies</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">648</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2017.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1016%2Fj.tips.2017.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=28455089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtFOiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=637-648&author=M.+E.+Orrauthor=A.+C.+Sullivanauthor=B.+Frost&title=A+Brief+overview+of+tauopathy%3A+causes%2C+consequences%2C+and+therapeutic+strategies&doi=10.1016%2Fj.tips.2017.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies</span></div><div class="casAuthors">Orr, Miranda E.; Sullivan, A. Campbell; Frost, Bess</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">637-648</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">There are currently no disease-modifying therapies for the treatment of tauopathies, a group of progressive neurodegenerative disorders that are pathol. defined by the presence of tau protein aggregates in the brain.  Current challenges for the treatment of tauopathies include the inability to diagnose early and to confidently discriminate between distinct tauopathies in patients, alongside an incomplete understanding of the cellular mechanisms involved in pathogenic tau-induced neuronal death and dysfunction.  In this review, we describe current diagnostic and therapeutic strategies, known drivers of pathogenic tau formation, recent contributions to our current mechanistic understanding of how pathogenic tau induces neuronal death, and potential diagnostic and therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo67tWmxH7Qa7Vg90H21EOLACvtfcHk0lhqTHxwvj6vbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtFOiu7g%253D&md5=7529288546143a87ce13f2168884046a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2017.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2017.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DOrr%26aufirst%3DM.%2BE.%26aulast%3DSullivan%26aufirst%3DA.%2BC.%26aulast%3DFrost%26aufirst%3DB.%26atitle%3DA%2520Brief%2520overview%2520of%2520tauopathy%253A%2520causes%252C%2520consequences%252C%2520and%2520therapeutic%2520strategies%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2017%26volume%3D38%26spage%3D637%26epage%3D648%26doi%3D10.1016%2Fj.tips.2017.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knerr, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundgren-Andersson, A. K.</span></span> <span> </span><span class="NLM_article-title">The conundrum of GSK3 inhibitors: is it the dawn of a new beginning?</span>. <i>J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">S547</span>– <span class="NLM_lpage">S554</span>, <span class="refDoi"> DOI: 10.3233/JAD-179934.</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.3233%2FJAD-179934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=29758944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFGgsL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2018&pages=S547-S554&author=R.+V.+Bhatauthor=U.+Anderssonauthor=S.+Anderssonauthor=L.+Knerrauthor=U.+Bauerauthor=A.+K.+Sundgren-Andersson&title=The+conundrum+of+GSK3+inhibitors%3A+is+it+the+dawn+of+a+new+beginning%3F&doi=10.3233%2FJAD-179934."target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The Conundrum of GSK3 Inhibitors: Is it the Dawn of a New Beginning?</span></div><div class="casAuthors">Bhat, Ratan V.; Andersson, Ulf; Andersson, Shalini; Knerr, Laurent; Bauer, Udo; Sundgren-Andersson, Anna K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">s1</span>),
    <span class="NLM_cas:pages">S547-S554</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">Spanning over three decades of extensive drug discovery research, the efforts to develop a potent and selective GSK3 inhibitor as a therapeutic for the treatment of type 2 diabetes, Alzheimer's disease (AD), bipolar disorders and cancer have been futile.  Since its initial discovery in 1980 and subsequent decades of research, one cannot underscore the importance of the target and the promise of a game changing disease modifier.  Several pharmaceutical companies, biotech companies, and academic institutions raged in a quest to unravel the biol. and discover potent and selective GSK3 inhibitors, some of which went through clin. trials.  However, the conundrum of what happened to the fate of the AstraZeneca's GSK3 inhibitors and the undertaking to find a therapeutic that could control glycogen metab. and aberrant tau hyperphosphorylation in the brain, and rescue synaptic dysfunction has largely been untold.  AstraZeneca was in the forefront of GSK3 drug discovery research with six GSK3 drug candidates, one of which progressed up to Phase II clin. trials in the quest to untangle the tau hypothesis for AD.  Anal. of key toxicity issues, serendipitous findings and efficacy, and biomarker considerations in relation to safety margins have limited the potential of small mol. therapeutics as a way forward.  To guide future innovation of this important target, we reveal the roller coaster journey comprising of two decades of preclin. and clin. GSK3 drug discovery at AstraZeneca; the understanding of which could lead to improved GSK3 therapies for disease.  These learnings in combination with advances in achieving kinase selectivity, different modes of action as well as the recent discovery of novel conjugated peptide technol. targeting specific tissues have potentially provided a venue for scientific innovation and a new beginning for GSK3 drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLP9jk6RTw_7Vg90H21EOLACvtfcHk0lhqTHxwvj6vbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFGgsL7E&md5=4ee97abb934c85d809591e6a4caf8356</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3233%2FJAD-179934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-179934%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DR.%2BV.%26aulast%3DAndersson%26aufirst%3DU.%26aulast%3DAndersson%26aufirst%3DS.%26aulast%3DKnerr%26aufirst%3DL.%26aulast%3DBauer%26aufirst%3DU.%26aulast%3DSundgren-Andersson%26aufirst%3DA.%2BK.%26atitle%3DThe%2520conundrum%2520of%2520GSK3%2520inhibitors%253A%2520is%2520it%2520the%2520dawn%2520of%2520a%2520new%2520beginning%253F%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2018%26volume%3D64%26spage%3DS547%26epage%3DS554%26doi%3D10.3233%2FJAD-179934." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">and references therein.</p></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wadhwa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, H. R.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase 3 (GSK3): its role and inhibitors</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1522</span>– <span class="NLM_lpage">1534</span>, <span class="refDoi"> DOI: 10.2174/1568026620666200516153136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.2174%2F1568026620666200516153136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=32416693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslKisr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=1522-1534&author=P.+Wadhwaauthor=P.+Jainauthor=H.+R.+Jadhav&title=Glycogen+synthase+kinase+3+%28GSK3%29%3A+its+role+and+inhibitors&doi=10.2174%2F1568026620666200516153136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen Synthase Kinase 3 (GSK3): Its Role and Inhibitors</span></div><div class="casAuthors">Wadhwa, Pankaj; Jain, Priti; Jadhav, Hemant R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1522-1534</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Glycogen Synthase Kinase 3 (GSK3) is one of the Serine/Threonine protein kinases, which has gained a lot of attention for its role in a variety of pathways.  It has two isoforms, GSK3α and GSK3β.  However, GSK3β is highly expressed in different areas of the brain and has been implicated in Alzheimers disease as it is involved in tau phosphorylation.  Due to its high specificity concerning substrate recognition, GSK3 has been considered as an important target.  In the last decade, several GSK3 inhibitors have been reported and two mols. are in clin. trials.  This review collates the information published in the last decade about the role of GSK3 in Alzheimers disease and progress in the development of its inhibitors.  Using this collated information medicinal chemists can strategize and design novel GSK3 inhibitors that could be useful in the treatment of Alzheimers disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxZmZdyp3j-7Vg90H21EOLACvtfcHk0lhqTHxwvj6vbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslKisr7E&md5=e1f9fbad989f694f6f76c65fb5530bd6</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F1568026620666200516153136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026620666200516153136%26sid%3Dliteratum%253Aachs%26aulast%3DWadhwa%26aufirst%3DP.%26aulast%3DJain%26aufirst%3DP.%26aulast%3DJadhav%26aufirst%3DH.%2BR.%26atitle%3DGlycogen%2520synthase%2520kinase%25203%2520%2528GSK3%2529%253A%2520its%2520role%2520and%2520inhibitors%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2020%26volume%3D20%26spage%3D1522%26epage%3D1534%26doi%3D10.2174%2F1568026620666200516153136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goetz, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liem, K. F.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. V.</span></span> <span> </span><span class="NLM_article-title">The spinocerebellar ataxia-associated gene tau tubulin kinase 2 controls the initiation of ciliogenesis</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">847</span>– <span class="NLM_lpage">858</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2012.10.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1016%2Fj.cell.2012.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=23141541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Kjsr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2012&pages=847-858&author=S.+C.+Goetzauthor=K.+F.+Liemauthor=K.+V.+Anderson&title=The+spinocerebellar+ataxia-associated+gene+tau+tubulin+kinase+2+controls+the+initiation+of+ciliogenesis&doi=10.1016%2Fj.cell.2012.10.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The Spinocerebellar Ataxia-Associated Gene Tau Tubulin Kinase 2 Controls the Initiation of Ciliogenesis</span></div><div class="casAuthors">Goetz, Sarah C.; Liem, Karel F.; Anderson, Kathryn V.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">847-858</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The primary cilium has crit. roles in human development and disease, but the mechanisms that regulate ciliogenesis are not understood.  Here, we show that Tau tubulin kinase 2 (TTBK2) is a dedicated regulator of the initiation of ciliogenesis in vivo.  We identified a null allele of mouse Ttbk2 based on loss of Sonic hedgehog activity, a signaling pathway that requires the primary cilium.  Despite a normal basal body template, Ttbk2 mutants lack cilia.  TTBK2 acts at the distal end of the basal body, where it promotes the removal of CP110, which caps the mother centriole, and promotes recruitment of IFT proteins, which build the ciliary axoneme.  Dominant truncating mutations in human TTBK2 cause spinocerebellar ataxia type 11 (SCA11); these mutant proteins do not promote ciliogenesis and inhibit ciliogenesis in wild-type cells.  We propose that cell-cycle regulators target TTBK2 to the basal body, where it modifies specific targets to initiate ciliogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHV3kLyiUXQLVg90H21EOLACvtfcHk0ljWB-qMzqgYhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Kjsr%252FK&md5=6de9e5f8875a2ac5b6fd4d6fc20320e1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DGoetz%26aufirst%3DS.%2BC.%26aulast%3DLiem%26aufirst%3DK.%2BF.%26aulast%3DAnderson%26aufirst%3DK.%2BV.%26atitle%3DThe%2520spinocerebellar%2520ataxia-associated%2520gene%2520tau%2520tubulin%2520kinase%25202%2520controls%2520the%2520initiation%2520of%2520ciliogenesis%26jtitle%3DCell%26date%3D2012%26volume%3D151%26spage%3D847%26epage%3D858%26doi%3D10.1016%2Fj.cell.2012.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-W.</span></span> <span> </span><span class="NLM_article-title">TTBK2: A tau protein kinase beyond tau phosphorylation</span>. <i>BioMed Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">575170</span>, <span class="refDoi"> DOI: 10.1155/2015/575170</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1155%2F2015%2F575170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=25950000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A280%3ADC%252BC2Mbgs1aktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=575170&author=J.-C.+Liaoauthor=T.+T.+Yangauthor=R.+R.+Wengauthor=C.-T.+Kuoauthor=C.-W.+Chang&title=TTBK2%3A+A+tau+protein+kinase+beyond+tau+phosphorylation&doi=10.1155%2F2015%2F575170"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">TTBK2: a tau protein kinase beyond tau phosphorylation</span></div><div class="casAuthors">Liao Jung-Chi; Yang T Tony; Weng Rueyhung Roc; Kuo Ching-Te; Chang Chih-Wei</div><div class="citationInfo"><span class="NLM_cas:title">BioMed research international</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">575170</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tau tubulin kinase 2 (TTBK2) is a kinase known to phosphorylate tau and tubulin.  It has recently drawn much attention due to its involvement in multiple important cellular processes.  Here, we review the current understanding of TTBK2, including its sequence, structure, binding sites, phosphorylation substrates, and cellular processes involved.  TTBK2 possesses a casein kinase 1 (CK1) kinase domain followed by a ~900 amino acid segment, potentially responsible for its localization and substrate recruitment.  It is known to bind to CEP164, a centriolar protein, and EB1, a microtubule plus-end tracking protein.  In addition to autophosphorylation, known phosphorylation substrates of TTBK2 include tau, tubulin, CEP164, CEP97, and TDP-43, a neurodegeneration-associated protein.  Mutations of TTBK2 are associated with spinocerebellar ataxia type 11.  In addition, TTBK2 is essential for regulating the growth of axonemal microtubules in ciliogenesis.  It also plays roles in resistance of cancer target therapies and in regulating glucose and GABA transport.  Reported sites of TTBK2 localization include the centriole/basal body, the midbody, and possibly the mitotic spindles.  Together, TTBK2 is a multifunctional kinase involved in important cellular processes and demands augmented efforts in investigating its functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSK5qjjP0gzDrGbPKh4T9eAfW6udTcc2eYXaFrAZOzkMrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mbgs1aktA%253D%253D&md5=853d9f1c78eeb2c003cc427f04405f05</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1155%2F2015%2F575170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F575170%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DJ.-C.%26aulast%3DYang%26aufirst%3DT.%2BT.%26aulast%3DWeng%26aufirst%3DR.%2BR.%26aulast%3DKuo%26aufirst%3DC.-T.%26aulast%3DChang%26aufirst%3DC.-W.%26atitle%3DTTBK2%253A%2520A%2520tau%2520protein%2520kinase%2520beyond%2520tau%2520phosphorylation%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2015%26volume%3D2015%26spage%3D575170%26doi%3D10.1155%2F2015%2F575170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcotte, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spilker, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chodaparambil, J. V.</span></span> <span> </span><span class="NLM_article-title">The crystal structure of the catalytic domain of tau tubulin kinase 2 in complex with a small-molecule inhibitor</span>. <i>Acta Crystallogr., Sect. F: Struct. Biol. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1107/S2053230X2000031X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1107%2FS2053230X2000031X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=32133995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktlenu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2020&pages=103-108&author=D.+J.+Marcotteauthor=K.+A.+Spilkerauthor=D.+Wenauthor=T.+Hessonauthor=T.+A.+Pattersonauthor=P.+R.+Kumarauthor=J.+V.+Chodaparambil&title=The+crystal+structure+of+the+catalytic+domain+of+tau+tubulin+kinase+2+in+complex+with+a+small-molecule+inhibitor&doi=10.1107%2FS2053230X2000031X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The crystal structure of the catalytic domain of tau tubulin kinase 2 in complex with a small-molecule inhibitor</span></div><div class="casAuthors">Marcotte, Douglas J.; Spilker, Kerri A.; Wen, Dingyi; Hesson, Thomas; Patterson, Thomas A.; Kumar, P. Rajesh; Chodaparambil, Jayanth V.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section F: Structural Biology Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">103-108</span>CODEN:
                <span class="NLM_cas:coden">ACSFEN</span>;
        ISSN:<span class="NLM_cas:issn">2053-230X</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Tau proteins play an important role in the proper assembly and function of neurons.  Hyperphosphorylation of tau by kinases such as tau tubulin kinase (TTBK) has been hypothesized to cause the aggregation of tau and the formation of neurofibrillary tangles (NFTs) that lead to the destabilization of microtubules, thereby contributing to neurodegenerative diseases such as Alzheimer's disease (AD).  There are two TTBK isoforms with highly homologous catalytic sites but with distinct tissue distributions, tau phosphorylation patterns and loss-of-function effects.  Inhibition of TTBK1 reduces the levels of NFT formation involved in neurodegenerative diseases such as AD, whereas inhibition of TTBK2 may lead to the movement disorder spinocerebellar ataxia type 11 (SCA11).  Hence, it is crit. to obtain isoform-selective inhibitors.  Structure-based drug design (SBDD) has been used to design highly potent and exquisitely selective inhibitors.  While structures of TTBK1 have been reported in the literature, TTBK2 has evaded structural characterization.  Here, the first crystal structure of the TTBK2 kinase domain is described.  Furthermore, the crystal structure of human TTBK2 in complex with a small-mol. inhibitor has successfully been detd. to elucidate the structural differences in protein conformations between the two TTBK isoforms that could aid in SBDD for the design of inhibitors that selectively target TTBK1 over TTBK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrqhRtU3UmrLVg90H21EOLACvtfcHk0ljWB-qMzqgYhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktlenu7o%253D&md5=bff94b403224841ba31becae4dba1661</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1107%2FS2053230X2000031X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053230X2000031X%26sid%3Dliteratum%253Aachs%26aulast%3DMarcotte%26aufirst%3DD.%2BJ.%26aulast%3DSpilker%26aufirst%3DK.%2BA.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DHesson%26aufirst%3DT.%26aulast%3DPatterson%26aufirst%3DT.%2BA.%26aulast%3DKumar%26aufirst%3DP.%2BR.%26aulast%3DChodaparambil%26aufirst%3DJ.%2BV.%26atitle%3DThe%2520crystal%2520structure%2520of%2520the%2520catalytic%2520domain%2520of%2520tau%2520tubulin%2520kinase%25202%2520in%2520complex%2520with%2520a%2520small-molecule%2520inhibitor%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520F%253A%2520Struct.%2520Biol.%2520Commun.%26date%3D2020%26volume%3D76%26spage%3D103%26epage%3D108%26doi%3D10.1107%2FS2053230X2000031X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span>Some of our findings
in this area have been recently reported; see ref <a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Some+of+our+findings%0Ain+this+area+have+been+recently+reported%3B+see+ref+%284%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="note"><p class="first last">See:</p></div><div class="NLM_citation" id="rightTab-cit16"><span> <i>List of Kinase Targets
at US Facility</i>; .</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+List+of+Kinase+Targets%0Aat+US+Facility%3B+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DList%2520of%2520Kinase%2520Targets%250Aat%2520US%2520Facility" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">(accessed Mar 30, 2021)</p></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillertz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweikart, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wissler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dekker, N.</span></span> <span> </span><span class="NLM_article-title">X-ray Structural analysis of tau-tubulin kinase 1 and its interactions with small molecular inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1846</span>– <span class="NLM_lpage">1854</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201300274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1002%2Fcmdc.201300274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=24039150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVeqsL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1846-1854&author=Y.+Xueauthor=P.+T.+Wanauthor=P.+Hillertzauthor=F.+Schweikartauthor=Y.+Zhaoauthor=L.+Wisslerauthor=N.+Dekker&title=X-ray+Structural+analysis+of+tau-tubulin+kinase+1+and+its+interactions+with+small+molecular+inhibitors&doi=10.1002%2Fcmdc.201300274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">X-ray structural analysis of tau-tubulin kinase 1 and its interactions with small molecular inhibitors</span></div><div class="casAuthors">Xue, Yafeng; Wan, Paul T.; Hillertz, Per; Schweikart, Fritz; Zhao, Yanlong; Wissler, Lisa; Dekker, Niek</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1846-1854</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Tau-tubulin kinase 1 (I) is a serine/threonine/tyrosine kinase that putatively phosphorylates residues including Ser-422 in tau protein.  Hyperphosphorylation of tau protein is the primary cause of tau pathol. and neuronal death assocd. with Alzheimer's disease.  Here, a library of 12 truncation variants comprising the I kinase domain was screened for expression in Escherichia coli and insect cells.  One variant (residues 14-313) could be purified, but mass spectrometric anal. revealed extensive phosphorylation of the protein.  Co-expression with phage λ phosphatase in Escherichia coli resulted in the prodn. of homogeneous, nonphosphorylated I.  The binding of ATP and several compds. to I was characterized by surface plasmon resonance.  Crystal structures of I in the unliganded form and in complex with ATP, and 2 high-affinity ATP-competitive inhibitors, 3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol and Me 2-bromo-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)benzoate (II), were elucidated.  The structure revealed 2 clear basic patches near the ATP pocket providing an explanation of I for phosphorylation-primed substrates.  Interestingly, II displayed slow binding kinetics with I and the structure of I in complex with this compd. revealed a reorganization of the Lue-199-Asp-200 peptide backbone conformation together with altered H-bonding with II.  These conformational changes necessary for the binding of II are likely the basis of the slow kinetics.  This 1st I structure can assist the discovery of novel inhibitors for the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_Z_a4ZEZKz7Vg90H21EOLACvtfcHk0ljmpXLt30t9iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVeqsL%252FE&md5=467e2009dc3d5b8a5bf662048d5c6d8e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300274%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DY.%26aulast%3DWan%26aufirst%3DP.%2BT.%26aulast%3DHillertz%26aufirst%3DP.%26aulast%3DSchweikart%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DWissler%26aufirst%3DL.%26aulast%3DDekker%26aufirst%3DN.%26atitle%3DX-ray%2520Structural%2520analysis%2520of%2520tau-tubulin%2520kinase%25201%2520and%2520its%2520interactions%2520with%2520small%2520molecular%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D1846%26epage%3D1854%26doi%3D10.1002%2Fcmdc.201300274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastalerz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cacace, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheriff, S.</span></span> <span> </span><span class="NLM_article-title">The structure of human tau-tubulin kinase 1 both in the apo form and in complex with an inhibitor</span>. <i>Acta Crystallogr., Sect. F: Struct. Biol. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1107/S2053230X14000144</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1107%2FS2053230X14000144" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=24637750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVejsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2014&pages=173-181&author=S.+E.+Kieferauthor=C.+J.+Changauthor=S.+R.+Kimuraauthor=M.+Gaoauthor=D.+Xieauthor=Y.+Zhangauthor=G.+Zhangauthor=M.+B.+Gillauthor=H.+Mastalerzauthor=L.+A.+Thompsonauthor=A.+M.+Cacaceauthor=S.+Sheriff&title=The+structure+of+human+tau-tubulin+kinase+1+both+in+the+apo+form+and+in+complex+with+an+inhibitor&doi=10.1107%2FS2053230X14000144"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The structure of human tau-tubulin kinase 1 both in the apo form and in complex with an inhibitor</span></div><div class="casAuthors">Kiefer, Susan E.; Chang, Chieh Ying J.; Kimura, S. Roy; Gao, Mian; Xie, Dianlin; Zhang, Yaqun; Zhang, Guifen; Gill, Martin B.; Mastalerz, Harold; Thompson, Lorin A.; Cacace, Angela M.; Sheriff, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section F: Structural Biology Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">173-181</span>CODEN:
                <span class="NLM_cas:coden">ACSFEN</span>;
        ISSN:<span class="NLM_cas:issn">2053-230X</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Tau-tubulin kinase 1 (TTBK1) is a dual-specificity (serine/threonine and tyrosine) kinase belonging to the casein kinase 1 superfamily.  TTBK1 is a neuron-specific kinase that regulates tau phosphorylation.  Hyperphosphorylation of tau is implicated in the pathogenesis of Alzheimer's disease.  Two kinase-domain constructs of TTBK1 were expressed in a baculovirus-infected insect-cell system and purified.  The purified TTBK1 kinase-domain proteins were crystd. using the hanging-drop vapor-diffusion method.  X-ray diffraction data were collected and the structure of TTBK1 was detd. by mol. replacement both as an apo structure and in complex with a kinase inhibitor (I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKB-lyYNRRVbVg90H21EOLACvtfcHk0ljmpXLt30t9iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVejsrY%253D&md5=f37ee6f58921bb5ac72877888129bc0b</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1107%2FS2053230X14000144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053230X14000144%26sid%3Dliteratum%253Aachs%26aulast%3DKiefer%26aufirst%3DS.%2BE.%26aulast%3DChang%26aufirst%3DC.%2BJ.%26aulast%3DKimura%26aufirst%3DS.%2BR.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DGill%26aufirst%3DM.%2BB.%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DThompson%26aufirst%3DL.%2BA.%26aulast%3DCacace%26aufirst%3DA.%2BM.%26aulast%3DSheriff%26aufirst%3DS.%26atitle%3DThe%2520structure%2520of%2520human%2520tau-tubulin%2520kinase%25201%2520both%2520in%2520the%2520apo%2520form%2520and%2520in%2520complex%2520with%2520an%2520inhibitor%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520F%253A%2520Struct.%2520Biol.%2520Commun.%26date%3D2014%26volume%3D70%26spage%3D173%26epage%3D181%26doi%3D10.1107%2FS2053230X14000144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span> <i>The biochemical potency was determined at Reaction Biology</i>: see: <a href="https://www.reactionbiology.com/list-kinase-targets-us-facility" class="extLink">https://www.reactionbiology.com/list-kinase-targets-us-facility</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+The+biochemical+potency+was+determined+at+Reaction+Biology%3A+see%3A+https%3A%2F%2Fwww.reactionbiology.com%2Flist-kinase-targets-us-facility."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520biochemical%2520potency%2520was%2520determined%2520at%2520Reaction%2520Biology" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">(accessed Mar 30, 2021)</p></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span> <i>MRC
PPU International Centre for Kinase Profiling</i> .</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+MRC%0APPU+International+Centre+for+Kinase+Profiling+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DMRC%250APPU%2520International%2520Centre%2520for%2520Kinase%2520Profiling" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">(accessed Mar 30, 2021)</p></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="note"><p class="first last">Compound <b>3</b> was first disclosed by:</p></div><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubenstein, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Answer, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waszkowycz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plotnikova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrelly, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Inhibiting NF-κB-inducing kinase (NIK): discovery, structure-based design, synthesis, structure–activity relationship, and co-crystal structures</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1238</span>– <span class="NLM_lpage">1244</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1016%2Fj.bmcl.2013.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=23374866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=1238-1244&author=K.+Liauthor=L.+R.+McGeeauthor=B.+Fisherauthor=A.+Sudomauthor=J.+Liuauthor=S.+M.+Rubensteinauthor=M.+K.+Answerauthor=T.+D.+Cushingauthor=Y.+Shinauthor=M.+Ayresauthor=F.+Leeauthor=J.+Eksterowiczauthor=P.+Faulderauthor=B.+Waszkowyczauthor=O.+Plotnikovaauthor=E.+Farrellyauthor=S.-H.+Xiaoauthor=G.+Chenauthor=Z.+Wang&title=Inhibiting+NF-%CE%BAB-inducing+kinase+%28NIK%29%3A+discovery%2C+structure-based+design%2C+synthesis%2C+structure%E2%80%93activity+relationship%2C+and+co-crystal+structures&doi=10.1016%2Fj.bmcl.2013.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting NF-κB-inducing kinase (NIK): Discovery, structure-based design, synthesis, structure-activity relationship, and co-crystal structures</span></div><div class="casAuthors">Li, Kexue; McGee, Lawrence R.; Fisher, Ben; Sudom, Athena; Liu, Jinsong; Rubenstein, Steven M.; Anwer, Mohmed K.; Cushing, Timothy D.; Shin, Youngsook; Ayres, Merrill; Lee, Fei; Eksterowicz, John; Faulder, Paul; Waszkowycz, Bohdan; Plotnikova, Olga; Farrelly, Ellyn; Xiao, Shou-Hua; Chen, Guoqing; Wang, Zhulun</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1238-1244</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery, structure-based design, synthesis, and optimization of NIK inhibitors are described.  Our work began with an HTS hit, imidazopyridinyl pyrimidinamine I.  We utilized homol. modeling and conformational anal. to optimize the indole scaffold leading to the discovery of novel and potent conformationally constrained inhibitors such as compds. II [R1 = Br, C≡CCMe2OH].  Compds. II [R1 = Br] and III were co-crystd. with NIK kinase domain to provide structural insights.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm5WqvTIrBqrVg90H21EOLACvtfcHk0ljmpXLt30t9iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGmt7s%253D&md5=a382078cf3bf84a41749783be33a5988</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DK.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DSudom%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DRubenstein%26aufirst%3DS.%2BM.%26aulast%3DAnswer%26aufirst%3DM.%2BK.%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DF.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DFaulder%26aufirst%3DP.%26aulast%3DWaszkowycz%26aufirst%3DB.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DFarrelly%26aufirst%3DE.%26aulast%3DXiao%26aufirst%3DS.-H.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DInhibiting%2520NF-%25CE%25BAB-inducing%2520kinase%2520%2528NIK%2529%253A%2520discovery%252C%2520structure-based%2520design%252C%2520synthesis%252C%2520structure%25E2%2580%2593activity%2520relationship%252C%2520and%2520co-crystal%2520structures%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D1238%26epage%3D1244%26doi%3D10.1016%2Fj.bmcl.2013.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Morais, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalvass, J. C.</span></span> <span> </span><span class="NLM_article-title">In vitro P-glycoprotein efflux ratio can predict the in vivo brain penetration regardless of biopharmaceutics drug disposition classification system class</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">2012</span>– <span class="NLM_lpage">2017</span>, <span class="refDoi"> DOI: 10.1124/dmd.113.053868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1124%2Fdmd.113.053868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=24009309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVCjtbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=2012-2017&author=R.+Kikuchiauthor=S.+M.+de+Moraisauthor=J.+C.+Kalvass&title=In+vitro+P-glycoprotein+efflux+ratio+can+predict+the+in+vivo+brain+penetration+regardless+of+biopharmaceutics+drug+disposition+classification+system+class&doi=10.1124%2Fdmd.113.053868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro P-glycoprotein efflux ratio can predict the in vivo brain penetration regardless of biopharmaceutics drug disposition classification system class</span></div><div class="casAuthors">Kikuchi, Ryota; de Morais, Sonia M.; Kalvass, J. Cory</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2012-2017</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">P-glycoprotein (P-gp) is expressed at the blood-brain barrier (BBB) and restricts the penetration of its substrates into the central nervous system (CNS).  In vitro substrate assessment for P-gp is frequently used to predict the in vivo relevance of P-gp-mediated efflux at the BBB.  We have conducted a comprehensive review of literature focusing on the in vitro-in vivo correlation of P-gp efflux ratio (ER), and demonstrated that in vitro substrates of P-gp are also in vivo substrates at the BBB.  It was of note that the in vitro ER in the MDCK-MDR1 cell line from National Institutes of Health was found to be a better predictor of in vivo ER than that from Netherlands Cancer Institute, with r2 values of 0.813 and 0.531, resp.  Recently, a research group proposed that 98% of Biopharmaceutics Drug Disposition Classification System (BDDCS) class 1 drugs can penetrate the brain even when those compds. are shown as P-gp substrates in vitro.  However, our data anal. suggested that in vitro ER can predict the in vivo brain penetration regardless of the class in BDDCS.  Considering that very few marketed CNS drugs are in vivo substrates for P-gp, the in vitro substrate assessment of P-gp should be used in the early stages of drug discovery to select compds. that are most likely to penetrate the CNS to exert their pharmacol. action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFQtEu5USc2LVg90H21EOLACvtfcHk0lgDL96DegW8JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVCjtbvO&md5=f4e32455375b1bd684ba38174a71657c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1124%2Fdmd.113.053868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.113.053868%26sid%3Dliteratum%253Aachs%26aulast%3DKikuchi%26aufirst%3DR.%26aulast%3Dde%2BMorais%26aufirst%3DS.%2BM.%26aulast%3DKalvass%26aufirst%3DJ.%2BC.%26atitle%3DIn%2520vitro%2520P-glycoprotein%2520efflux%2520ratio%2520can%2520predict%2520the%2520in%2520vivo%2520brain%2520penetration%2520regardless%2520of%2520biopharmaceutics%2520drug%2520disposition%2520classification%2520system%2520class%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2013%26volume%3D41%26spage%3D2012%26epage%3D2017%26doi%3D10.1124%2Fdmd.113.053868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moustakas, D. T.</span></span> <span> </span><span class="NLM_article-title">The necessary nitrogen atom: a versatile high-impact design element for multiparameter optimization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">3552</span>– <span class="NLM_lpage">3579</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01807</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01807" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BC2sXit1yit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3552-3579&author=L.+D.+Penningtonauthor=D.+T.+Moustakas&title=The+necessary+nitrogen+atom%3A+a+versatile+high-impact+design+element+for+multiparameter+optimization&doi=10.1021%2Facs.jmedchem.6b01807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The Necessary Nitrogen Atom: A Versatile High-Impact Design Element for Multiparameter Optimization</span></div><div class="casAuthors">Pennington, Lewis D.; Moustakas, Demetri T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3552-3579</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  There is a continued desire in biomedical research to reduce the no. and duration of design cycles required to optimize lead compds. into high-quality chem. probes or safe and efficacious drug candidates.  The insightful application of impactful mol. design elements is one approach toward achieving this goal.  The replacement of a CH group with a N atom in arom. and heteroarom. ring systems can have many important effects on mol. and physicochem. properties and intra- and intermol. interactions that can translate to improved pharmacol. profiles.  In this Perspective, the "necessary nitrogen atom" is shown to be a versatile high-impact design element for multiparameter optimization, wherein ≥10-, 100-, or 1000-fold improvement in a variety of key pharmacol. parameters can be realized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8ZLKZMgt6IbVg90H21EOLACvtfcHk0lgDL96DegW8JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXit1yit74%253D&md5=002aaee48995e7954647a1f75183db4d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01807%26sid%3Dliteratum%253Aachs%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DMoustakas%26aufirst%3DD.%2BT.%26atitle%3DThe%2520necessary%2520nitrogen%2520atom%253A%2520a%2520versatile%2520high-impact%2520design%2520element%2520for%2520multiparameter%2520optimization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D3552%26epage%3D3579%26doi%3D10.1021%2Facs.jmedchem.6b01807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grootenhuis, P. D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayada, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delbressine, L. P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploemen, J.-P.</span></span> <span> </span><span class="NLM_article-title">Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1514</span>– <span class="NLM_lpage">1519</span>, <span class="refDoi"> DOI: 10.1023/A:1015040217741</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1023%2FA%3A1015040217741" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10554091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADyaK1MXntVOhtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1999&pages=1514-1519&author=J.+Kelderauthor=P.+D.+J.+Grootenhuisauthor=D.+M.+Bayadaauthor=L.+P.+C.+Delbressineauthor=J.-P.+Ploemen&title=Polar+molecular+surface+as+a+dominating+determinant+for+oral+absorption+and+brain+penetration+of+drugs&doi=10.1023%2FA%3A1015040217741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs</span></div><div class="casAuthors">Kelder, Jan; Grootenhuis, Peter D. J.; Bayada, Denis M.; Delbressine, Leon P. C.; Ploemen, Jan-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1514-1519</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic/Plenum Publishers</span>)
        </div><div class="casAbstract">Purpose: To study oral absorption and brain penetration as a function of polar mol. surface area.  Methods: Measured brain penetration data of 45 drug mols. were investigated.  The dynamic polar surface areas were calcd. and correlated with the brain penetration data.  Also the static polar surface areas of 776 orally administered CNS drugs that have reached at least Phase II efficacy studies were calcd.  The same was done for a series of 1590 orally administered non-CNS drugs that have reached at least Phase II efficacy studies.  Results: A linear relationship between brain penetration and dynamic polar surface area (A2) was found (n = 45, R = 0.917, F1,43 = 229).  Brain penetration decreases with increasing polar surface area.  A clear difference between the distribution of the polar surface area of the 776 CNS and 1590 non-CNS drugs was found.  It was deduced that orally active drugs that are transported passively by the transcellular route should not exceed a polar surface area of about 120 A2.  They can be tailored to brain penetration by decreasing the polar surface to <60-70 A2.  This conclusion is supported by the inverse linear relationship between exptl. brain penetration data and the dynamic polar surface area of 45 drug mols.  Conclusions: The polar mol. surface area is a dominating determinant for oral absorption and brain penetration of drugs that are transported by the transcellular route.  This property should be considered in the early phase of drug screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmc3v7TzWM4LVg90H21EOLACvtfcHk0lgDL96DegW8JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntVOhtb8%253D&md5=868fe1e9491dd3b8b92b326d28ee48f9</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1023%2FA%3A1015040217741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1015040217741%26sid%3Dliteratum%253Aachs%26aulast%3DKelder%26aufirst%3DJ.%26aulast%3DGrootenhuis%26aufirst%3DP.%2BD.%2BJ.%26aulast%3DBayada%26aufirst%3DD.%2BM.%26aulast%3DDelbressine%26aufirst%3DL.%2BP.%2BC.%26aulast%3DPloemen%26aufirst%3DJ.-P.%26atitle%3DPolar%2520molecular%2520surface%2520as%2520a%2520dominating%2520determinant%2520for%2520oral%2520absorption%2520and%2520brain%2520penetration%2520of%2520drugs%26jtitle%3DPharm.%2520Res.%26date%3D1999%26volume%3D16%26spage%3D1514%26epage%3D1519%26doi%3D10.1023%2FA%3A1015040217741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makarov, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brocklehurst, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaghiosoff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knochel, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis of bicyclo[1.1.1]pentane bioisosteres of internal alkynes and <i>para</i>-disubstituted benzenes from [1.1.1]propellane</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">12774</span>– <span class="NLM_lpage">12777</span>, <span class="refDoi"> DOI: 10.1002/anie.201706799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1002%2Fanie.201706799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVansrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=12774-12777&author=I.+S.+Makarovauthor=C.+E.+Brocklehurstauthor=K.+Karaghiosoffauthor=G.+Kochauthor=P.+Knochel&title=Synthesis+of+bicyclo%5B1.1.1%5Dpentane+bioisosteres+of+internal+alkynes+and+para-disubstituted+benzenes+from+%5B1.1.1%5Dpropellane&doi=10.1002%2Fanie.201706799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Bicyclo[1.1.1]pentane Bioisosteres of Internal Alkynes and para-Disubstituted Benzenes from [1.1.1]Propellane</span></div><div class="casAuthors">Makarov, Ilya S.; Brocklehurst, Cara E.; Karaghiosoff, Konstantin; Koch, Guido; Knochel, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">12774-12777</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A general prepn. of arylated bicyclo[1.1.1]pentanes through the opening of [1.1.1]propellane with various arylmagnesium halides is reported.  After transmetalation with ZnCl2 and Negishi cross-coupling with aryl and heteroaryl halides, bis-arylated bicyclo[1.1.1]pentanes are obtained.  These bis-arylated bicyclo[1.1.1]pentanes may be considered as bioisosteres of internal alkynes.  Bioisosteres I and II of tazarotene and the metabotropic glutamate receptor 5 (mGluR5) antagonist 2-methyl-6-(phenylethynyl)pyridine, resp., were prepd. and their physicochem. properties were evaluated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouj5jm5mNiTbVg90H21EOLACvtfcHk0ljCZa6g-QqZrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVansrvF&md5=4a7c5dcb5de7763fc410151aa653a502</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fanie.201706799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201706799%26sid%3Dliteratum%253Aachs%26aulast%3DMakarov%26aufirst%3DI.%2BS.%26aulast%3DBrocklehurst%26aufirst%3DC.%2BE.%26aulast%3DKaraghiosoff%26aufirst%3DK.%26aulast%3DKoch%26aufirst%3DG.%26aulast%3DKnochel%26aufirst%3DP.%26atitle%3DSynthesis%2520of%2520bicyclo%255B1.1.1%255Dpentane%2520bioisosteres%2520of%2520internal%2520alkynes%2520and%2520para-disubstituted%2520benzenes%2520from%2520%255B1.1.1%255Dpropellane%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D12774%26epage%3D12777%26doi%3D10.1002%2Fanie.201706799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span> <span> </span><span class="NLM_article-title">Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1410</span>, <span class="refDoi"> DOI: 10.1021/tx200168d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx200168d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1345-1410&author=A.+F.+Stepanauthor=D.+P.+Walkerauthor=J.+Baumanauthor=D.+A.+Priceauthor=T.+A.+Baillieauthor=A.+S.+Kalgutkarauthor=M.+D.+Aleo&title=Structural+alert%2Freactive+metabolite+concept+as+applied+in+medicinal+chemistry+to+mitigate+the+risk+of+idiosyncratic+drug+toxicity%3A+a+perspective+based+on+the+critical+examination+of+trends+in+the+top+200+drugs+marketed+in+the+United+States&doi=10.1021%2Ftx200168d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Ftx200168d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200168d%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DBauman%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26atitle%3DStructural%2520alert%252Freactive%2520metabolite%2520concept%2520as%2520applied%2520in%2520medicinal%2520chemistry%2520to%2520mitigate%2520the%2520risk%2520of%2520idiosyncratic%2520drug%2520toxicity%253A%2520a%2520perspective%2520based%2520on%2520the%2520critical%2520examination%2520of%2520trends%2520in%2520the%2520top%2520200%2520drugs%2520marketed%2520in%2520the%2520United%2520States%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D24%26spage%3D1345%26epage%3D1410%26doi%3D10.1021%2Ftx200168d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talele, T. T.</span></span> <span> </span><span class="NLM_article-title">Acetylene group, friend or foe in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">5625</span>– <span class="NLM_lpage">5663</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01617</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01617" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisVygsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=5625-5663&author=T.+T.+Talele&title=Acetylene+group%2C+friend+or+foe+in+medicinal+chemistry&doi=10.1021%2Facs.jmedchem.9b01617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Acetylene Group, Friend or Foe in Medicinal Chemistry</span></div><div class="casAuthors">Talele, Tanaji T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5625-5663</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The use of an acetylene (ethynyl) group in medicinal chem. coincides with the launch of the Journal of Medicinal Chem. in 1959.  Since then, the acetylene group has been broadly exploited in drug discovery and development.  As a result, it has become recognized as a privileged structural feature for targeting a wide range of therapeutic target proteins, including MAO, tyrosine kinases, BACE1, steroid receptors, mGlu5 receptors, FFA1/GPR40, and HIV-1 RT.  Furthermore, a terminal alkyne functionality is frequently introduced in chem. biol. probes as a click handle to identify mol. targets and to assess target engagement.  This Perspective is divided into three parts encompassing: (1) the physicochem. properties of the ethynyl group, (2) the advantages and disadvantages of the ethynyl group in medicinal chem., and (3) the impact of the ethynyl group on chem. biol. approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotTcNwOy0swrVg90H21EOLACvtfcHk0ljCZa6g-QqZrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisVygsr8%253D&md5=199e9f0139337753617b6718e95de5ec</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01617%26sid%3Dliteratum%253Aachs%26aulast%3DTalele%26aufirst%3DT.%2BT.%26atitle%3DAcetylene%2520group%252C%2520friend%2520or%2520foe%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D5625%26epage%3D5663%26doi%3D10.1021%2Facs.jmedchem.9b01617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Planel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyasaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Launey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chui, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanemura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murayama, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishiguro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatebayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takashima, A.</span></span> <span> </span><span class="NLM_article-title">Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer’s disease</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2401</span>– <span class="NLM_lpage">2411</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.5561-03.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1523%2FJNEUROSCI.5561-03.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=15014115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisVKhsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=2401-2411&author=E.+Planelauthor=T.+Miyasakaauthor=T.+Launeyauthor=D.+H.+Chuiauthor=K.+Tanemuraauthor=S.+Satoauthor=O.+Murayamaauthor=K.+Ishiguroauthor=Y.+Tatebayashiauthor=A.+Takashima&title=Alterations+in+glucose+metabolism+induce+hypothermia+leading+to+tau+hyperphosphorylation+through+differential+inhibition+of+kinase+and+phosphatase+activities%3A+implications+for+Alzheimer%E2%80%99s+disease&doi=10.1523%2FJNEUROSCI.5561-03.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease</span></div><div class="casAuthors">Planel, Emmanuel; Miyasaka, Tomohiro; Launey, Thomas; Chui, De-Hua; Tanemura, Kentaro; Sato, Shinji; Murayama, Ohoshi; Ishiguro, Koichi; Tatebayashi, Yoshitaka; Takashima, Akihiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2401-2411</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) brains contain neurofibrillary tangles (NFTs) composed of abnormally hyperphosphorylated tau protein.  Regional redns. in cerebral glucose metab. correlating to NFT densities were reported in AD brains.  Assuming that reduced glucose metab. might cause abnormal tau hyperphosphorylation, the authors induced in vivo alterations of glucose metab. in mice by starvation or i.p. injections of either insulin or deoxyglucose.  We found that the treatments led to abnormal tau hyperphosphorylation with patterns resembling those in early AD brains and also resulted in hypothermia.  Surprisingly, tau hyperphosphorylation could be traced down to a differential effect of low temps. on kinase and phosphatase activities.  These data indicate that abnormal tau hyperphosphorylation is assocd. with altered glucose metab. through hypothermia.  These results imply that serine-threonine protein phosphatase 2A plays a major role in regulating tau phosphorylation in the adult brain and provide in vivo evidence for its crucial role in abnormal tau hyperphosphorylation in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmIJmL4o2h97Vg90H21EOLACvtfcHk0ljCZa6g-QqZrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisVKhsLk%253D&md5=9b55d8d0df1b56ff2bd04c2eeffe4b96</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.5561-03.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.5561-03.2004%26sid%3Dliteratum%253Aachs%26aulast%3DPlanel%26aufirst%3DE.%26aulast%3DMiyasaka%26aufirst%3DT.%26aulast%3DLauney%26aufirst%3DT.%26aulast%3DChui%26aufirst%3DD.%2BH.%26aulast%3DTanemura%26aufirst%3DK.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DMurayama%26aufirst%3DO.%26aulast%3DIshiguro%26aufirst%3DK.%26aulast%3DTatebayashi%26aufirst%3DY.%26aulast%3DTakashima%26aufirst%3DA.%26atitle%3DAlterations%2520in%2520glucose%2520metabolism%2520induce%2520hypothermia%2520leading%2520to%2520tau%2520hyperphosphorylation%2520through%2520differential%2520inhibition%2520of%2520kinase%2520and%2520phosphatase%2520activities%253A%2520implications%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurosci.%26date%3D2004%26volume%3D24%26spage%3D2401%26epage%3D2411%26doi%3D10.1523%2FJNEUROSCI.5561-03.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guillozet-Bongaarts, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cahill, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cryns, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binder, L. I.</span></span> <span> </span><span class="NLM_article-title">Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1014</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2006.03784.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1111%2Fj.1471-4159.2006.03784.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=16606369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsVOntro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2006&pages=1005-1014&author=A.+L.+Guillozet-Bongaartsauthor=M.+E.+Cahillauthor=V.+L.+Crynsauthor=M.+R.+Reynoldsauthor=R.+W.+Berryauthor=L.+I.+Binder&title=Pseudophosphorylation+of+tau+at+serine+422+inhibits+caspase+cleavage%3A+in+vitro+evidence+and+implications+for+tangle+formation+in+vivo&doi=10.1111%2Fj.1471-4159.2006.03784.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo</span></div><div class="casAuthors">Guillozet-Bongaarts, Angela L.; Cahill, Michael E.; Cryns, Vincent L.; Reynolds, Matthew R.; Berry, Robert W.; Binder, Lester I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1005-1014</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The tangles of Alzheimer's disease (AD) are comprised of the tau protein displaying numerous alterations, including phosphorylation at serine 422 (S422) and truncation at aspartic acid 421 (D421).  Truncation at the latter site appears to result from activation of caspases, a class of proteases that cleave specifically at aspartic acid residues.  It has been proposed that phosphorylation at or near caspase cleavage sites could regulate the ability of the protease to cleave at those sites.  Here, we use tau pseudophosphorylated at S422 (S422E) to examine the effects of tau phosphorylation on its cleavage by caspase 3.  We find that S422E tau is more resistant to proteolysis by caspase 3 than non-pseudophosphorylated tau.  Addnl., we use antibodies directed against the phosphorylation site and against the truncation epitope to assess the presence of these epitopes in neurofibrillary tangles in the aged human brain.  We show that phosphorylation precedes truncation during tangle maturation.  Moreover, the distribution of the two epitopes suggests that a significant length of time (perhaps as much as two decades) elapses between S422 phosphorylation and cleavage at D421.  We further conclude that tau phosphorylation at S422 may be a protective mechanism that inhibits cleavage in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8FRMpyiZv4bVg90H21EOLACvtfcHk0lg1SZJ74hpAsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsVOntro%253D&md5=6124e371597607c8482e7e046e782b3e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2006.03784.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2006.03784.x%26sid%3Dliteratum%253Aachs%26aulast%3DGuillozet-Bongaarts%26aufirst%3DA.%2BL.%26aulast%3DCahill%26aufirst%3DM.%2BE.%26aulast%3DCryns%26aufirst%3DV.%2BL.%26aulast%3DReynolds%26aufirst%3DM.%2BR.%26aulast%3DBerry%26aufirst%3DR.%2BW.%26aulast%3DBinder%26aufirst%3DL.%2BI.%26atitle%3DPseudophosphorylation%2520of%2520tau%2520at%2520serine%2520422%2520inhibits%2520caspase%2520cleavage%253A%2520in%2520vitro%2520evidence%2520and%2520implications%2520for%2520tangle%2520formation%2520in%2520vivo%26jtitle%3DJ.%2520Neurochem.%26date%3D2006%26volume%3D97%26spage%3D1005%26epage%3D1014%26doi%3D10.1111%2Fj.1471-4159.2006.03784.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vana, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanaan, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugwu, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mufson, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binder, L. I.</span></span> <span> </span><span class="NLM_article-title">Progression of tau pathology in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer’s disease</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">2533</span>– <span class="NLM_lpage">2550</span>, <span class="refDoi"> DOI: 10.1016/j.ajpath.2011.07.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.1016%2Fj.ajpath.2011.07.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=21945902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCmu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2011&pages=2533-2550&author=L.+Vanaauthor=N.+M.+Kanaanauthor=I.+C.+Ugwuauthor=J.+Wuuauthor=E.+J.+Mufsonauthor=L.+I.+Binder&title=Progression+of+tau+pathology+in+cholinergic+basal+forebrain+neurons+in+mild+cognitive+impairment+and+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.ajpath.2011.07.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Progression of Tau pathology in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease</span></div><div class="casAuthors">Vana, Laurel; Kanaan, Nicholas M.; Ugwu, Isabella C.; Wuu, Joanne; Mufson, Elliott J.; Binder, Lester I.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2533-2550</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Tau is a microtubule-assocd. protein that forms neurofibrillary tangles (NFTs) in the selective vulnerable long projection neurons of the cholinergic basal forebrain (CBF) in Alzheimer's disease (AD).  Although CBF neurodegeneration correlates with cognitive decline during AD progression, little is known about the temporal changes of tau accumulation in this region.  We investigated tau posttranslational modifications during NFT evolution within the CBF neurons of the nucleus basalis (NB) using tissue from subjects with no cognitive impairment, mild cognitive impairment, and AD.  The pS422 antibody was used as an early tau pathol. marker that labels tau phosphorylated at Ser422; the TauC3 antibody was used to detect later stage tau pathol.  Stereol. evaluation of NB tissue immunostained for pS422 and TauC3 revealed an increase in neurons expressing these tau epitopes during disease progression.  We also investigated the occurrence of pretangle tau events within cholinergic NB neurons by dual staining for the cholinergic cell marker, p75NTR, which displays a phenotypic down-regulation within CBF perikarya in AD.  As pS422+ neurons increased in no., p75NTR+ neurons decreased, and these changes correlated with both AD neuropathol. and cognitive decline.  Also, NFTs developed slower in the CBF compared with previously examd. cortical regions.  Taken together, these results suggest that changes in cognition are assocd. with pretangle events within NB cholinergic neurons before frank NFT deposition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonBSJihBY7h7Vg90H21EOLACvtfcHk0lg1SZJ74hpAsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCmu7jI&md5=87c73eff0b88ec1c724a101704d33cbb</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.ajpath.2011.07.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajpath.2011.07.044%26sid%3Dliteratum%253Aachs%26aulast%3DVana%26aufirst%3DL.%26aulast%3DKanaan%26aufirst%3DN.%2BM.%26aulast%3DUgwu%26aufirst%3DI.%2BC.%26aulast%3DWuu%26aufirst%3DJ.%26aulast%3DMufson%26aufirst%3DE.%2BJ.%26aulast%3DBinder%26aufirst%3DL.%2BI.%26atitle%3DProgression%2520of%2520tau%2520pathology%2520in%2520cholinergic%2520basal%2520forebrain%2520neurons%2520in%2520mild%2520cognitive%2520impairment%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2011%26volume%3D179%26spage%3D2533%26epage%3D2550%26doi%3D10.1016%2Fj.ajpath.2011.07.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowie, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetz, S. C.</span></span> <span> </span><span class="NLM_article-title">TTBK2 and primary cilia are essential for the connectivity and survival of cerebellar Purkinje neurons</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e511166</span> <span class="refDoi"> DOI: 10.7554/eLife.51166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;key=10.7554%2FeLife.51166" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&author=E.+Bowieauthor=S.+C.+Goetz&title=TTBK2+and+primary+cilia+are+essential+for+the+connectivity+and+survival+of+cerebellar+Purkinje+neurons&doi=10.7554%2FeLife.51166"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.7554%2FeLife.51166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.51166%26sid%3Dliteratum%253Aachs%26aulast%3DBowie%26aufirst%3DE.%26aulast%3DGoetz%26aufirst%3DS.%2BC.%26atitle%3DTTBK2%2520and%2520primary%2520cilia%2520are%2520essential%2520for%2520the%2520connectivity%2520and%2520survival%2520of%2520cerebellar%2520Purkinje%2520neurons%26jtitle%3DeLife%26date%3D2020%26volume%3D9%26doi%3D10.7554%2FeLife.51166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JXX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JXX','PDB','7JXX'); return false;">PDB: 7JXX</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JXY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JXY','PDB','7JXY'); return false;">PDB: 7JXY</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i94"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00382">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_70027"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00382?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00382</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Description of biochemical and cellular assays; description of glutathione (GSH) experiments; experimental conditions for crystallization, collection, and refinement statistics for compounds <b>3</b> and <b>18</b>; description of cytotoxicity assay; selectivity profile of compounds <b>18</b>, <b>19</b>, and <b>31</b>; description of K<sub>p,uu</sub> studies; (Figure S1) unaltered western blots supporting quantification of tau phosphorylation summarized in <a id="rightTab-" class=" internalNav" href="#fig7">Figure <a id="rightTab-" class=" internalNav" href="#fig7">7</a></a>; (Figure S2) basal Ser 422 levels in the developing rat brain; (Figure S3) unaltered western blots supporting quantification of tau phosphorylation summarized in <a id="rightTab-" class=" internalNav" href="#fig8">Figure <a id="rightTab-" class=" internalNav" href="#fig8">8</a></a>; (Figure S4) neurotoxicity of lead compound <b>31</b> in primary mouse neurons; methods supporting in vivo pharmacology; general description of in vitro DMPK assays; and HPLC data for compounds <b>18</b>, <b>19</b>, and <b>31</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00382/suppl_file/jm1c00382_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00382/suppl_file/jm1c00382_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00382/suppl_file/jm1c00382_si_001.pdf">jm1c00382_si_001.pdf (3.13 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00382/suppl_file/jm1c00382_si_002.csv">jm1c00382_si_002.csv (2.33 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00382&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-9%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00382%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00382" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679910fc5b133d18","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
